[{"id": 250001, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Diclofenac (topical)", "severity": "Moderate", "effect": "Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.  Close clinical and laboratory observation for hematologic complications is recommended.  Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296177/", "reference_text": "[1] \"Product Information. Acular (ketorolac).\" Allergan Inc  (2001):[2] \"Product Information. Xibrom (bromfenac ophthalmic).\" ISTA Pharmaceuticals  (2005):[3] \"Product Information. Nevanac (nepafenac ophthalmic).\" Alcon Laboratories Inc  (2005):", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Salicylic acid, Fluocinolone acetonide, Cortisone, More", "alternatives_b": "Iodide I-131", "updated_at": 1767369485}, {"id": 250002, "ingredient1": "Diclofenac (topical)", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Use of hepatotoxic drugs together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.  Patients treated with levoketoconazole or ketoconazole should have liver tests performed prior to and during treatment.  Levoketoconazole manufacturer recommends interrupting treatment immediately if signs of hepatotoxicity occur.  Refer to levoketoconazole labeling for specific instructions on management of hepatotoxicity.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296178/", "reference_text": "[1] \"Product Information. Ketoconazole (ketoconazole).\" Mylan Pharmaceuticals Inc  (2019):[2] \"Product Information. Recorlev (levoketoconazole).\" Xeris Pharmaceuticals Inc  (2022):[3] Auchus R, Pivonello R, Fleseriu M, et al. \"Levoketoconazole: a novel treatment for endogenous Cushing's syndrome.  https://www.tandfonline.com/doi/pdf/10.1080/17446651.2021.1945440\"   (2022):", "alternatives_a": "Indomethacin, Fluocinolone acetonide, Fluorometholone, Salicylic acid, Ketorolac, Indomethacin, Fluocinolone acetonide, Piroxicam, Flurbiprofen, Fluorometholone, Bromfenac, More", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "updated_at": 1767369485}, {"id": 250003, "ingredient1": "Brentuximab vedotin", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Polyneuropathy has been reported during treatment with levodopa/carbidopa combinations, and concurrent use of other medications that are also associated with this adverse effect may potentiate the risk and/or severity of nerve damage.", "source": "DDInter", "management_text": "Before initiating treatment with enteral formulations of levodopa/carbidopa, the manufacturers recommend evaluating patients for history or signs of polyneuropathy and known risk factors such as diabetes mellitus, hypothyroidism, or concomitant use of other medications associated with polyneuropathy.  For patients with preexisting polyneuropathy, the benefits of treatment should be carefully weighed against the potential risks, including the potential for impaired mobility.  Plasma concentrations of vitamin B12, vitamin B6, homocysteine, methylmalonic acid, and folic acid should be obtained at baseline and at regular intervals during treatment.  Patients who develop symptoms of peripheral neuropathy and low plasma concentrations of vitamin B6 and/or vitamin B12, or elevated homocysteine or methylmalonic acid concentrations, may benefit from vitamin supplementation.  Physicians should carefully evaluate if a dose adjustment is warranted and assess the benefit versus risk of continued treatment.", "mechanism_text": "Synergism", "recommendation": "Before initiating treatment with enteral formulations of levodopa/carbidopa, the manufacturers recommend evaluating patients for history or signs of polyneuropathy and known risk factors such as diabetes mellitus, hypothyroidism, or concomitant use of other medications associated with polyneuropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296179/", "reference_text": "[1] \"Product Information. Duopa (carbidopa-levodopa).\" AbbVie US LLC  (2022):[2] \"Product Information. Duodopa (carbidopa-levodopa).\" AbbVie Corporation  (2022):[3] \"Product Information. Duodopa (carbidopa-levodopa).\" AbbVie Pty Ltd  (2021):", "alternatives_a": "Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Rotigotine, Bromocriptine, Pergolide, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 250004, "ingredient1": "Diamorphine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296180/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 250005, "ingredient1": "Nitroprusside", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "The hypotensive effects of levodopa and antihypertensive agents may be additive.  Postural hypotension may occur.", "source": "DDInter", "management_text": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.  Dose adjustments of the antihypertensive agent may be required.  Patients should be advised to notify their physician if they experience dizziness or syncope.", "mechanism_text": "Synergism", "recommendation": "Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296182/", "reference_text": "[1] \"Product Information. Stalevo 150 (carbidopa/entacapone/levodopa).\" Novartis Pharmaceuticals  (2003):", "alternatives_a": "Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole, Amantadine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250006, "ingredient1": "Entacapone", "ingredient2": "Diamorphine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296183/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 250007, "ingredient1": "Salbutamol", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296186/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250008, "ingredient1": "Amisulpride", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296187/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250009, "ingredient1": "Amitriptyline", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.  Several-fold increases in the effects of norepinephrine and, to a lesser extent, epinephrine and phenylephrine were reported in healthy subjects pretreated with desipramine, imipramine, or nortriptyline.  The mechanism is TCA inhibition of norepinephrine reuptake in adrenergic neurons, resulting in increased stimulation of adrenergic receptors.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis).  If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely.  Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296188/", "reference_text": "[1] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970):  1596-604[2] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968):  77-84[3] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[4] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979):  198-205[5] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982):  1025-8[6] ed., Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press  (1977):  275-83[7] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965):  403-16[8] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988):  566-8[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977):  238-53[11] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980):  1251-4", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250010, "ingredient1": "Amoxapine", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.  Several-fold increases in the effects of norepinephrine and, to a lesser extent, epinephrine and phenylephrine were reported in healthy subjects pretreated with desipramine, imipramine, or nortriptyline.  The mechanism is TCA inhibition of norepinephrine reuptake in adrenergic neurons, resulting in increased stimulation of adrenergic receptors.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis).  If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely.  Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296189/", "reference_text": "[1] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970):  1596-604[2] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968):  77-84[3] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[4] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979):  198-205[5] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982):  1025-8[6] ed., Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press  (1977):  275-83[7] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965):  403-16[8] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988):  566-8[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977):  238-53[11] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980):  1251-4", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250011, "ingredient1": "Amphetamine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296190/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250012, "ingredient1": "Arformoterol", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296192/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250013, "ingredient1": "Aripiprazole", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296193/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250014, "ingredient1": "Asenapine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296194/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250015, "ingredient1": "Atomoxetine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296195/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250016, "ingredient1": "Benzphetamine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296196/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250017, "ingredient1": "Brexpiprazole", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296198/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250018, "ingredient1": "Bupropion", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Translated with DeepL", "source": "DDInter", "management_text": "Caution is advised when bupropion is used with other drugs that increase dopaminergic or noradrenergic activity due to an increased risk of hypertension.  Blood pressure and heart rate should be measured prior to initiating bupropion therapy and monitored at regular intervals consistent with usual clinical practice, particularly in patients with preexisting hypertension.  Dose reduction or discontinuation of bupropion should be considered in patients who experience clinically significant and sustained increases in blood pressure or heart rate.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bupropion is used with other drugs that increase dopaminergic or noradrenergic activity due to an increased risk of hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296199/", "reference_text": "[1] \"Product Information. Zyban (bupropion).\" GlaxoSmithKline UK Ltd  (2022):[2] \"Product Information. Auvelity (bupropion-dextromethorphan).\" Axsome Therapeutics, Inc.  (2022):[3] \"Product Information. Wellbutrin XL (bupropion).\" Bausch Health, Canada Inc.  (2022):[4] \"Product Information. Contrave (bupropion-naltrexone).\" Currax Pharmaceuticals LLC  (2021):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Orlistat, Lorcaserin, Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250019, "ingredient1": "Chlorpromazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296200/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250020, "ingredient1": "Clomipramine", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.  Several-fold increases in the effects of norepinephrine and, to a lesser extent, epinephrine and phenylephrine were reported in healthy subjects pretreated with desipramine, imipramine, or nortriptyline.  The mechanism is TCA inhibition of norepinephrine reuptake in adrenergic neurons, resulting in increased stimulation of adrenergic receptors.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis).  If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely.  Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296201/", "reference_text": "[1] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970):  1596-604[2] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968):  77-84[3] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[4] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979):  198-205[5] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982):  1025-8[6] ed., Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press  (1977):  275-83[7] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965):  403-16[8] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988):  566-8[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977):  238-53[11] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980):  1251-4", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250021, "ingredient1": "Clozapine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296202/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250022, "ingredient1": "Cocaine (nasal)", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Concomitant use of cocaine with sympathomimetic agents such as epinephrine and phenylephrine may lead to additive cardiovascular effects.", "source": "DDInter", "management_text": "Concomitant use of cocaine with sympathomimetic agents should be avoided.  If coadministration is required, prolonged vital sign and ECG monitoring may be necessary.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cocaine with sympathomimetic agents should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296203/", "reference_text": "[1] \"Product Information. Adrenalin (EPINEPHrine).\" Apothecon Inc  (2022):[2] Nicholson K, Rogers J \"Cocaine and adrenaline paste: a fatal combination?\" Br Med J 311 (1995):  250-1[3] \"Product Information. Cocaine Hydrochloride (cocaine topical).\" Mallinckrodt Medical Inc  (2003):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cocaine Hydrochloride Nasal (cocaine nasal).\" Genus Lifesciences Inc.  (2018):[6] Thevasagyam M, Jindal M, Allsop P, Oates J \"Does epinephrine infiltration in septoplasty make any difference?\" Eur Arch Otorhinolaryngol 264 (2007):  1175-8[7] Kara CO, Kaftan A, Atalay H, Pinar HS, Ogmen G \"Cardiovascular safety of cocaine anaesthesia in the presence of adrenaline during septal surger.\" J Otolaryngol 30 (2001):  145-8", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250023, "ingredient1": "Cocaine (topical)", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Concomitant use of cocaine with sympathomimetic agents such as epinephrine and phenylephrine may lead to additive cardiovascular effects.", "source": "DDInter", "management_text": "Concomitant use of cocaine with sympathomimetic agents should be avoided.  If coadministration is required, prolonged vital sign and ECG monitoring may be necessary.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cocaine with sympathomimetic agents should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296204/", "reference_text": "[1] \"Product Information. Adrenalin (EPINEPHrine).\" Apothecon Inc  (2022):[2] Nicholson K, Rogers J \"Cocaine and adrenaline paste: a fatal combination?\" Br Med J 311 (1995):  250-1[3] \"Product Information. Cocaine Hydrochloride (cocaine topical).\" Mallinckrodt Medical Inc  (2003):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Cocaine Hydrochloride Nasal (cocaine nasal).\" Genus Lifesciences Inc.  (2018):[6] Thevasagyam M, Jindal M, Allsop P, Oates J \"Does epinephrine infiltration in septoplasty make any difference?\" Eur Arch Otorhinolaryngol 264 (2007):  1175-8[7] Kara CO, Kaftan A, Atalay H, Pinar HS, Ogmen G \"Cardiovascular safety of cocaine anaesthesia in the presence of adrenaline during septal surger.\" J Otolaryngol 30 (2001):  145-8", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250024, "ingredient1": "Deserpidine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296205/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Prazosin, Clonidine, Hydralazine, Guanfacine, Clonidine, Methyldopa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250025, "ingredient1": "Desipramine", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.  Several-fold increases in the effects of norepinephrine and, to a lesser extent, epinephrine and phenylephrine were reported in healthy subjects pretreated with desipramine, imipramine, or nortriptyline.  The mechanism is TCA inhibition of norepinephrine reuptake in adrenergic neurons, resulting in increased stimulation of adrenergic receptors.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis).  If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely.  Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296206/", "reference_text": "[1] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970):  1596-604[2] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968):  77-84[3] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[4] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979):  198-205[5] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982):  1025-8[6] ed., Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press  (1977):  275-83[7] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965):  403-16[8] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988):  566-8[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977):  238-53[11] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980):  1251-4", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250026, "ingredient1": "Desvenlafaxine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors.", "source": "DDInter", "management_text": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.  Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter.  Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296207/", "reference_text": "[1] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[2] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[3] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[4] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[5] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250027, "ingredient1": "Dexmethylphenidate", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296208/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250028, "ingredient1": "Dextroamphetamine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296209/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250029, "ingredient1": "Diethylpropion", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296210/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Orlistat, Lorcaserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250030, "ingredient1": "Digoxin", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "The concomitant use of sympathomimetic agents and cardiac glycosides may increase the risk of cardiac arrhythmias.", "source": "DDInter", "management_text": "Caution should be exercised if these two drugs are coadministered.  Electrocardiogram monitoring (ECG) is recommended.  The use of epinephrine (adrenaline) with high doses of digitalis glycosides is not recommended.", "mechanism_text": "Synergism", "recommendation": "Caution should be exercised if these two drugs are coadministered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296211/", "reference_text": "[1] \"Product Information. Isuprel (isoproterenol).\" Sanofi Winthrop Pharmaceuticals  (2001):[2] \"Product Information. Lanoxin (digoxin).\" Glaxo Wellcome  (2001):[3] \"Product Information. EPINEPHrine Hydrochloride (EPINEPHrine).\" Abbott Pharmaceutical  (2022):[4] \"Product Information. Claritin-D (loratadine-pseudoephedrine).\" Schering-Plough  (2001):[5] \"Product Information. Allegra-D (fexofenadine-pseudoephedrine).\" Chattem Consumer Products  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Digitoxin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250031, "ingredient1": "Dihydroergotamine", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors.", "source": "DDInter", "management_text": "Concomitant use of dihydroergotamine with other vasoconstrictive agents is considered contraindicated by the manufacturer.  Patients treated with dihydroergotamine should be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of dihydroergotamine with other vasoconstrictive agents is considered contraindicated by the manufacturer.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296212/", "reference_text": "[1] Buchanan N, Cane RD, Miller M \"Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine administration.\" Intensive Care Med 3 (1977):  55-6[2] Barthel W, Glusa E, Koth W \"Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.\" Int J Clin Pharmacol Ther Toxicol 25 (1987):  63-9[3] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[4] Chuang SS \"Finger ischemia secondary to the synergistic agonist effect of norepinephrine and ergonovine and in a burn patient.\" Burns 29 (2003):  92-4", "alternatives_a": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Zolmitriptan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250032, "ingredient1": "Doxapram", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296213/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Nitric Oxide, Ivacaftor, Elexacaftor, Lumacaftor", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250033, "ingredient1": "Doxepin", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.  Several-fold increases in the effects of norepinephrine and, to a lesser extent, epinephrine and phenylephrine were reported in healthy subjects pretreated with desipramine, imipramine, or nortriptyline.  The mechanism is TCA inhibition of norepinephrine reuptake in adrenergic neurons, resulting in increased stimulation of adrenergic receptors.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis).  If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely.  Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296214/", "reference_text": "[1] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970):  1596-604[2] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968):  77-84[3] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[4] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979):  198-205[5] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982):  1025-8[6] ed., Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press  (1977):  275-83[7] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965):  403-16[8] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988):  566-8[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977):  238-53[11] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980):  1251-4", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250034, "ingredient1": "Droxidopa", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Agents that increase blood pressure such as vasopressors, triptans, decongestants, beta-2 agonists, and amphetamines may potentiate the risk of supine hypertension associated with the use of droxidopa in the treatment of neurogenic orthostatic hypotension.", "source": "DDInter", "management_text": "Supine blood pressure should be monitored prior to and during droxidopa treatment, and more frequently when increasing dosage.  Patients should elevate the head of the bed when resting or sleeping, and have blood pressure also measured in this position.  Dosage reduction or discontinuation of droxidopa is recommended if supine hypertension cannot be managed by elevation of the head of the bed.  Supine hypertension that is not well managed may increase the risk of cardiovascular events, particularly stroke.", "mechanism_text": "Synergism", "recommendation": "Supine blood pressure should be monitored prior to and during droxidopa treatment, and more frequently when increasing dosage.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296215/", "reference_text": "[1] \"Product Information. Northera (droxidopa).\" Chelsea Therapeutics Inc  (2014):", "alternatives_a": "Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250035, "ingredient1": "Duloxetine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors.", "source": "DDInter", "management_text": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.  Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter.  Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296216/", "reference_text": "[1] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[2] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[3] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[4] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[5] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250036, "ingredient1": "Ergometrine", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors.  Ergot alkaloids produce arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors and inhibiting endothelial-derived relaxation factor release.", "source": "DDInter", "management_text": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.  If concomitant use is required, patients should be monitored for excessive vasoconstriction and have vital signs measured regularly.  Patients should also be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296217/", "reference_text": "[1] Buchanan N, Cane RD, Miller M \"Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine administration.\" Intensive Care Med 3 (1977):  55-6[2] Barthel W, Glusa E, Koth W \"Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.\" Int J Clin Pharmacol Ther Toxicol 25 (1987):  63-9[3] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[4] \"Product Information. Bellergal-S (ergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[5] \"Product Information. ProAmatine (midodrine).\" Roberts Pharmaceutical Corporation  (2001):[6] Chuang SS \"Finger ischemia secondary to the synergistic agonist effect of norepinephrine and ergonovine and in a burn patient.\" Burns 29 (2003):  92-4", "alternatives_a": "Misoprostol, Dinoprostone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250037, "ingredient1": "Ergotamine", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors.  Ergot alkaloids produce arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors and inhibiting endothelial-derived relaxation factor release.", "source": "DDInter", "management_text": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.  If concomitant use is required, patients should be monitored for excessive vasoconstriction and have vital signs measured regularly.  Patients should also be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296218/", "reference_text": "[1] Buchanan N, Cane RD, Miller M \"Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine administration.\" Intensive Care Med 3 (1977):  55-6[2] Barthel W, Glusa E, Koth W \"Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.\" Int J Clin Pharmacol Ther Toxicol 25 (1987):  63-9[3] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[4] \"Product Information. Bellergal-S (ergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[5] \"Product Information. ProAmatine (midodrine).\" Roberts Pharmaceutical Corporation  (2001):[6] Chuang SS \"Finger ischemia secondary to the synergistic agonist effect of norepinephrine and ergonovine and in a burn patient.\" Burns 29 (2003):  92-4", "alternatives_a": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Zolmitriptan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250038, "ingredient1": "Fluphenazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296219/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250039, "ingredient1": "Formoterol", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296220/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250040, "ingredient1": "Guanadrel", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296222/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250041, "ingredient1": "Guanethidine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296223/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Neostigmine, Brimonidine, Timolol, Levobunolol, Methazolamide, Pilocarpine, Physostigmine, Bimatoprost, Brinzolamide, Acetylcholine, Betaxolol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250042, "ingredient1": "Haloperidol", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296224/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250043, "ingredient1": "Iloperidone", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296225/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250044, "ingredient1": "Imipramine", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.  Several-fold increases in the effects of norepinephrine and, to a lesser extent, epinephrine and phenylephrine were reported in healthy subjects pretreated with desipramine, imipramine, or nortriptyline.  The mechanism is TCA inhibition of norepinephrine reuptake in adrenergic neurons, resulting in increased stimulation of adrenergic receptors.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis).  If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely.  Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296226/", "reference_text": "[1] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970):  1596-604[2] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968):  77-84[3] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[4] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979):  198-205[5] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982):  1025-8[6] ed., Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press  (1977):  275-83[7] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965):  403-16[8] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988):  566-8[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977):  238-53[11] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980):  1251-4", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250045, "ingredient1": "Indacaterol", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296227/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250046, "ingredient1": "Isocarboxazid", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296228/", "reference_text": "[1] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982):  482-4[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967):  75-8[5] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[6] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978):  284-5[7] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[8] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[9] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966):  673-83[10] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[11] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[12] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991):  462-7[14] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997):  322-3", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250047, "ingredient1": "Isoetharine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296229/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250048, "ingredient1": "Isoprenaline", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296230/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250049, "ingredient1": "Levonordefrin", "ingredient2": "Ketamine", "severity": "Moderate", "effect": "Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index.  Coadministration of ketamine with direct or indirect acting sympathomimetics or vasopressin may enhance the sympathomimetic effects of ketamine leading to additive increases in blood pressure and heart rate.", "source": "DDInter", "management_text": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.  Dosage adjustments should be considered according to the patient's clinical situation.  Some authorities suggest avoiding the use of ketamine in patients receiving drugs with a hypertensive effect such as ergometrine.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of vital signs, including blood pressure and heart rate is recommended whenever ketamine is used concomitantly with direct or indirect acting sympathomimetics or vasopressin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296231/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250050, "ingredient1": "Levosalbutamol", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296232/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250051, "ingredient1": "Levonordefrin", "ingredient2": "Levomilnacipran", "severity": "Moderate", "effect": "Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors.", "source": "DDInter", "management_text": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.  Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter.  Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296233/", "reference_text": "[1] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[2] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[3] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[4] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[5] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250052, "ingredient1": "Linezolid", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Linezolid may potentiate the pressor response to sympathomimetic agents.  Linezolid is a reversible, nonselective monoamine oxidase inhibitor (MAOI) and, as such, may enhance sympathomimetic effect by increasing norepinephrine storage in adrenergic neurons.  The interaction may be more likely to occur with indirect- or mixed-acting sympathomimetics such as pseudoephedrine or ephedrine than with direct-acting agents like epinephrine, norepinephrine, and isoproterenol.", "source": "DDInter", "management_text": "Unless blood pressure and clinical status can be closely monitored, linezolid should not be administered in combination with direct- or indirect-acting sympathomimetic agents (e.g., pseudoephedrine, phenylpropanolamine), vasopressive agents (e.g., epinephrine, norepinephrine), or dopaminergic agents (e.g., dopamine, dobutamine).  If the combination is used, lower initial dosages of adrenergic agents such as dopamine or epinephrine are recommended, with careful titration to the desired response.", "mechanism_text": "Synergism", "recommendation": "Unless blood pressure and clinical status can be closely monitored, linezolid should not be administered in combination with direct- or indirect-acting sympathomimetic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296235/", "reference_text": "[1] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[2] Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK \"Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.\" J Clin Pharmacol 41 (2001):  563-72", "alternatives_a": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Lefamulin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250053, "ingredient1": "Lisdexamfetamine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296237/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250054, "ingredient1": "Loxapine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296238/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250055, "ingredient1": "Lumateperone", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296239/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250056, "ingredient1": "Lurasidone", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296240/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250057, "ingredient1": "Mazindol", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296242/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Orlistat, Lorcaserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250058, "ingredient1": "Mesoridazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296243/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250059, "ingredient1": "Orciprenaline", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296244/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250060, "ingredient1": "Metamfetamine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296245/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250061, "ingredient1": "Methdilazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296246/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250062, "ingredient1": "Methotrimeprazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296247/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250063, "ingredient1": "Methylene blue", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296248/", "reference_text": "[1] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982):  482-4[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967):  75-8[5] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[6] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978):  284-5[7] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[8] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[9] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966):  673-83[10] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[11] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[12] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991):  462-7[14] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997):  322-3", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250064, "ingredient1": "Methylergometrine", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors.  Ergot alkaloids produce arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors and inhibiting endothelial-derived relaxation factor release.", "source": "DDInter", "management_text": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.  If concomitant use is required, patients should be monitored for excessive vasoconstriction and have vital signs measured regularly.  Patients should also be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296249/", "reference_text": "[1] Buchanan N, Cane RD, Miller M \"Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine administration.\" Intensive Care Med 3 (1977):  55-6[2] Barthel W, Glusa E, Koth W \"Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.\" Int J Clin Pharmacol Ther Toxicol 25 (1987):  63-9[3] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[4] \"Product Information. Bellergal-S (ergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[5] \"Product Information. ProAmatine (midodrine).\" Roberts Pharmaceutical Corporation  (2001):[6] Chuang SS \"Finger ischemia secondary to the synergistic agonist effect of norepinephrine and ergonovine and in a burn patient.\" Burns 29 (2003):  92-4", "alternatives_a": "Misoprostol, Dinoprostone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250065, "ingredient1": "Methylphenidate", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296250/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250066, "ingredient1": "Methysergide", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central vasoconstrictors.  Ergot alkaloids produce arterial vasoconstriction by stimulating alpha-adrenergic and serotonin receptors and inhibiting endothelial-derived relaxation factor release.", "source": "DDInter", "management_text": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.  If concomitant use is required, patients should be monitored for excessive vasoconstriction and have vital signs measured regularly.  Patients should also be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Ergot alkaloids should generally not be administered in combination with other vasoconstrictive agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296251/", "reference_text": "[1] Buchanan N, Cane RD, Miller M \"Symmetrical gangrene of the extremities associated with the use of dopamine subsequent to ergometrine administration.\" Intensive Care Med 3 (1977):  55-6[2] Barthel W, Glusa E, Koth W \"Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ.\" Int J Clin Pharmacol Ther Toxicol 25 (1987):  63-9[3] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[4] \"Product Information. Bellergal-S (ergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[5] \"Product Information. ProAmatine (midodrine).\" Roberts Pharmaceutical Corporation  (2001):[6] Chuang SS \"Finger ischemia secondary to the synergistic agonist effect of norepinephrine and ergonovine and in a burn patient.\" Burns 29 (2003):  92-4", "alternatives_a": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Zolmitriptan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250067, "ingredient1": "Midodrine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "The pressor effects of midodrine may be potentiated by the concomitant use of other agents that cause vasoconstriction, including sympathomimetics and ergot alkaloids.  Midodrine is an alpha-adrenergic agonist and may cause marked elevation of supine arterial blood pressure, or supine hypertension.", "source": "DDInter", "management_text": "Caution is advised if midodrine must be used in combination with other agents that can increase blood pressure.  Supine and sitting blood pressures should be closely monitored.  Supine hypertension can often be controlled by keeping the patient from being fully supine, for example, sleeping with the head of the bed elevated.  Taking the last daily dose of midodrine 3 to 4 hours before bedtime may also help to minimize nighttime supine hypertension.  Patients should be advised to contact their physician immediately if they experience symptoms of supine hypertension such as cardiac awareness, pounding in the ears, headache, and blurred vision.  Midodrine should be discontinued if supine hypertension persists.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if midodrine must be used in combination with other agents that can increase blood pressure.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296252/", "reference_text": "[1] \"Product Information. ProAmatine (midodrine).\" Roberts Pharmaceutical Corporation  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250068, "ingredient1": "Milnacipran", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors.", "source": "DDInter", "management_text": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.  Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter.  Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296253/", "reference_text": "[1] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[2] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[3] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[4] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[5] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250069, "ingredient1": "Molindone", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296254/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250070, "ingredient1": "Nortriptyline", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.  Several-fold increases in the effects of norepinephrine and, to a lesser extent, epinephrine and phenylephrine were reported in healthy subjects pretreated with desipramine, imipramine, or nortriptyline.  The mechanism is TCA inhibition of norepinephrine reuptake in adrenergic neurons, resulting in increased stimulation of adrenergic receptors.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis).  If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely.  Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296255/", "reference_text": "[1] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970):  1596-604[2] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968):  77-84[3] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[4] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979):  198-205[5] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982):  1025-8[6] ed., Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press  (1977):  275-83[7] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965):  403-16[8] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988):  566-8[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977):  238-53[11] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980):  1251-4", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250071, "ingredient1": "Olanzapine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296256/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250072, "ingredient1": "Olodaterol", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296257/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250073, "ingredient1": "Oxytocin", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Concomitant use of oxytocic agents with sympathomimetic amines may increase the risk of hypertension due to additive vasoconstrictive effects.", "source": "DDInter", "management_text": "Close monitoring of blood pressure is recommended during coadministration.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of blood pressure is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296258/", "reference_text": "[1] \"Product Information. Syntocinon (oxytocin).\" Sandoz Pharmaceuticals Corporation  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Misoprostol, Dinoprostone, Terlipressin, Desmopressin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250074, "ingredient1": "Ozanimod", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296259/", "reference_text": "[1] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982):  482-4[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967):  75-8[5] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[6] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978):  284-5[7] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[8] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[9] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966):  673-83[10] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[11] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[12] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991):  462-7[14] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997):  322-3", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250075, "ingredient1": "Paliperidone", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296260/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250076, "ingredient1": "Perphenazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296261/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250077, "ingredient1": "Phendimetrazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296262/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250078, "ingredient1": "Phenelzine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296263/", "reference_text": "[1] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982):  482-4[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967):  75-8[5] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[6] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978):  284-5[7] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[8] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[9] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966):  673-83[10] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[11] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[12] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991):  462-7[14] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997):  322-3", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250079, "ingredient1": "Phentermine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296264/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Orlistat, Lorcaserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250080, "ingredient1": "Phenylpropanolamine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents.  Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.  Pulse and blood pressure should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296265/", "reference_text": "[1] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr \"Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients.\" Psychiatry Res 1 (1979):  45-52[2] Cavanaugh JH, Griffith JD, Oates JA \"Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.\" Clin Pharmacol Ther 11 (1970):  656[3] \"Product Information. Adderall (amphetamine-dextroamphetamine).\" Shire Richwood Pharmaceutical Company Inc  (2001):[4] \"Product Information. Tenuate (diethylpropion).\" Aventis Pharmaceuticals  (2001):[5] \"Product Information. Sanorex (mazindol).\" Novartis Pharmaceuticals  (2001):[6] \"Product Information. Focalin (dexmethylphenidate).\" Mikart Inc  (2001):[7] \"Product Information. Strattera (atomoxetine).\" Lilly, Eli and Company  (2002):", "alternatives_a": "Pseudoephedrine, Phenylephrine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250081, "ingredient1": "Pimozide", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296266/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250082, "ingredient1": "Pirbuterol", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296267/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Ephedrine, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250083, "ingredient1": "Procarbazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296268/", "reference_text": "[1] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982):  482-4[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967):  75-8[5] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[6] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978):  284-5[7] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[8] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[9] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966):  673-83[10] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[11] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[12] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991):  462-7[14] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997):  322-3", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250084, "ingredient1": "Prochlorperazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296269/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250085, "ingredient1": "Promazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296270/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250086, "ingredient1": "Promethazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296271/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250087, "ingredient1": "Propiomazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296272/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250088, "ingredient1": "Protriptyline", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.  Several-fold increases in the effects of norepinephrine and, to a lesser extent, epinephrine and phenylephrine were reported in healthy subjects pretreated with desipramine, imipramine, or nortriptyline.  The mechanism is TCA inhibition of norepinephrine reuptake in adrenergic neurons, resulting in increased stimulation of adrenergic receptors.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis).  If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely.  Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296273/", "reference_text": "[1] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970):  1596-604[2] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968):  77-84[3] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[4] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979):  198-205[5] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982):  1025-8[6] ed., Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press  (1977):  275-83[7] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965):  403-16[8] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988):  566-8[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977):  238-53[11] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980):  1251-4", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250089, "ingredient1": "Quetiapine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296274/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250090, "ingredient1": "Racepinephrine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296275/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250091, "ingredient1": "Rasagiline", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296276/", "reference_text": "[1] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982):  482-4[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967):  75-8[5] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[6] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978):  284-5[7] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[8] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[9] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966):  673-83[10] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[11] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[12] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991):  462-7[14] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997):  322-3", "alternatives_a": "Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Entacapone, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250092, "ingredient1": "Reserpine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished.  Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.", "source": "DDInter", "management_text": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.  Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines.  If the combination is used, blood pressure and heart rate should be closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296278/", "reference_text": "[1] Spiers AS, Calne DB \"Action of dopamine on the human iris.\" Br Med J 4 (1969):  333-5[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS \"Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine.\" Clin Pharmacol Ther 6 (1965):  757-62[3] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Prazosin, Clonidine, Hydralazine, Guanfacine, Clonidine, Methyldopa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250093, "ingredient1": "Risperidone", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296279/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250094, "ingredient1": "Ritodrine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296280/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250095, "ingredient1": "Salmeterol", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296281/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250096, "ingredient1": "Selegiline", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296282/", "reference_text": "[1] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982):  482-4[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967):  75-8[5] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[6] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978):  284-5[7] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[8] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[9] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966):  673-83[10] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[11] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[12] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991):  462-7[14] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997):  322-3", "alternatives_a": "Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Entacapone, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250097, "ingredient1": "Sibutramine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Additive or synergistic effects on blood pressure and heart rate may occur when sibutramine is combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors.", "source": "DDInter", "management_text": "Caution is advised if sibutramine is coadministered with other drugs that can increase blood pressure and/or heart rate.  Blood pressure and pulse should be measured prior to initiating therapy with sibutramine and monitored at regular intervals thereafter.  Dose reduction or discontinuation of sibutramine should be considered in patients who experience a sustained increase in blood pressure or pulse rate.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if sibutramine is coadministered with other drugs that can increase blood pressure and/or heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296283/", "reference_text": "[1] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Orlistat, Lorcaserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250098, "ingredient1": "Solriamfetol", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Additive or synergistic effects on blood pressure and/or heart rate may occur when solriamfetol is combined with other drugs that increase blood pressure and/or heart rate.", "source": "DDInter", "management_text": "Caution is advised if solriamfetol is used with other drugs that increase blood pressure and/or heart rate.  Blood pressure should be monitored prior to initiating solriamfetol therapy and regularly during treatment.  In addition, hypertension should be controlled prior to treatment, and any new-onset hypertension or exacerbations of pre-existing hypertension that occur during solriamfetol therapy should be treated.  Discontinuation of solriamfetol should be considered in patients who experience an increase in blood pressure or heart rate that cannot be managed with dose reduction of solriamfetol or other appropriate medical intervention.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if solriamfetol is used with other drugs that increase blood pressure and/or heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296284/", "reference_text": "[1] \"Product Information. Sunosi (solriamfetol).\" Jazz Pharmaceuticals  (2019):", "alternatives_a": "Pemoline, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250099, "ingredient1": "Tapentadol", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors.", "source": "DDInter", "management_text": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.  Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter.  Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296285/", "reference_text": "[1] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[2] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[3] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[4] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[5] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):", "alternatives_a": "Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Ibuprofen, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250100, "ingredient1": "Terbutaline", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects.", "source": "DDInter", "management_text": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.  Blood pressure and heart rate should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296286/", "reference_text": "[1] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE \"Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.\" Lancet 336 (1990):  1396-9[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Serevent (salmeterol).\" Glaxo Wellcome[4] \"Product Information. Maxair (pirbuterol).\" 3M Pharmaceuticals  (2001):[5] \"Product Information. Xopenex (levalbuterol).\" Sepracor Inc  (2001):[6] \"Product Information. Foradil (formoterol).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[8] Lowe MD, Rowland E, Brown MJ, Grace AA \"Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium.\" Heart 86 (2001):  45-51[9] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[10] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[11] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Ephedrine, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Epinephrine, Fluticasone, Cromoglicic acid, Ipratropium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250101, "ingredient1": "Thiethylperazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296287/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250102, "ingredient1": "Thioridazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296288/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250103, "ingredient1": "Thiothixene", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296289/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250104, "ingredient1": "Thyroid, porcine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "The concomitant use of thyroid hormones, especially large doses, with sympathomimetic drugs may potentiate sympathomimetic effects and increase the risk of cardiac insufficiency in patients who have coronary artery disease.", "source": "DDInter", "management_text": "Monitoring for increased sympathomimetic effects and cardiac function may be advisable.", "mechanism_text": "Synergism", "recommendation": "Monitoring for increased sympathomimetic effects and cardiac function may be advisable.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296290/", "reference_text": "[1] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[2] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250105, "ingredient1": "Tranylcypromine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "While monoamine oxidase inhibitors (MAOIs) reportedly do not significantly enhance the hypertensive effects of direct-acting sympathomimetic amines, caution is nevertheless advised when these agents are used together.", "source": "DDInter", "management_text": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, methylene blue, procarbazine).", "mechanism_text": "Synergism", "recommendation": "Blood pressure and heart rate should be monitored during coadministration of direct-acting sympathomimetic agents with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296291/", "reference_text": "[1] Smookler S, Barmudez AJ \"Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant.\" Ann Emerg Med 11 (1982):  482-4[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Elis J, Laurence DR, Mattie H, Prichard BN \"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.\" Br Med J 2 (1967):  75-8[5] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[6] Wright SP \"Hazards with monoamine-oxidase inhibitors: a persistent problem.\" Lancet 1 (1978):  284-5[7] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[8] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[9] Sjoerdsma A \"Catecholamine-drug interactions in man.\" Pharmacol Rev 18 (1966):  673-83[10] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[11] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[12] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[13] Cusson JR, Goldenberg E, Larochelle P \"Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.\" J Clin Pharmacol 31 (1991):  462-7[14] Thompson DS, Sweet RA, Marzula K, Peredes JC \"Lack of interaction of monoamine oxidase inhibitors and epinephrine in an older patient.\" J Clin Psychopharmacol 17 (1997):  322-3", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250106, "ingredient1": "Trifluoperazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296292/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250107, "ingredient1": "Triflupromazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296293/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250108, "ingredient1": "Alimemazine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296294/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250109, "ingredient1": "Trimipramine", "ingredient2": "Levonordefrin", "severity": "Major", "effect": "Tricyclic antidepressants (TCAs) may markedly enhance the pressor response to parenteral direct-acting sympathomimetic agents and vasoconstrictor-containing local anesthetics.  Several-fold increases in the effects of norepinephrine and, to a lesser extent, epinephrine and phenylephrine were reported in healthy subjects pretreated with desipramine, imipramine, or nortriptyline.  The mechanism is TCA inhibition of norepinephrine reuptake in adrenergic neurons, resulting in increased stimulation of adrenergic receptors.", "source": "DDInter", "management_text": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.g., treatment of anaphylaxis).  If concomitant use is necessary, initial dose and rate of administration of the sympathomimetic should be reduced, and cardiovascular status including blood pressure should be monitored closely.  Although clinical data are lacking, it may be prudent to follow the same precaution with mixed-acting sympathomimetic agents.", "mechanism_text": "Synergism", "recommendation": "Parenteral administration of direct-acting sympathomimetic agents should preferably be avoided during therapy with tricyclic antidepressants except in cases of emergency (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296295/", "reference_text": "[1] Mitchell JR, Cavanaugh JH, Arias L, Oates JA \"Guanethidine and related agents. III: antagonism by drugs which inhibit the norepinephrine pump in man.\" J Clin Invest 49 (1970):  1596-604[2] Svedmyr N \"The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man.\" Life Sci 7 (1968):  77-84[3] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN \"Interactions between sympathomimetic amines and antidepressant agents in man.\" Br Med J 1 (1973):  311-5[4] Borg KO, Johnsson G, Jordo L, Lundborg P, Ronn O, Welin-Fogelberg I \"Interaction studies between three antidepressant drugs (zimelidine, imipramine and chlorimipramine) and noradrenaline in healthy volunteers and some pharmacokinetics of the drugs studied.\" Acta Pharmacol Toxicol (Copenh) 45 (1979):  198-205[5] Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ \"Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients.\" Arch Gen Psychiatry 39 (1982):  1025-8[6] ed., Boakes AJ. Vasoconstrictors in local anaesthetics and tricyclic antidepressants. In: Grahame-Smith, DG \"Drug Interactions. QV 38 D7932 1975.\" Baltimore, MD: University Park Press  (1977):  275-83[7] Fritz H, Hagstam KE, Lindqvist B \"Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases.\" Acta Med Scand 178 (1965):  403-16[8] Teba L, Schiebel F, Dedhia HV, Lazzell VA \"Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose.\" Am J Emerg Med 6 (1988):  566-8[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] Niemegeers CJ, Lenaerts FM, Artois KS, Janssen PA \"Interaction of drugs with apomorphine, tryptamine and norepinephrine. A new 'in vivo' approach: the ATN-test in rats.\" Arch Int Pharmacodyn Ther 227 (1977):  238-53[11] Ghose K \"Sympathomimetic amines and tricyclic antidepressant drugs.\" Neuropharmacology 19 (1980):  1251-4", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250110, "ingredient1": "Venlafaxine", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors.", "source": "DDInter", "management_text": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.  Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter.  Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296296/", "reference_text": "[1] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[2] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[3] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[4] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[5] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[6] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):", "alternatives_a": "Citalopram, Sertraline, Paroxetine, Maprotiline, Fluoxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250111, "ingredient1": "Ziprasidone", "ingredient2": "Levonordefrin", "severity": "Moderate", "effect": "Phenothiazines and other neuroleptics may inhibit or reverse the pressor effect of adrenaline (epinephrine), dopamine, and similar vasoconstrictors.  Many of these agents, including the atypical antipsychotics, exhibit alpha-1 adrenergic blocking activity and produce hypotension as an adverse effect.  Use of adrenaline or dopamine for drug-induced hypotension and circulatory collapse in patients receiving neuroleptic therapy may cause a paradoxical further lowering of blood pressure, since beta stimulation may worsen hypotension in the setting of alpha blockade.", "source": "DDInter", "management_text": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.  Alternative vasopressor agents such as metaraminol, noradrenaline (norepinephrine), or phenylephrine should be considered, and vital signs closely monitored.", "mechanism_text": "Antagonism", "recommendation": "Adrenaline, dopamine, and similar vasoconstrictors should not be used to treat drug-induced hypotension and circulatory collapse in patients taking phenothiazines or other neuroleptic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296297/", "reference_text": "[1] Foster CA, O'Mullane EJ, Gaskell P, Churchill-Davidson HC \"Chlorpromazine: a study of its action on the circulation in man.\" Lancet 2 (1954):  614-7[2] Ginsburg J, Duff RS \"Effect of chlorpromazine on adrenaline vasoconstriction in man.\" Br J Pharmacol 11 (1956):  180-5[3] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[4] \"Product Information. Phenergan (promethazine).\" Wyeth-Ayerst Laboratories  (2001):[5] \"Product Information. Navane (thiothixene).\" Roerig Division  (2001):[6] Lear E, Chiron AE, Pallin IM \"A clinical study of mechanisms of action of chlorpromazine.\" JAMA 163 (1957):  30-6[7] Gonzalez ER \"Catecholamine selection for vasopressor-dependent patients.\" Clin Pharm 7 (1988):  493, 496[8] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[9] Goulet JP, Perusse R, Turcotte JY \"Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions.\" Oral Surg Oral Med Oral Pathol 74 (1992):  692-7[10] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[11] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[12] \"Product Information. Moban (molindone).\" Gate Pharmaceuticals  (2001):[13] \"Product Information. Torecan (thiethylperazine).\" Roxane Laboratories Inc  (2001):[14] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[15] \"Product Information. Loxitane C (loxapine).\" Apothecon Inc  (2022):[16] Sletten IW, Lang WJ, Brown ML, Ballou SR, Gershon S \"Chronic chlorpromazine administration: some pharmacological and psychological effects in man.\" Clin Pharmacol Ther 6 (1965):  575-86[17] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[18] \"Product Information. Invega (paliperidone).\" Janssen Pharmaceuticals  (2007):", "alternatives_a": "Cariprazine, Droperidol, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250112, "ingredient1": "Human adenovirus e serotype 4 strain cl-68578 antigen", "ingredient2": "Decitabine", "severity": "Moderate", "effect": "There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.  It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.", "source": "DDInter", "management_text": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.  Caution is advised.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296298/", "reference_text": "[1] \"Product Information. Adenovirus Vaccine Type 4 and Type 7 (adenovirus vaccine, live).\" Teva Pharmaceuticals USA  (2016):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250113, "ingredient1": "Cedazuridine", "ingredient2": "Azacitidine", "severity": "Moderate", "effect": "Coadministration with cedazuridine may increase the systemic exposure of drugs that are metabolized by the cytidine deaminase (CDA) enzyme.  The mechanism involves inhibition of CDA by cedazuridine.  Increased toxicity or altered efficacy of CDA substrates may result.", "source": "DDInter", "management_text": "Coadministration of cedazuridine with drugs that are metabolized by CDA should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of cedazuridine with drugs that are metabolized by CDA should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296299/", "reference_text": "[1] \"Product Information. Xeloda (capecitabine).\" Roche Laboratories  (2001):[2] Garcia-Manero G, Stoltz M, Ward M, et al. \"A pilot pharmacokinetic study of oral azacitidine.\" Leukemia 22 (2008):  1680-4[3] Bhatla D, Gerbing RB, Alonzo TA, et al. \"Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.\" Br J Haematol 144 (2009):  388-94[4] Gilbert JA, Salavaggione OE, Ji Y, et al. \"Gemcitabine pharmacogenomics: dytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.\" Clin Cancer Res 12 (2006):  1794-803[5] \"Product Information. Inqovi (cedazuridine-decitabine).\" Taiho Oncology, Inc.  (2020):", "alternatives_a": "Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250114, "ingredient1": "Cedazuridine", "ingredient2": "Capecitabine", "severity": "Moderate", "effect": "Coadministration with cedazuridine may increase the systemic exposure of drugs that are metabolized by the cytidine deaminase (CDA) enzyme.  The mechanism involves inhibition of CDA by cedazuridine.  Increased toxicity or altered efficacy of CDA substrates may result.", "source": "DDInter", "management_text": "Coadministration of cedazuridine with drugs that are metabolized by CDA should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of cedazuridine with drugs that are metabolized by CDA should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296300/", "reference_text": "[1] \"Product Information. Xeloda (capecitabine).\" Roche Laboratories  (2001):[2] Garcia-Manero G, Stoltz M, Ward M, et al. \"A pilot pharmacokinetic study of oral azacitidine.\" Leukemia 22 (2008):  1680-4[3] Bhatla D, Gerbing RB, Alonzo TA, et al. \"Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.\" Br J Haematol 144 (2009):  388-94[4] Gilbert JA, Salavaggione OE, Ji Y, et al. \"Gemcitabine pharmacogenomics: dytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.\" Clin Cancer Res 12 (2006):  1794-803[5] \"Product Information. Inqovi (cedazuridine-decitabine).\" Taiho Oncology, Inc.  (2020):", "alternatives_a": "Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250115, "ingredient1": "Cytarabine", "ingredient2": "Cedazuridine", "severity": "Moderate", "effect": "Coadministration with cedazuridine may increase the systemic exposure of drugs that are metabolized by the cytidine deaminase (CDA) enzyme.  The mechanism involves inhibition of CDA by cedazuridine.  Increased toxicity or altered efficacy of CDA substrates may result.", "source": "DDInter", "management_text": "Coadministration of cedazuridine with drugs that are metabolized by CDA should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of cedazuridine with drugs that are metabolized by CDA should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296301/", "reference_text": "[1] \"Product Information. Xeloda (capecitabine).\" Roche Laboratories  (2001):[2] Garcia-Manero G, Stoltz M, Ward M, et al. \"A pilot pharmacokinetic study of oral azacitidine.\" Leukemia 22 (2008):  1680-4[3] Bhatla D, Gerbing RB, Alonzo TA, et al. \"Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.\" Br J Haematol 144 (2009):  388-94[4] Gilbert JA, Salavaggione OE, Ji Y, et al. \"Gemcitabine pharmacogenomics: dytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.\" Clin Cancer Res 12 (2006):  1794-803[5] \"Product Information. Inqovi (cedazuridine-decitabine).\" Taiho Oncology, Inc.  (2020):", "alternatives_a": "Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250116, "ingredient1": "Cytarabine (liposomal)", "ingredient2": "Cedazuridine", "severity": "Moderate", "effect": "Coadministration with cedazuridine may increase the systemic exposure of drugs that are metabolized by the cytidine deaminase (CDA) enzyme.  The mechanism involves inhibition of CDA by cedazuridine.  Increased toxicity or altered efficacy of CDA substrates may result.", "source": "DDInter", "management_text": "Coadministration of cedazuridine with drugs that are metabolized by CDA should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of cedazuridine with drugs that are metabolized by CDA should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296302/", "reference_text": "[1] \"Product Information. Xeloda (capecitabine).\" Roche Laboratories  (2001):[2] Garcia-Manero G, Stoltz M, Ward M, et al. \"A pilot pharmacokinetic study of oral azacitidine.\" Leukemia 22 (2008):  1680-4[3] Bhatla D, Gerbing RB, Alonzo TA, et al. \"Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.\" Br J Haematol 144 (2009):  388-94[4] Gilbert JA, Salavaggione OE, Ji Y, et al. \"Gemcitabine pharmacogenomics: dytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.\" Clin Cancer Res 12 (2006):  1794-803[5] \"Product Information. Inqovi (cedazuridine-decitabine).\" Taiho Oncology, Inc.  (2020):", "alternatives_a": "Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250117, "ingredient1": "Gemcitabine", "ingredient2": "Cedazuridine", "severity": "Moderate", "effect": "Coadministration with cedazuridine may increase the systemic exposure of drugs that are metabolized by the cytidine deaminase (CDA) enzyme.  The mechanism involves inhibition of CDA by cedazuridine.  Increased toxicity or altered efficacy of CDA substrates may result.", "source": "DDInter", "management_text": "Coadministration of cedazuridine with drugs that are metabolized by CDA should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of cedazuridine with drugs that are metabolized by CDA should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296303/", "reference_text": "[1] \"Product Information. Xeloda (capecitabine).\" Roche Laboratories  (2001):[2] Garcia-Manero G, Stoltz M, Ward M, et al. \"A pilot pharmacokinetic study of oral azacitidine.\" Leukemia 22 (2008):  1680-4[3] Bhatla D, Gerbing RB, Alonzo TA, et al. \"Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.\" Br J Haematol 144 (2009):  388-94[4] Gilbert JA, Salavaggione OE, Ji Y, et al. \"Gemcitabine pharmacogenomics: dytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.\" Clin Cancer Res 12 (2006):  1794-803[5] \"Product Information. Inqovi (cedazuridine-decitabine).\" Taiho Oncology, Inc.  (2020):", "alternatives_a": "Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250118, "ingredient1": "Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)", "ingredient2": "Decitabine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition.  Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.  However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases.  Local guidelines and prescribing information for individual vaccines should be consulted.  For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease.  For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.  For SARS-CoV-2 (COVID-19) vaccines, vaccination should preferably be completed at least two weeks before initiation or resumption of immunosuppressive therapies; however, decisions to delay or temporarily withhold immunosuppressive therapy to complete COVID-19 vaccination should consider the individual's risks relative to their underlying condition.  Additional shots and/or boosters may be appropriate depending on age, prior COVID-19 vaccine formulation(s) received, and other factors in individuals with moderate to severe immune compromise due to medical conditions or immunosuppressive medications or treatments (e.g., solid organ transplant recipients on immunosuppressive therapy; patients on active treatment for solid tumor and hematologic malignancies).  Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "In general, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296304/", "reference_text": "[1] \"Product Information. Fluzone (influenza virus vaccine, inactivated).\" Connaught Laboratories Inc[2] \"Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete)).\" SmithKline Beecham[3] \"Product Information. Havrix (hepatitis A adult vaccine).\" SmithKline Beecham[4] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993):  1-18[5] \"Product Information. Imovax Rabies (rabies vaccine, human diploid cell).\" sanofi pasteur  (2022):[6] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc.  (2003):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline  (2022):[9] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence.  https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf\"   (2019):[10] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations.  https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf\"   (2019):[11] CDC Centers for Disease Control and Prevention \"Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States.  https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html\"   (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250119, "ingredient1": "Decitabine", "ingredient2": "Radium Ra 223 dichloride", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296307/", "reference_text": "[1] \"Product Information. Xofigo (radium Ra 223 dichloride).\" Bayer Pharmaceutical Inc  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250120, "ingredient1": "Decitabine", "ingredient2": "Tafasitamab", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.  Dosing adjustments may be necessary.  The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296308/", "reference_text": "[1] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb  (2001):[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):[3] \"Product Information. Fluorouracil (fluorouracil).\" Roche Laboratories  (2022):[4] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn  (2001):[5] \"Product Information. Ellence (epirubicin).\" Pharmacia and Upjohn  (2001):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 250121, "ingredient1": "Valproic acid", "ingredient2": "Benzocaine (topical)", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296309/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250122, "ingredient1": "Benzocaine (topical)", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296310/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Minoxidil, Diazoxide, Hydralazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250123, "ingredient1": "Tetracaine (topical)", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296311/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Fluorometholone, Zinc gluconate, Nitroglycerin, Meloxicam, Tripelennamine, More", "alternatives_b": "Minoxidil, Diazoxide, Hydralazine", "updated_at": 1767369485}, {"id": 250124, "ingredient1": "Benzocaine (topical)", "ingredient2": "Nitrous oxide", "severity": "Moderate", "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.", "source": "DDInter", "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296312/", "reference_text": "[1] Karim A, Ahmed S, Siddiqui R, Mattana J \"Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.\" Am J Med 111 (2001):  150-3[2] \"Product Information. Hurricaine (benzocaine topical).\" Beutlich  (2005):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Guay J \"Methemoglobinemia related to local anesthetics: a summary of 242 episodes.\" Anesth Analg 108 (2009):  837-45[6] Skold A, Cosco DL, Klein R \"Methemoglobinemia: pathogenesis, diagnosis, and management.\" South Med J 104 (2011):  757-61[7] \"Product Information. Chloraseptic (benzocaine-menthol topical).\" Prestige Brands (formerly MedTech)  (2020):[8] \"Product Information. Diclona (diclofenac-lidocaine topical).\" Terrain Pharmaceuticals  (2022):", "alternatives_a": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Sufentanil, Propofol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250125, "ingredient1": "Benzocaine (topical)", "ingredient2": "Sulfadiazine", "severity": "Moderate", "effect": "Ester-type local anesthetics are hydrolyzed to paraaminobenzoic acid, which can inhibit the action of sulfonamides.", "source": "DDInter", "management_text": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.  Amide-type anesthetics are not expected to inhibit the action of sulfonamides and may be considered as alternatives (e.g., bupivacaine, levobupivacaine, lidocaine, mepivacaine).  However, caution is advised due to the potential for development of methemoglobinemia.  Likewise, caution should be exercised when topical formulations of ester-type local anesthetics are administered to patients receiving sulfonamides, particularly when applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Antagonism", "recommendation": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296313/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Trimethoprim, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250126, "ingredient1": "Benzocaine (topical)", "ingredient2": "Sulfadoxine", "severity": "Moderate", "effect": "Ester-type local anesthetics are hydrolyzed to paraaminobenzoic acid, which can inhibit the action of sulfonamides.", "source": "DDInter", "management_text": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.  Amide-type anesthetics are not expected to inhibit the action of sulfonamides and may be considered as alternatives (e.g., bupivacaine, levobupivacaine, lidocaine, mepivacaine).  However, caution is advised due to the potential for development of methemoglobinemia.  Likewise, caution should be exercised when topical formulations of ester-type local anesthetics are administered to patients receiving sulfonamides, particularly when applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Antagonism", "recommendation": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296314/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Tamsulosin, Tinidazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250127, "ingredient1": "Benzocaine (topical)", "ingredient2": "Sulfamethoxazole", "severity": "Moderate", "effect": "Ester-type local anesthetics are hydrolyzed to paraaminobenzoic acid, which can inhibit the action of sulfonamides.", "source": "DDInter", "management_text": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.  Amide-type anesthetics are not expected to inhibit the action of sulfonamides and may be considered as alternatives (e.g., bupivacaine, levobupivacaine, lidocaine, mepivacaine).  However, caution is advised due to the potential for development of methemoglobinemia.  Likewise, caution should be exercised when topical formulations of ester-type local anesthetics are administered to patients receiving sulfonamides, particularly when applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Antagonism", "recommendation": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296315/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250128, "ingredient1": "Benzocaine (topical)", "ingredient2": "Sulfasalazine", "severity": "Moderate", "effect": "Ester-type local anesthetics are hydrolyzed to paraaminobenzoic acid, which can inhibit the action of sulfonamides.", "source": "DDInter", "management_text": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.  Amide-type anesthetics are not expected to inhibit the action of sulfonamides and may be considered as alternatives (e.g., bupivacaine, levobupivacaine, lidocaine, mepivacaine).  However, caution is advised due to the potential for development of methemoglobinemia.  Likewise, caution should be exercised when topical formulations of ester-type local anesthetics are administered to patients receiving sulfonamides, particularly when applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Antagonism", "recommendation": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296316/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250129, "ingredient1": "Tetracaine (topical)", "ingredient2": "Sulfasalazine", "severity": "Moderate", "effect": "Ester-type local anesthetics are hydrolyzed to paraaminobenzoic acid, which can inhibit the action of sulfonamides.", "source": "DDInter", "management_text": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.  Amide-type anesthetics are not expected to inhibit the action of sulfonamides and may be considered as alternatives (e.g., bupivacaine, levobupivacaine, lidocaine, mepivacaine).  However, caution is advised due to the potential for development of methemoglobinemia.  Likewise, caution should be exercised when topical formulations of ester-type local anesthetics are administered to patients receiving sulfonamides, particularly when applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Antagonism", "recommendation": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296317/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate, Clemastine, Mepyramine, Diphenhydramine, More", "updated_at": 1767369485}, {"id": 250130, "ingredient1": "Clofedanol", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296318/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Benzonatate", "alternatives_b": "Vilazodone, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Bupropion", "updated_at": 1767369485}, {"id": 250131, "ingredient1": "Chlorcyclizine", "ingredient2": "Azatadine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296319/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Chlorcyclizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, Tripelennamine, Azelastine, Cyclizine, More", "updated_at": 1767369485}, {"id": 250132, "ingredient1": "Chlorcyclizine", "ingredient2": "Candida albicans", "severity": "Moderate", "effect": "Antihistamines may diminish the response to diagnostic skin test antigens.", "source": "DDInter", "management_text": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "mechanism_text": "Antagonism", "recommendation": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296320/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] NLM. National Library of Medicine. NIH. National Institutes of Health \"Trichophyton for intradermal skin testing (trichophyton mentagrophytes and trichophyton rubrum) injection [Allermed Laboratories, Inc.]  http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaeffe62-b538-43ca-a3b9-47e28b765d89\"   (2014):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Doxylamine, Meclizine, Dimenhydrinate, Alimemazine, Thiethylperazine, Trimethobenzamide, Phenindamine, Tripelennamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250133, "ingredient1": "Coccidioides immitis spherule", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Antihistamines may diminish the response to diagnostic skin test antigens.", "source": "DDInter", "management_text": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "mechanism_text": "Antagonism", "recommendation": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296322/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] NLM. National Library of Medicine. NIH. National Institutes of Health \"Trichophyton for intradermal skin testing (trichophyton mentagrophytes and trichophyton rubrum) injection [Allermed Laboratories, Inc.]  http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaeffe62-b538-43ca-a3b9-47e28b765d89\"   (2014):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Doxylamine, Meclizine, Dimenhydrinate, Alimemazine, Thiethylperazine, Trimethobenzamide, Phenindamine, Tripelennamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250134, "ingredient1": "Cyclizine", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296323/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, Tripelennamine, Azelastine, Cyclizine, More", "alternatives_b": "Ketotifen, Chlorcyclizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 250135, "ingredient1": "Demecarium (ophthalmic)", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296324/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Phenindamine, Desloratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250136, "ingredient1": "Dezocine", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296325/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, Tripelennamine, Azelastine, Cyclizine, More", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 250137, "ingredient1": "Glycopyrronium (topical)", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296326/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250138, "ingredient1": "Halazepam", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296327/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Alimemazine, Fexofenadine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, More", "alternatives_b": "Meprobamate, Oxazepam", "updated_at": 1767369485}, {"id": 250139, "ingredient1": "Diamorphine", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296328/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, Tripelennamine, Azelastine, Cyclizine, More", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 250140, "ingredient1": "Isoflurophate (ophthalmic)", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296330/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Phenindamine, Desloratadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250141, "ingredient1": "Chlorcyclizine", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296331/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, Tripelennamine, Azelastine, Cyclizine, Astemizole", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 250142, "ingredient1": "Chlorcyclizine", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296332/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Trimethobenzamide, Phenindamine, Desloratadine, Tripelennamine, Azelastine, More", "alternatives_b": "Ketotifen, Chlorcyclizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 250143, "ingredient1": "Chlorcyclizine", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296333/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Trimethobenzamide, Phenindamine, Desloratadine, Tripelennamine, Azelastine, More", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 250144, "ingredient1": "Chlorcyclizine", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296334/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Trimethobenzamide, Phenindamine, Desloratadine, Tripelennamine, Azelastine, More", "alternatives_b": "Ketotifen, Chlorcyclizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "updated_at": 1767369485}, {"id": 250145, "ingredient1": "Chlorcyclizine", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296335/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, Tripelennamine, Azelastine, Cyclizine, Astemizole", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 250146, "ingredient1": "Chlorcyclizine", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296336/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, Tripelennamine, Azelastine, Cyclizine, More", "alternatives_b": "Temazepam, Butabarbital, Chloral hydrate, Nitrazepam, Paraldehyde, Amobarbital, Meprobamate, Butalbital, Eszopiclone, Estazolam, Methylphenobarbital, More", "updated_at": 1767369485}, {"id": 250147, "ingredient1": "Chlorcyclizine", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296339/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, Tripelennamine, Azelastine, Cyclizine, Astemizole", "alternatives_b": "Amisulpride, Pimavanserin", "updated_at": 1767369485}, {"id": 250148, "ingredient1": "Alimemazine", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296340/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Chlorcyclizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, Tripelennamine, Azelastine, Cyclizine, Astemizole", "updated_at": 1767369485}, {"id": 250149, "ingredient1": "Chlorcyclizine", "ingredient2": "Tripelennamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296341/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, Tripelennamine, Azelastine, Cyclizine, More", "alternatives_b": "Ketotifen, Chlorcyclizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine", "updated_at": 1767369485}, {"id": 250150, "ingredient1": "Chlorcyclizine", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296342/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Temazepam, Butabarbital, Chloral hydrate, Nitrazepam, Paraldehyde, Amobarbital, Meprobamate, Butalbital, Eszopiclone, Estazolam, Methylphenobarbital, More", "updated_at": 1767369485}, {"id": 250151, "ingredient1": "Glycopyrronium (topical)", "ingredient2": "Clidinium", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296343/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250152, "ingredient1": "Carteolol", "ingredient2": "Oxtriphylline", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite.  Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation.  Ophthalmic beta-blockers undergo significant systemic absorption and may also interact.  In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases.  Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm.  If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Metabolism, Distribution", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296347/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991):  135-50[2] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980):  463-7[3] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978):  1-6[4] Mue S, Sasaki T, Shibahara S, et al. \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979):  346-50[5] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987):  523-9", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 250153, "ingredient1": "Enoxacin", "ingredient2": "Oxtriphylline", "severity": "Major", "effect": "Enoxacin has been shown to reduce theophylline clearance by up to 75%. The mechanism is inhibition of CYP450 1A2 hepatic metabolism.", "source": "DDInter", "management_text": "If possible, enoxacin therapy should be avoided in patients receiving theophylline.  Levofloxacin, sparfloxacin, moxifloxacin, gatifloxacin, trovafloxacin, and lomefloxacin have been reported to cause minor or no changes in theophylline levels and may be considered as alternatives.  If enoxacin is given concomitantly with theophylline, the theophylline dosage should be reduced approximately 50% or more, and theophylline serum levels should be closely monitored.  Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats to their physician.", "mechanism_text": "Metabolism", "recommendation": "If possible, enoxacin therapy should be avoided in patients receiving theophylline.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296349/", "reference_text": "[1] Wijnands WJ, Vree TB \"Interaction between the fluoroquinolones and the bronchodilator theophylline.\" J Antimicrob Chemother 22 (1988):  109-14[2] Sano M, Kawakatsu K, Yamamoto I, et al. \"Inhibitory effect of enoxacin, ofloxacin and norfloxacin on renal excretion of theophylline in humans.\" Eur J Clin Pharmacol 36 (1989):  323-4[3] Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL \"Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintneance treatment with theophylline.\" Drugs 34 (1987):  159-69[4] Sorgel F, Mahr G, Granneman GR, et al. \"Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.\" Clin Pharmacokinet 22 (1992):  65-74[5] Koup JR, Toothaker RD, Posvar E, et al. \"Theophylline dosage adjustment during enoxacin coadministration.\" Antimicrob Agents Chemother 34 (1990):  803-7[6] Rogge MC, Solomon WR, Sedman AJ, et al. \"The theophylline-enoxacin interaction. II: Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin.\" Clin Pharmacol Ther 46 (1989):  420-8[7] Wijnands GJ, Vree TB, Janssen TJ, Guelen PJ \"Drug-drug interactions affecting fluoroquinolones.\" Am J Med 87 (1989):  s47-51[8] Harris JM \"Drug interaction affecting theophylline clearance.\" J Pediatr 116 (1990):  838-9[9] Takagi K, Hasegawa T, Ogura Y, et al. \"Comparative studies on interaction between theophylline and quinolones.\" J Asthma 25 (1988):  63-70[10] Rogge MC, Solomon WR, Sedman AJ, et al. \"The theophylline-enoxacin interaction. I: effect of enoxacin dose size on theophylline disposition.\" Clin Pharmacol Ther 44 (1988):  579-87[11] Takagi K, Hasegawa T, Yamaki K, et al. \"Interaction between theophylline and enoxacin.\" Int J Clin Pharmacol Ther Toxicol 26 (1988):  288-92[12] Beckmann J, Elsaber W, Gundert-Remy U, Hertrampf R \"Enoxacin: a potent inhibitor of theophylline metabolism.\" Eur J Clin Pharmacol 33 (1987):  227-30[13] Wijnands WJ, Van Herwaarden CL \"Enoxacin raises plasma theophylline concentrations.\" Lancet 2 (1984):  108-9[14] Wijnands WJ, Vree TB, van Herwaarden CL \"Enoxacin decreases the clearance of theophylline in man.\" Br J Clin Pharmacol 20 (1985):  583-8[15] Sano M, Kawakatsu K, Yamamoto I, et al. \"Inhibitory effect of enoxacin, ofloxacin and norfloxacin on renal excretion of theophylline in humans.\" Eur J Clin Pharmacol 36 (1989):  323-4[16] Sana M, Kawakatsu K, Ohkita C, et al. \"Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans.\" Eur J Clin Pharmacol 35 (1988):  161-5[17] Sijnands WJ, Vree TB, Baars AM, Van Herwaarden CL \"Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theopylline.\" Drugs 34 (1987):  159-69[18] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991):  66-80[19] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):", "alternatives_a": "Gatifloxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Moxifloxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 250154, "ingredient1": "Ephedrine (nasal)", "ingredient2": "Oxtriphylline", "severity": "Minor", "effect": "Ephedrine-methylxanthine combinations are used for the treatment of asthma but the efficacy of the combination has been questioned.  This combination may lead to increased xanthine side effects.  The mechanism is unknown, but may be related to synergistic pharmacologic effects.", "source": "DDInter", "management_text": "Patients using this combination should be closely monitored for side effects such as nausea, vomiting, tachycardia, nervousness, or insomnia.  If side effects are noted, the dosage of the xanthine may need to be decreased.", "mechanism_text": "Synergism", "recommendation": "Patients using this combination should be closely monitored for side effects such as nausea, vomiting, tachycardia, nervousness, or insomnia.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296350/", "reference_text": "[1] Weinberger M, Bronsky E, Bensch GW, Bock GN, Yecies JJ \"Interaction of ephedrine and theophylline.\" Clin Pharmacol Ther 17 (1975):  585-92[2] Sims JA, doPico GA, Reed CE \"Bronchodilating effect of oral theophylline-ephedrine combination.\" J Allergy Clin Immunol 62 (1978):  15-21[3] Tinkelman DG, Avner SE \"Ephedrine therapy in asthmatic children. Clinical tolerance and absence of side effects.\" JAMA 237 (1977):  553-7[4] Weinberger MM, Brousky EA \"Evaluation of oral bronchodilator therapy in asthmatic children: bronchodilators in asthmatic children.\" J Pediatr 84 (1974):  421-7[5] Badiei B, Faciane J, Sly M \"Effect of throphylline, ephedrine and theri combination upon exercise-induced airway obstruction.\" Ann Allergy 35 (1975):  32-6", "alternatives_a": "Ketorolac, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 250155, "ingredient1": "Grepafloxacin", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "The coadministration with grepafloxacin may increase the serum concentrations of theophylline.  The mechanism is grepafloxacin inhibition of CYP450 1A2, the isoenzyme primarily responsible for the metabolic clearance of theophylline.", "source": "DDInter", "management_text": "A 50% reduction in theophylline maintenance dosage is recommended during grepafloxacin treatment, and serum theophylline levels should be monitored to further guide any therapy adjustments.  Patients should be advised to notify their physician if they experience possible signs of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats.", "mechanism_text": "Metabolism", "recommendation": "A 50% reduction in theophylline maintenance dosage is recommended during grepafloxacin treatment, and serum theophylline levels should be monitored to further guide any therapy adjustments.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296352/", "reference_text": "[1] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome  (2001):[2] Efthymiopoulos C, Bramer SL, Maroli A, Blum B \"Theophylline and warfarin interaction studies with grepafloxacin.\" Clin Pharmacokinet 33(Suppl 1) (1997):  39-46", "alternatives_a": "Gatifloxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Moxifloxacin, Trovafloxacin, Delafloxacin, Sparfloxacin", "alternatives_b": "Omalizumab, Tezepelumab, Benralizumab, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 250156, "ingredient1": "Halazepam", "ingredient2": "Oxtriphylline", "severity": "Minor", "effect": "Methylxanthines may antagonize the sedative effects of benzodiazepines.  Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam.  The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.", "source": "DDInter", "management_text": "Methylxanthines may antagonize the sedative effects of benzodiazepines.  Aminophylline in particular has been demonstrated to attenuate the sedative effects of diazepam.  The mechanism of this interaction may be related to competitive binding to intracerebral adenosine receptors.  One study demonstrated that alprazolam serum concentrations were significantly lower in patients receiving chronic theophylline therapy than in patients not receiving theophylline.  Clinical and laboratory monitoring is warranted if these agents are given concurrently.  Patients receiving this combination should be monitored for adequate response to the benzodiazepine.", "mechanism_text": "Antagonism", "recommendation": "Methylxanthines may antagonize the sedative effects of benzodiazepines.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296353/", "reference_text": "[1] Bonfiglio MF, Dasta JF \"Clinical significance of the benzodiazepine-theophylline interaction.\" Pharmacotherapy 11 (1991):  85-7[2] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991):  135-50[3] Stirt JA \"Aminophylline is a diazepam antagonist.\" Anesth Analg 60 (1981):  767-8[4] Gallen JS \"Aminophylline reversal of midazolam sedation.\" Anesth Analg 69 (1989):  268[5] Tuncok Y, Akpinar O, Guven H, Akkoclu A \"The effects of theophylline on serum alprazolam levels.\" Int J Clin Pharmacol Ther 32 (1994):  642-5", "alternatives_a": "Meprobamate, Buspirone, Hydroxyzine", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 250157, "ingredient1": "Interferon alfa-n1", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of theophylline.  The mechanism is unknown but may be related to interferon-induced suppression of hepatic CYP450 enzymes, particularly, CYP450 1A2.  Physiologic events and drugs that induce interferon synthesis (e.g., viral infection, influenza vaccination) have also been reported to decrease metabolism and potentiate the effects of certain drugs including theophylline.", "source": "DDInter", "management_text": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.  Pharmacologic response and serum theophylline levels should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of interferon therapy in patients who are stabilized on their methylxanthine regimen.  Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if theophylline or other methylxanthines are administered with an interferon.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296355/", "reference_text": "[1] Kramer P, Tsuru M, Cook CE, et al. \"Effect of influenza vaccine on warfarin anticoagulation.\" Clin Pharmacol Ther 35 (1984):  416-8[2] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991):  135-50[3] Williams SJ, Baird-Lambert JA, Farrell GC \"Inhibition of theophylline metabolism by interferon.\" Lancet 10/24/87 (1987):  939-41[4] Jonkman JH, Nicholson KG, Farrow PR, et al. \"Effects of alpha-interferon on theophylline pharmacokinetics and metabolism.\" Br J Clin Pharmacol 27 (1989):  795-802[5] Okuno H, Takasu M, Kano H, Seki T, Shiozaki Y, Inoue K \"Depression of drug-metabolizing activity in the human liver by interferon-beta.\" Hepatology 17 (1993):  65-9[6] \"Product Information. Intron A (interferon alfa-2b).\" Schering Corporation  (2001):[7] Sakai H, Okamoto T, Kikkawa Y \"Suppression of hepatic drug metabolism by the interferon inducer polyriboinosinic acid:polyribocitidylic acid.\" J Pharmacol Exp Ther 263 (1992):  381-6[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Sargramostim, Histamine, Aldesleukin, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Pentoxifylline, Bromotheophylline", "updated_at": 1767369485}, {"id": 250158, "ingredient1": "Isoetharine", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation.", "source": "DDInter", "management_text": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.  Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption.  Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296356/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991):  66-80[2] Coleman JJ, Vollmer WM, Barker AF, et al. \"Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline.\" Chest 90 (1986):  45-51[3] Cusack BJ, Nielson CP, Morgan ME, Vestal RE \"Additive effect of theophylline on the cardiac response to isoproterenol.\" Clin Pharmacol Ther 41 (1987):  289-96[4] Deenstra M, Haalboom JR, Struyvenberg A \"Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline.\" Eur J Clin Invest 18 (1988):  162-5[5] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE \"Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects.\" Br J Clin Pharmacol 26 (1988):  285-93[6] Garty M, Paul-Keslin L, Ilfeld DN, et al. \"Increased theophylline clearance in asthmatic patients due to terbutaline.\" Eur J Clin Pharmacol 36 (1989):  25-8[7] Amitai Y, Glustein J, Godfrey S \"Enhancement of theophylline clearance by oral albuterol.\" Chest 102 (1992):  786-9[8] Amirav I, Amitai Y, Avital A, Godfrey S \"Enhancement of theophylline clearance by intravenous albuterol.\" Chest 94 (1988):  444-5[9] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL \"Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline.\" Br J Clin Pharmacol 25 (1988):  571-8[10] Kelly HW \"Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists.\" Clin Pharm 3 (1984):  386-95[11] Griffith JA, Kozloski GD \"Isoproterenol-theophylline interaction: possible potentiation by other drugs.\" Clin Pharm 9 (1990):  54-7[12] Chow OK, Fung KP \"Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions.\" Pediatrics 84 (1989):  119-25[13] Smith SR, Kendall MJ \"Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.\" Br J Clin Pharmacol 21 (1986):  451-3[14] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G \"Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol.\" Chest 78 (1980):  429-35[15] \"Interactions between methyl xanthines and beta adrenergic agonists.\" FDA Drug Bull 11 (1981):  19-20[16] Conrad KA, Woodworth JR \"Orciprenaline does not alter theophylline elimination.\" Br J Clin Pharmacol 12 (1981):  756-7[17] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987):  523-9[18] O'Rourke PP, Crone RK \"Effect of isoproterenol on measured theophylline levels.\" Crit Care Med 12 (1984):  373-5[19] Hemstreet MP, Miles MV, Rutland RO \"Effect of intravenous isoproterenol on theophylline kinetics.\" J Allergy Clin Immunol 69 (1982):  360-4[20] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB \"Reduction of serum theophylline levels by terbutaline in children with asthma.\" Clin Pharmacol Ther 37 (1985):  469-71[21] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC \"Metaproterenol and theophylline in asthmatic children.\" Ann Allergy 45 (1980):  207-12[22] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[23] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[24] Dawson KP, Fergusson DM \"Effects of oral theophylline and oral salbutamol in the treatment of asthma.\" Arch Dis Child 57 (1982):  674-6[25] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J \"The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline.\" Chest 96 (1989):  1317-20[26] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250159, "ingredient1": "Oxtriphylline", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite.  Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation.  Ophthalmic beta-blockers undergo significant systemic absorption and may also interact.  In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases.  Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm.  If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Metabolism, Distribution", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296357/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991):  135-50[2] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980):  463-7[3] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978):  1-6[4] Mue S, Sasaki T, Shibahara S, et al. \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979):  346-50[5] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987):  523-9", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250160, "ingredient1": "Oxtriphylline", "ingredient2": "Metocurine", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296359/", "reference_text": "[1] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991):  983-5[2] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979):  139-40[3] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982):  280-2", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250161, "ingredient1": "Oxtriphylline", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "The coadministration with contraceptive steroids may increase the plasma concentrations of theophylline and other methylxanthines.  The proposed mechanism is inhibition of methylxanthine metabolism via hepatic microsomal enzymes, of which estrogens and progestins are also substrates.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives.  Serum theophylline levels and pharmacologic response should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their theophylline regimen.  Patients should be advised to notify their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296361/", "reference_text": "[1] Tornatore KM, Kanarkowski R, McCarthy TL, et al. \"Effect of chronic oral contraceptive steroids on theophylline disposition.\" Eur J Clin Pharmacol 23 (1982):  129-34[2] Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R \"Effects of tobacco smoking and oral contraceptive use on theophylline disposition.\" Br J Clin Pharmacol 16 (1983):  271-80[3] Roberts RK, Grice J, McGuffie, Heilbronn L \"Oral contraceptive steroids impair the elimination of theophylline.\" J Lab Clin Med 101 (1983):  821-25", "alternatives_a": "Megestrol acetate, Progesterone, Medroxyprogesterone acetate, Megestrol acetate, Ulipristal, Estetrol, Medroxyprogesterone acetate", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "updated_at": 1767369485}, {"id": 250162, "ingredient1": "Pipecuronium", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296362/", "reference_text": "[1] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991):  983-5[2] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979):  139-40[3] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982):  280-2", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 250163, "ingredient1": "Ranitidine (bismuth citrate)", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "Cimetidine may increase theophylline plasma concentrations by as much as 70%.  The mechanism is related to inhibition of liver CYP450 enzymes responsible for theophylline metabolism.", "source": "DDInter", "management_text": "Clinical monitoring of patient response, tolerance, and laboratory theophylline serum concentrations is recommended.  Patients should be advised to report any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat to their physician.", "mechanism_text": "Metabolism", "recommendation": "Clinical monitoring of patient response, tolerance, and laboratory theophylline serum concentrations is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296363/", "reference_text": "[1] Schwartz JI, Bachmann KA, Bond LW, Mahajan VK \"Impact of cimetidine on the pharmacokinetics of the theophylline.\" Clin Pharm 1 (1982):  534-8[2] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991):  135-50[3] Campbell MA, Plachetka JR, Jackson JE, Moon JF, Finley PR \"Cimetidine decreases theophylline clearance.\" Ann Intern Med 95 (1981):  68-9[4] Bauman JH, Kimelblatt BJ, Caraccio TR, Silverman HM, Simon GI, Beck GJ \"Cimetidine-theophylline interaction: report of four patients.\" Ann Allergy 48 (1982):  100-2[5] Hsu K, Garton A, Sproule BJ, Tam YK, Leggatt D, Herbert FA \"The influence of orally administered cimetidine and theophylline on the elimination of each drug in patients with chronic airways obstruction.\" Am Rev Respir Dis 130 (1984):  740-3[6] Powell JR, Rogers JF, Wargin WA, Cross RE, Eshelman FN \"Inhibition of theophylline clearance by cimetidine but not ranitidine.\" Arch Intern Med 144 (1984):  484-6[7] Anderson JR, Poklis A, Slavin RG \"A fatal case of theophylline intoxication.\" Arch Intern Med 143 (1983):  559-60[8] Boehning W \"Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids.\" Eur J Clin Pharmacol 38 (1990):  43-5[9] Jackson JE, Powell JR, Wandell M, Bentley J, Dorr R \"Cimetidine decreases theophylline clearance.\" Am Rev Respir Dis 123 (1981):  615-7[10] Kelly HW \"Lack of evidence for reduction of theophylline clearance by ranitidine.\" Am J Med 86 (1989):  629-32[11] Lofgren RP, Gilbertson RA \"Cimetidine and theophylline.\" Ann Intern Med 96 (1982):  378[12] Reitberg DP, Bernhard H, Schentag JJ \"Alteration of theophylline clearance and half-life by cimetidine in normal volunteers.\" Ann Intern Med 95 (1981):  582-5[13] Fenje PC, Isles AF, Baltodano A, MacLeod SM, Soldin S \"Interaction of cimetidine and theophylline in two infants.\" Can Med Assoc J 126 (1982):  1178[14] Weinberger MM, Smith G, Milavetz G, Hendeles L \"Decreased clearance of theophylline due to cimetidine .\" N Engl J Med 304 (1981):  672[15] Lin JH, Chremos AN, Chiou R, Yeh KC, Williams R \"Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers.\" Br J Clin Pharmacol 24 (1987):  669-72[16] Dal Negro R, Pomari C, Turco P \"Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease.\" Clin Pharmacokinet 24 (1993):  255-8[17] Fernandes E, Melewicz FM \"Ranitidine and theophylline.\" Ann Intern Med 100 (1984):  459[18] Roy AK, Cuda MP, Levine RA \"Induction of theophylline toxicity and inhibition of clearance rates by ranitidine.\" Am J Med 85 (1988):  525-7[19] Skinner MH, Lenert L, Blaschke TF \"Theophylline toxicity subsequent to ranitidine administration: a possible drug-drug interaction.\" Am J Med 86 (1989):  129-32[20] Hegman GW, Gilbert RP \"Ranitidine-theophylline interaction--fact or fiction?\" Ann Pharmacother 25 (1991):  21-5[21] Boehning W \"Effect of cimetidine and ranitidine on plasma theophylline in patients with chronic obstructive airways disease treated with theophylline and corticosteroids.\" Eur J Clin Pharmacol 38 (1990):  43-5[22] Kelly HW, Powell JR, Donohue JF \"Ranitidine at very large doses does not inhibit theophylline elimination.\" Clin Pharmacol Ther 39 (1986):  577-81[23] Ohashi K, Sakamoto K, Sudo T, Tateishi T, Fujimura A, Shiga T, Ebihara A \"Effects of diltiazem and cimetidine on theophylline oxidative metabolism.\" J Clin Pharmacol 33 (1993):  1233-7[24] Bachmann KA, Sullivan TJ, Jauregui L, Reese J, Miller K, Levine L \"Drug interactions of h-2-receptor antagonists.\" Scand J Gastroenterol 29 (1994):  14-9[25] Bachmann K, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, Yeh KC, Stepanavage M, King JD, Schwartz J \"Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease.\" J Clin Pharmacol 35 (1995):  529-35[26] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):[27] Pride M, Deamer RL \"Over-the-counter cimetidine and theophylline interaction.\" Am Fam Physician 52 (1995):  2180[28] Kehoe WA, Sands CD, Long LF, et al. \"Effect of ranitidine on theophylline metabolism in healthy Koreans living in China.\" Ann Pharmacother 30 (1996):  133-7[29] Loi CM, Parker BM, Cusack BJ, Vestal RE \"Aging and drug interactions .3. individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers.\" J Pharmacol Exp Ther 280 (1997):  627-37[30] Verdiani P, Di Carlo S, Baronti A \"Famotidine effects on theophylline pharmacokinetics in subjects affected by COPD: comparison with cimetidine and placebo.\" Chest 94 (1988):  807-10", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250164, "ingredient1": "Rapacuronium", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296364/", "reference_text": "[1] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991):  983-5[2] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979):  139-40[3] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982):  280-2", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250165, "ingredient1": "St. John's Wort", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "Coadministration with St. John's wort may decrease the serum concentrations of theophylline.  The proposed mechanism is accelerated clearance of theophylline due to induction of hepatic CYP450 isoenzymes, namely 1A2, by constituents of St. John's wort.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  Pharmacologic response and serum theophylline levels should be monitored more closely whenever St. John's wort is added to or withdrawn from therapy, and the methylxanthine dosage adjusted as necessary.  Patients should be advised to notify their physician if they experience loss of asthma control or worsening of respiratory symptoms.", "mechanism_text": "Metabolism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296365/", "reference_text": "[1] Nebel A, Schneider BJ, Baker RK, Kroll DJ \"Potential metabolic interaction between St. John's wort and theophylline.\" Ann Pharmacother 33 (1999):  502[2] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[3] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "updated_at": 1767369485}, {"id": 250166, "ingredient1": "Troleandomycin", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "Coadministration with certain macrolide antibiotics may increase the serum concentrations of methylxanthines such as theophylline, which may result in toxicity.  In one case report, a pediatric patient developed seizures in association with theophylline toxicity shortly after the addition of erythromycin.  The proposed mechanism is macrolide inhibition of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of theophylline.", "source": "DDInter", "management_text": "Pharmacologic response and serum theophylline levels should be monitored more closely whenever a macrolide antibiotic is added to or withdrawn from therapy, and the methylxanthine dosage adjusted as necessary.  For patients with theophylline levels at the upper end of the therapeutic range (15 to 20 mcg/mL), some clinicians suggest an initial reduction of the methylxanthine dosage by 25% when given with erythromycin and 50% with troleandomycin.  Patients should be advised to contact their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response and serum theophylline levels should be monitored more closely whenever a macrolide antibiotic is added to or withdrawn from therapy, and the methylxanthine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296366/", "reference_text": "[1] Branigan TA, Robbins RA, Cady WJ, et al. \"The effects of erythromycin on the absorption and disposition kinetics of theophylline.\" Eur J Clin Pharmacol 21 (1981):  115-20[2] Zarowitz BJ, Szefler SJ, Lasezkay GM \"Effect of erythromycin base on theophylline kinetics.\" Clin Pharmacol Ther 29 (1981):  601-5[3] Prince RA, Wing DS, Weinberger MM, et al. \"Effect of erythromycin on theophylline kinetics.\" J Allergy Clin Immunol 68 (1981):  427-31[4] May DC, Jarboe CH, Ellenburg DT, et al. \"The effects of erythromycin on theophylline elimination in normal males.\" J Clin Pharmacol 22 (1982):  125-30[5] Iliopoulou A, Aldhous ME, Johnston A, Turner P \"Pharmacokinetic interaction between theophylline and erythromycin.\" Br J Clin Pharmacol 14 (1982):  495-9[6] Paulsen O, Hoglund P, Nilsson LG, Bengtsson HI \"The interaction of erythromycin with theophylline.\" Eur J Clin Pharmacol 32 (1987):  493-8[7] Hildebrandt R, Moller H, Gundert-Remy U \"Influence of theophylline on the renal clearance of erythromycin.\" Int J Clin Pharmacol Ther Toxicol 25 (1987):  601-4[8] Renton KW, Gray JD, Hung OR \"Depression of theophylline elimination by erythromycin.\" Clin Pharmacol Ther 30 (1981):  422-6[9] Richer C, Mathieu M, Bah H, Thuillez C, Duroux P, Giudicelli JF \"Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: influence of erythromycin.\" Clin Pharmacol Ther 31 (1982):  579-86[10] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991):  66-80[11] Peters DH, Friedel HA, McTavish D \"Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.\" Drugs 44 (1992):  750-99[12] Maddux MS, Leeds NH, Organek HW, Hasegawa GR, Bauman JL \"The effect of erythromycin on theophylline pharmacokinetics at steady state.\" Chest 81 (1982):  563-5[13] Descotes J, Andre P, Evreux JC \"Pharmacokinetic drug interactions with macrolide antibiotics.\" J Antimicrob Chemother 15 (1985):  659-64[14] Ludden TM \"Pharmacokinetic interactions of the macrolide antibiotics.\" Clin Pharmacokinet 10 (1985):  63-79[15] Reisz G, Pingleton SK, Melethil S, Ryan PB \"The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis.\" Am Rev Respir Dis 127 (1983):  581-4[16] Jonkman JH, Upton RA \"Pharmacokinetic drug interactions with theophylline.\" Clin Pharmacokinet 9 (1984):  309-34[17] Pfeifer HJ, Greenblatt DJ, Friedman P \"Effects of three antibiotics on theophylline kinetics.\" Clin Pharmacol Ther 26 (1979):  36-40[18] Wiggins J, Arbab O, Ayres JG, Skinner C \"Elevated serum theophylline concentration following cessation of erythromycin treatment.\" Eur J Respir Dis 68 (1986):  298-300[19] Rockwood RP, Embardo LS \"Theophylline, ciprofloxacin, erythromycin: a potentially harmful regimen.\" Ann Pharmacother 27 (1993):  651-2[20] Kozak PP, Cummins LH, Gillman SH \"Administration of erythromycin to patients on theophylline.\" J Allergy Clin Immunol 60 (1977):  149-51[21] Parish RA, Haulman NJ, Burns RM \"Interaction of theophylline with erythromycin base in a patient with seizure activity.\" Pediatrics 72 (1983):  828-30[22] Tenenbein M \"Theophylline toxicity due to drug interaction.\" J Emerg Med 7 (1989):  249-51[23] Bachmann K, Nunlee M, Martin M, et al. \"Changes in the steady-state pharmacokinetics of theophylline during treatment with dirithromycin.\" J Clin Pharmacol 30 (1990):  1001-5[24] Bachmann K, Jauregui L, Sides G, Sullivan TJ \"Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin.\" J Clin Pharmacol 33 (1993):  861-5[25] Amsden GW \"Macrolides versus azalides: a drug interaction update.\" Ann Pharmacother 29 (1995):  906-17[26] Amsden GW \"Erythromycin, clarithromycin, and azithromycin: are the differences real?\" Clin Ther 18 (1996):  56-72[27] Gillum JG, Israel DS, Scott RB, Climo MW, Polk RE \"Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers.\" Antimicrob Agents Chemother 40 (1996):  1715-6[28] Pollak PT, Slayter KL \"Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction.\" Pharmacotherapy 17 (1997):  827-9[29] Nahata M \"Drug interactions with azithromycin and the macrolides: an overview.\" J Antimicrob Chemother 37 Suppl C (1996):  133-42[30] von Rosenstiel NA, Adam D \"Macrolide antibacterials. Drug interactions of clinical significance.\" Drug Saf 13 (1995):  105-22[31] Principi N, Esposito S \"Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric: Patients.\" Drug Safety 20 (1999):  25-41[32] Kamada AK, Hill MR, Brenner AM, Szefler SJ \"Effect of low-dose troleandomycin on theophylline clearance: implications for therapeutic drug monitoring.\" Pharmacotherapy 12 (1992):  98-102", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Telithromycin, Lincomycin, Clindamycin", "updated_at": 1767369485}, {"id": 250167, "ingredient1": "Tubocurarine", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296367/", "reference_text": "[1] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991):  983-5[2] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979):  139-40[3] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982):  280-2", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 250168, "ingredient1": "Choline salicylate", "ingredient2": "Baricitinib", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296369/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, More", "alternatives_b": "Acetaminophen, Methoxyflurane, Ziconotide, Salsalate", "updated_at": 1767369485}, {"id": 250169, "ingredient1": "Dimethyl fumarate", "ingredient2": "Choline salicylate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296371/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Acetaminophen, Salsalate, Ziconotide, Diflunisal, Methoxyflurane, Acetylsalicylic acid", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, More", "updated_at": 1767369485}, {"id": 250170, "ingredient1": "Diroximel fumarate", "ingredient2": "Choline salicylate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296372/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Acetaminophen, Salsalate, Ziconotide, Diflunisal, Methoxyflurane", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, More", "updated_at": 1767369485}, {"id": 250171, "ingredient1": "Erlotinib", "ingredient2": "Choline salicylate", "severity": "Moderate", "effect": "Coadministration of erlotinib with anti-angiogenic agents, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or taxane-based chemotherapy may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using erlotinib in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as anti-angiogenic agents, corticosteroids, NSAIDs, and taxane-based chemotherapy.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.  The manufacturer recommends that erlotinib should be permanently discontinued in patients who develop gastrointestinal perforation.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using erlotinib in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as anti-angiogenic agents, corticosteroids, NSAIDs, and taxane-based chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296373/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Tarceva (erlotinib).\" Genentech  (2018):[4] \"Product Information. Tarceva (erlotinib).\" Hoffmann-La Roche Limited  (2018):[5] \"Product Information. Tarceva (erlotinib).\" Roche Products Ltd  (2022):[6] \"Product Information. Tarceva (erlotinib).\" Roche Products Pty Ltd  (2022):[7] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140", "alternatives_a": "Diflunisal, Methoxyflurane, Ziconotide, Salsalate", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 250172, "ingredient1": "Choline salicylate", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296376/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Acetaminophen, Salsalate, Ziconotide, Diflunisal, Methoxyflurane", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250173, "ingredient1": "Choline salicylate", "ingredient2": "Tofacitinib", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296379/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Acetaminophen, Methoxyflurane, Ziconotide, Salsalate", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, More", "updated_at": 1767369485}, {"id": 250174, "ingredient1": "Choline salicylate", "ingredient2": "Upadacitinib", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296380/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Acetaminophen, Salsalate, Ziconotide, Diflunisal, Methoxyflurane", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, More", "updated_at": 1767369485}, {"id": 250175, "ingredient1": "Abarelix", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296382/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250176, "ingredient1": "Abiraterone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296383/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250177, "ingredient1": "Acetazolamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296384/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250178, "ingredient1": "Salbutamol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296386/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250179, "ingredient1": "Aldesleukin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296387/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250180, "ingredient1": "Alfentanil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296388/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250181, "ingredient1": "Alfuzosin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296389/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Terazosin, Tadalafil, Finasteride, Silodosin, Dutasteride", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250182, "ingredient1": "Amantadine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296390/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ropinirole, Opicapone, Cabergoline, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250183, "ingredient1": "Amifampridine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296391/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250184, "ingredient1": "Amikacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296392/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Mupirocin, Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250185, "ingredient1": "Amikacin (liposome)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296393/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Mupirocin, Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250186, "ingredient1": "Amiloride", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296394/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Eplerenone, Finerenone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250187, "ingredient1": "Aminophylline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296395/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250188, "ingredient1": "Aminosalicylic acid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296396/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250189, "ingredient1": "Amiodarone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296397/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "updated_at": 1767369485}, {"id": 250190, "ingredient1": "Amisulpride", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296398/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250191, "ingredient1": "Amitriptyline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296399/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250192, "ingredient1": "Amoxapine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296400/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250193, "ingredient1": "Amoxicillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296401/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250194, "ingredient1": "Amphetamine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296402/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, More", "updated_at": 1767369485}, {"id": 250195, "ingredient1": "Ampicillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296403/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250196, "ingredient1": "Anagrelide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296404/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250197, "ingredient1": "Picosulfuric acid", "ingredient2": "Apalutamide", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296405/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250198, "ingredient1": "Picosulfuric acid", "ingredient2": "Apomorphine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296406/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250199, "ingredient1": "Picosulfuric acid", "ingredient2": "Aripiprazole", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296407/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250200, "ingredient1": "Picosulfuric acid", "ingredient2": "Arsenic trioxide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296408/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250201, "ingredient1": "Picosulfuric acid", "ingredient2": "Asenapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296410/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250202, "ingredient1": "Acetylsalicylic acid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296411/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ticagrelor, Betrixaban, Clopidogrel, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, Magnesium citrate, More", "updated_at": 1767369485}, {"id": 250203, "ingredient1": "Picosulfuric acid", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296412/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 250204, "ingredient1": "Picosulfuric acid", "ingredient2": "Atomoxetine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296413/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250205, "ingredient1": "Picosulfuric acid", "ingredient2": "Atovaquone", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296414/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Quinacrine, Nitazoxanide, Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250206, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296415/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250207, "ingredient1": "Azithromycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296416/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 250208, "ingredient1": "Aztreonam", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296417/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250209, "ingredient1": "Bacampicillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296418/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "updated_at": 1767369485}, {"id": 250210, "ingredient1": "Bacitracin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296419/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Mupirocin, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250211, "ingredient1": "Bedaquiline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296420/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250212, "ingredient1": "Benazepril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296421/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, More", "updated_at": 1767369485}, {"id": 250213, "ingredient1": "Bendroflumethiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296422/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250214, "ingredient1": "Benznidazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296423/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Miltefosine, Nifurtimox", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250215, "ingredient1": "Benzphetamine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296424/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250216, "ingredient1": "Benzthiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296425/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 250217, "ingredient1": "Bepridil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296426/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250218, "ingredient1": "Betamethasone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296427/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250219, "ingredient1": "Bethanechol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296428/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ambenonium, Pilocarpine, Cevimeline, Pyridostigmine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250220, "ingredient1": "Bicalutamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296429/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane, Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250221, "ingredient1": "Blinatumomab", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296430/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250222, "ingredient1": "Bosutinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296431/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250223, "ingredient1": "Brexpiprazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296432/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250224, "ingredient1": "Bromfenac", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296433/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250225, "ingredient1": "Bumetanide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296434/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250226, "ingredient1": "Buprenorphine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296435/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250227, "ingredient1": "Bupropion", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296436/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250228, "ingredient1": "Butorphanol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296437/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250229, "ingredient1": "Cabozantinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296438/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250230, "ingredient1": "Capreomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296440/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250231, "ingredient1": "Captopril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296441/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250232, "ingredient1": "Carbenicillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296442/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250233, "ingredient1": "Cariprazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296443/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250234, "ingredient1": "Cefaclor", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296444/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250235, "ingredient1": "Cefadroxil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296445/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250236, "ingredient1": "Cefamandole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296446/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250237, "ingredient1": "Cefazolin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296447/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250238, "ingredient1": "Cefdinir", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296448/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "updated_at": 1767369485}, {"id": 250239, "ingredient1": "Cefditoren", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296449/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "updated_at": 1767369485}, {"id": 250240, "ingredient1": "Cefepime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296450/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem, Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250241, "ingredient1": "Cefiderocol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296451/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250242, "ingredient1": "Cefixime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296452/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem, Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250243, "ingredient1": "Cefmetazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296453/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250244, "ingredient1": "Cefonicid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296454/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250245, "ingredient1": "Cefoperazone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296455/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250246, "ingredient1": "Cefotaxime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296456/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250247, "ingredient1": "Cefotetan", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296457/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250248, "ingredient1": "Cefoxitin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296458/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250249, "ingredient1": "Cefpodoxime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296459/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250250, "ingredient1": "Cefprozil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296460/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250251, "ingredient1": "Ceftaroline fosamil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296461/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250252, "ingredient1": "Ceftazidime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296462/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250253, "ingredient1": "Ceftibuten", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296463/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250254, "ingredient1": "Ceftizoxime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296464/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250255, "ingredient1": "Ceftriaxone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296465/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 250256, "ingredient1": "Cefuroxime", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296466/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Imipenem, Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250257, "ingredient1": "Celecoxib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296467/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tamsulosin, Tinidazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250258, "ingredient1": "Picosulfuric acid", "ingredient2": "Microcrystalline cellulose", "severity": "Minor", "effect": "According to some manufacturers, bulk-forming laxatives may reduce the efficacy of bowel cleansing products containing sodium picosulfate, magnesium oxide, and citric acid anhydrous.", "source": "DDInter", "management_text": "Clinical significance is unknown.", "mechanism_text": "Antagonism", "recommendation": "Clinical significance is unknown.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296468/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250259, "ingredient1": "Cephalexin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296469/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 250260, "ingredient1": "Cefalotin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296470/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250261, "ingredient1": "Cefapirin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296471/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250262, "ingredient1": "Cefradine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296472/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250263, "ingredient1": "Ceritinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296473/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 250264, "ingredient1": "Chloramphenicol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296474/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Mupirocin, Chlorhexidine, Miconazole, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Ganciclovir, Acyclovir, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250265, "ingredient1": "Chloroquine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296475/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250266, "ingredient1": "Chlorothiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296476/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250267, "ingredient1": "Chlorpromazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296477/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250268, "ingredient1": "Chlorthalidone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296478/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250269, "ingredient1": "Choline salicylate", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296479/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250270, "ingredient1": "Cilostazol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296480/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ticagrelor, Betrixaban, Clopidogrel, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250271, "ingredient1": "Cinoxacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296481/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250272, "ingredient1": "Ciprofloxacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296482/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Chlorhexidine, Chlorhexidine, Miconazole, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 250273, "ingredient1": "Cisapride", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296483/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250274, "ingredient1": "Citalopram", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296484/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250275, "ingredient1": "Clarithromycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296485/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250276, "ingredient1": "Clindamycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296486/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250277, "ingredient1": "Clofazimine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296487/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250278, "ingredient1": "Clomipramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296488/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250279, "ingredient1": "Cloxacillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296489/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250280, "ingredient1": "Clozapine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296490/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250281, "ingredient1": "Cocaine (nasal)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296491/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250282, "ingredient1": "Codeine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296492/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone, Benzonatate, Clofedanol, Dextromethorphan, Pentoxyverine", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250283, "ingredient1": "Colistimethate", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296493/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250284, "ingredient1": "Corticotropin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296495/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250285, "ingredient1": "Tetracosactide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296497/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250286, "ingredient1": "Crizotinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296498/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250287, "ingredient1": "Cyclobenzaprine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296499/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Methocarbamol, Chlormezanone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250288, "ingredient1": "Cycloserine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296500/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250289, "ingredient1": "Dalbavancin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296501/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250290, "ingredient1": "Dalfampridine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296502/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250291, "ingredient1": "Dapsone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296503/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250292, "ingredient1": "Daptomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296504/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250293, "ingredient1": "Dasatinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296505/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250294, "ingredient1": "Daunorubicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296506/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250295, "ingredient1": "Doxorubicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296507/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250296, "ingredient1": "Deflazacort", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296508/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250297, "ingredient1": "Degarelix", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296509/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250298, "ingredient1": "Delafloxacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296510/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250299, "ingredient1": "Demeclocycline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296511/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Mupirocin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "updated_at": 1767369485}, {"id": 250300, "ingredient1": "Desipramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296512/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250301, "ingredient1": "Desvenlafaxine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296513/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250302, "ingredient1": "Deutetrabenazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296514/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250303, "ingredient1": "Dexamethasone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296515/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate", "updated_at": 1767369485}, {"id": 250304, "ingredient1": "Dexfenfluramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296516/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250305, "ingredient1": "Dexmethylphenidate", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296517/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250306, "ingredient1": "Dextroamphetamine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296518/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250307, "ingredient1": "Dezocine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296519/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250308, "ingredient1": "Diclofenamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296520/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250309, "ingredient1": "Diclofenac", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296521/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Fluocinolone acetonide, Fluorometholone, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250310, "ingredient1": "Dicloxacillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296522/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250311, "ingredient1": "Diethylpropion", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296523/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250312, "ingredient1": "Diflunisal", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance", "source": "DDInter", "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296524/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987):  607-17[2] Gaspari F, Vigano G, Locatelli M, Remuzzi G \"Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis.\" Am J Kidney Dis 11 (1988):  338-42[3] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988):  58-62[4] Miners JO \"Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.\" Clin Pharmacokinet 17 (1989):  327-44[5] Levy G, Lampman T, Kamath BL, Garrettson LK \"Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid.\" N Engl J Med 293 (1975):  323-5[6] Shastri RA \"Effect of antacids on salicylate kinetics.\" Int J Clin Pharmacol Ther Toxicol 23 (1985):  480-4[7] Covington TR, eds., Lawson LC, Young LL \"Handbook of Nonprescription Drugs.\" Washington, DC: American Pharmaceutical Association  (1993):[8] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Magnesium gluconate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, Alvimopan, Sorbitol, More", "updated_at": 1767369485}, {"id": 250313, "ingredient1": "Diflunisal", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296525/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250314, "ingredient1": "Digitoxin", "ingredient2": "Picosulfuric acid", "severity": "Minor", "effect": "Due to a potential risk of water or electrolyte imbalance, the manufacturer recommends caution during concomitant administration of sodium picosulfate with cardiac glycosides, lithium, nonsteroidal anti-inflammatory agents, or drugs which may cause SIADH.", "source": "DDInter", "management_text": "The clinical significance is unknown.", "mechanism_text": "Others", "recommendation": "The clinical significance is unknown.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296526/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250315, "ingredient1": "Digoxin", "ingredient2": "Picosulfuric acid", "severity": "Minor", "effect": "Due to a potential risk of water or electrolyte imbalance, the manufacturer recommends caution during concomitant administration of sodium picosulfate with cardiac glycosides, lithium, nonsteroidal anti-inflammatory agents, or drugs which may cause SIADH.", "source": "DDInter", "management_text": "The clinical significance is unknown.", "mechanism_text": "Others", "recommendation": "The clinical significance is unknown.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296527/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Linaclotide, Plecanatide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250316, "ingredient1": "Disopyramide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296529/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250317, "ingredient1": "Dofetilide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296530/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250318, "ingredient1": "Dolasetron", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296531/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250319, "ingredient1": "Donepezil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296532/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250320, "ingredient1": "Doripenem", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296533/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250321, "ingredient1": "Doxapram", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296534/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Nitric Oxide, Ivacaftor, Elexacaftor, Lumacaftor", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250322, "ingredient1": "Doxepin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296535/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250323, "ingredient1": "Doxepin (topical)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296536/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250324, "ingredient1": "Doxycycline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296537/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Amphotericin B, Miconazole, Clotrimazole, Epinephrine, Chlorhexidine", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Bisacodyl, Lactitol, Sodium phosphate, monobasic, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250325, "ingredient1": "Dronabinol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296538/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250326, "ingredient1": "Dronedarone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296539/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "updated_at": 1767369485}, {"id": 250327, "ingredient1": "Droperidol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296540/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250328, "ingredient1": "Duloxetine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296541/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, Magnesium citrate, More", "updated_at": 1767369485}, {"id": 250329, "ingredient1": "Efavirenz", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296542/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250330, "ingredient1": "Enalapril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296543/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250331, "ingredient1": "Encorafenib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296544/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250332, "ingredient1": "Enoxacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296545/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250333, "ingredient1": "Entrectinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296546/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250334, "ingredient1": "Enzalutamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296547/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250335, "ingredient1": "Ephedrine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296548/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250336, "ingredient1": "Epirubicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296549/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250337, "ingredient1": "Eprosartan", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296550/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250338, "ingredient1": "Eravacycline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296551/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250339, "ingredient1": "Eribulin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296552/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250340, "ingredient1": "Ertapenem", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296553/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250341, "ingredient1": "Erythromycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296554/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 250342, "ingredient1": "Escitalopram", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296555/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250343, "ingredient1": "Etacrynic acid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296556/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250344, "ingredient1": "Ethambutol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296557/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250345, "ingredient1": "Ethionamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296558/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250346, "ingredient1": "Etodolac", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296559/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250347, "ingredient1": "Ezogabine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296560/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250348, "ingredient1": "Fenfluramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296561/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone, Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250349, "ingredient1": "Fenoprofen", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296562/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250350, "ingredient1": "Fentanyl", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296563/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine, Dihydrocodeine, More", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250351, "ingredient1": "Fidaxomicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296565/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Nystatin, Amphotericin B, Miconazole", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More", "updated_at": 1767369485}, {"id": 250352, "ingredient1": "Flecainide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296566/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250353, "ingredient1": "Fluconazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296567/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin, Selenium Sulfide, Thiabendazole, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate", "updated_at": 1767369485}, {"id": 250354, "ingredient1": "Fludeoxyglucose (18F)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference associated with the following medications:  colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of possible diagnostic interference associated with the following medications:  colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296568/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Capromab pendetide, Gallium Ga-68 gozetotide, Indium In-111 pentetreotide", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Mannitol, More", "updated_at": 1767369485}, {"id": 250355, "ingredient1": "Fludrocortisone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296569/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250356, "ingredient1": "Fluoxetine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296570/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250357, "ingredient1": "Fluphenazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296571/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250358, "ingredient1": "Flurbiprofen", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296572/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Chlorhexidine, Povidone-iodine, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250359, "ingredient1": "Flutamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296573/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250360, "ingredient1": "Fluvoxamine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296574/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250361, "ingredient1": "Foscarnet", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296575/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250362, "ingredient1": "Fosfomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296576/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250363, "ingredient1": "Fosinopril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296577/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250364, "ingredient1": "Fostemsavir", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296578/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250365, "ingredient1": "Furosemide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296580/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250366, "ingredient1": "Galantamine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296581/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250367, "ingredient1": "Gatifloxacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296582/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250368, "ingredient1": "Gefitinib", "ingredient2": "Magnesium oxide", "severity": "Major", "effect": "Coadministration with drugs that elevate gastric pH such as H2-receptor antagonists and antacids may decrease the plasma concentrations of gefitinib.  According to the manufacturer, the solubility of gefitinib is pH-dependent and decreases sharply between pH 4 and 6, becoming practically insoluble above pH 7.", "source": "DDInter", "management_text": "The possibility of a diminished therapeutic response to gefitinib should be considered during coadministration with H2-receptor antagonists or antacids.  If concomitant treatment is required, the manufacturer recommends administering gefitinib 6 hours before or 6 hours after an H2-receptor antagonist or antacid.", "mechanism_text": "Absorption", "recommendation": "The possibility of a diminished therapeutic response to gefitinib should be considered during coadministration with H2-receptor antagonists or antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296583/", "reference_text": "[1] \"Product Information. Iressa (gefitinib).\" Astra-Zeneca Pharmaceuticals  (2023):[2] \"Product Information. Apo-Gefitinib (gefitinib).\" Apotex Inc  (2022):[3] \"Product Information. Iressa (gefitinib).\" AstraZeneca UK Ltd  (2023):[4] \"Product Information. Iressa (gefitinib).\" AstraZeneca Pty Ltd  (2021):[5] Tang W, Tomkinson H, Masson E \"Effect of sustained elevated gastric pH levels on gefitinib exposure.\" Clin Pharmacol Drug Dev 6 (2017):  517-23", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "alternatives_b": "Magaldrate, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, Magnesium chloride, More", "updated_at": 1767369485}, {"id": 250369, "ingredient1": "Gemifloxacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296584/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250370, "ingredient1": "Gentamicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296585/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Chlorhexidine, Miconazole, Mupirocin, Chlorhexidine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250371, "ingredient1": "Gilteritinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296586/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "updated_at": 1767369485}, {"id": 250372, "ingredient1": "Glasdegib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296587/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, More", "updated_at": 1767369485}, {"id": 250373, "ingredient1": "Goserelin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296588/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250374, "ingredient1": "Granisetron", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296589/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250375, "ingredient1": "Grepafloxacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296590/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250376, "ingredient1": "Halofantrine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296592/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250377, "ingredient1": "Haloperidol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296593/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250378, "ingredient1": "Halothane", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296594/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250379, "ingredient1": "Diamorphine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296595/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250380, "ingredient1": "Histrelin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296596/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250381, "ingredient1": "Hydrochlorothiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296597/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Sacubitril, Aliskiren, Nebivolol, Amlodipine, Aliskiren, Tamsulosin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250382, "ingredient1": "Hydrocodone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296598/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Benzonatate, Clofedanol, Dextromethorphan, Pentoxyverine", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250383, "ingredient1": "Hydrocortisone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296599/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Amphotericin B, Miconazole, Clotrimazole, Epinephrine, Chlorhexidine, Fluocinolone acetonide, Fluorometholone, Mometasone furoate, Amcinonide, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, Magnesium carbonate", "updated_at": 1767369485}, {"id": 250384, "ingredient1": "Hydroflumethiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296600/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250385, "ingredient1": "Hydromorphone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296601/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250386, "ingredient1": "Hydroxychloroquine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296602/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250387, "ingredient1": "Hydroxyzine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296603/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Clobazam, Meprobamate, Alprazolam, Lorazepam, Chlordiazepoxide, Halazepam, Clorazepic acid, Buspirone, Diazepam, Oxazepam", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250388, "ingredient1": "Ibuprofen", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296604/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Alprostadil, Ubidecarenone, Ivabradine, Adenosine, Regadenoson, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250389, "ingredient1": "Ibutilide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296605/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250390, "ingredient1": "Idarubicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296606/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250391, "ingredient1": "Iloperidone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296607/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250392, "ingredient1": "Imipramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296608/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250393, "ingredient1": "Indapamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296609/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250394, "ingredient1": "Indomethacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296610/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Fluocinolone acetonide, Fluorometholone, Tolazoline, Rabeprazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Plecanatide, Magnesium citrate, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250395, "ingredient1": "Inotuzumab ozogamicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296611/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250396, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296612/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250397, "ingredient1": "Interferon alfa-2b", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296613/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250398, "ingredient1": "Interferon alfa-n1", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296614/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250399, "ingredient1": "Interferon alfa-n3", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296615/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250400, "ingredient1": "Interferon alfacon-1", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296616/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250401, "ingredient1": "Interferon beta-1a", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296617/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250402, "ingredient1": "Interferon gamma-1b", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296618/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250403, "ingredient1": "Irbesartan", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296619/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250404, "ingredient1": "Irinotecan", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Because irinotecan has been reported to cause diarrhea in the majority of treated patients, the use of laxatives may not be appropriate during irinotecan therapy.", "source": "DDInter", "management_text": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.  However, patients should be advised to inform their physician of any changes in their bowel habit so that dosage adjustments or discontinuation of laxatives may be done promptly.", "mechanism_text": "Synergism", "recommendation": "In patients requiring laxatives for constipation associated with narcotic administration, the standard regimen may be continued under supervision of the clinician.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296620/", "reference_text": "[1] \"Product Information. Camptosar (irinotecan).\" Pharmacia and Upjohn  (2001):", "alternatives_a": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Vincristine, Topotecan, Teniposide, Vinorelbine, Etoposide, Docetaxel", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 250405, "ingredient1": "Isocarboxazid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296622/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250406, "ingredient1": "Isoniazid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296623/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 250407, "ingredient1": "Picosulfuric acid", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296624/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250408, "ingredient1": "Picosulfuric acid", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296625/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Nystatin, Amphotericin B, Miconazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250409, "ingredient1": "Picosulfuric acid", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296626/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 250410, "ingredient1": "Picosulfuric acid", "ingredient2": "Ketoprofen", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296627/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250411, "ingredient1": "Picosulfuric acid", "ingredient2": "Ketorolac", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296628/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250412, "ingredient1": "Picosulfuric acid", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296630/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250413, "ingredient1": "Picosulfuric acid", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296631/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250414, "ingredient1": "Picosulfuric acid", "ingredient2": "Lenvatinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296632/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250415, "ingredient1": "Picosulfuric acid", "ingredient2": "Leuprolide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296633/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250416, "ingredient1": "Picosulfuric acid", "ingredient2": "Levofloxacin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296634/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250417, "ingredient1": "Picosulfuric acid", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296636/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250418, "ingredient1": "Picosulfuric acid", "ingredient2": "Levomilnacipran", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296637/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250419, "ingredient1": "Picosulfuric acid", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296638/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250420, "ingredient1": "Picosulfuric acid", "ingredient2": "Lidocaine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296639/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Chlorhexidine, Povidone-iodine, Tocainide, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250421, "ingredient1": "Picosulfuric acid", "ingredient2": "Linaclotide", "severity": "Minor", "effect": "The concomitant use of linaclotide with proton pump inhibitors, laxatives, or nonsteroidal anti-inflammatory drugs may increase the risk of diarrhea.", "source": "DDInter", "management_text": "Concurrent use of linaclotide with proton pump inhibitors, laxatives, or nonsteroidal anti-inflammatory drugs requires attention to whether the patient develops severe diarrhea.", "mechanism_text": "Synergism", "recommendation": "Concurrent use of linaclotide with proton pump inhibitors, laxatives, or nonsteroidal anti-inflammatory drugs requires attention to whether the patient develops severe diarrhea.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296640/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lactitol, Lubiprostone, Mannitol, More", "updated_at": 1767369485}, {"id": 250422, "ingredient1": "Picosulfuric acid", "ingredient2": "Lincomycin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296641/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250423, "ingredient1": "Picosulfuric acid", "ingredient2": "Lindane", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296642/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Disulfiram", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250424, "ingredient1": "Picosulfuric acid", "ingredient2": "Linezolid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296643/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250425, "ingredient1": "Picosulfuric acid", "ingredient2": "Lisdexamfetamine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296644/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250426, "ingredient1": "Picosulfuric acid", "ingredient2": "Lisinopril", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296645/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250427, "ingredient1": "Picosulfuric acid", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296646/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250428, "ingredient1": "Picosulfuric acid", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296647/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250429, "ingredient1": "Picosulfuric acid", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296648/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250430, "ingredient1": "Picosulfuric acid", "ingredient2": "Loracarbef", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296649/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250431, "ingredient1": "Picosulfuric acid", "ingredient2": "Losartan", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296650/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250432, "ingredient1": "Picosulfuric acid", "ingredient2": "Loxapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296651/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250433, "ingredient1": "Picosulfuric acid", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296652/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250434, "ingredient1": "Picosulfuric acid", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296653/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250435, "ingredient1": "Picosulfuric acid", "ingredient2": "Macimorelin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296655/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Gonadorelin, Vitamin A, Caffeine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250436, "ingredient1": "Magnesium gluconate", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "The concomitant administration of magnesium salts with other magnesium-containing preparations such as antacids or laxatives may increase the risk of magnesium toxicity, particularly in the presence of renal insufficiency.  Magnesium toxicity may result in respiratory depression, neuromuscular depression, and heart block.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for signs of hypermagnesemia and magnesium toxicity is advisable, especially in high-risk patients (e.g., elderly or renally impaired patients).", "mechanism_text": "Synergism", "recommendation": "Clinical and laboratory monitoring for signs of hypermagnesemia and magnesium toxicity is advisable, especially in high-risk patients (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296656/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Sodium sulfate, Zinc sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Magnesium oxide, Zinc gluconate", "alternatives_b": "Magaldrate, Calcium carbonate, Aluminum hydroxide, Magnesium gluconate, Sodium sulfate, Zinc sulfate, Magnesium aspartate, Magnesium lactate, Magnesium citrate, Sodium chloride, Zinc gluconate, More", "updated_at": 1767369485}, {"id": 250437, "ingredient1": "Picosulfuric acid", "ingredient2": "Mannitol", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296660/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Sorbitol, Sodium citrate, Magnesium citrate, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250438, "ingredient1": "Picosulfuric acid", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296661/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250439, "ingredient1": "Picosulfuric acid", "ingredient2": "Mazindol", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296662/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250440, "ingredient1": "Picosulfuric acid", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296663/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250441, "ingredient1": "Picosulfuric acid", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296664/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Plecanatide, More", "updated_at": 1767369485}, {"id": 250442, "ingredient1": "Picosulfuric acid", "ingredient2": "Mefloquine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296665/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250443, "ingredient1": "Picosulfuric acid", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296666/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ropivacaine, Chloroprocaine, Levobupivacaine, Tetracaine, Bupivacaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Rabeprazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250444, "ingredient1": "Picosulfuric acid", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296667/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250445, "ingredient1": "Picosulfuric acid", "ingredient2": "Meropenem", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296668/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Imipenem", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250446, "ingredient1": "Picosulfuric acid", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296669/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250447, "ingredient1": "Picosulfuric acid", "ingredient2": "Methadone", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296670/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250448, "ingredient1": "Picosulfuric acid", "ingredient2": "Metamfetamine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296671/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250449, "ingredient1": "Picosulfuric acid", "ingredient2": "Methazolamide", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296672/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250450, "ingredient1": "Picosulfuric acid", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296673/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250451, "ingredient1": "Picosulfuric acid", "ingredient2": "Methenamine", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296674/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "updated_at": 1767369485}, {"id": 250452, "ingredient1": "Picosulfuric acid", "ingredient2": "Meticillin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296675/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250453, "ingredient1": "Picosulfuric acid", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296676/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250454, "ingredient1": "Picosulfuric acid", "ingredient2": "Methylcellulose", "severity": "Minor", "effect": "According to some manufacturers, bulk-forming laxatives may reduce the efficacy of bowel cleansing products containing sodium picosulfate, magnesium oxide, and citric acid anhydrous.", "source": "DDInter", "management_text": "Clinical significance is unknown.", "mechanism_text": "Antagonism", "recommendation": "Clinical significance is unknown.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296678/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250455, "ingredient1": "Picosulfuric acid", "ingredient2": "Methylphenidate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296679/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250456, "ingredient1": "Picosulfuric acid", "ingredient2": "Methylprednisolone", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296680/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Fluocinolone acetonide, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, Magnesium carbonate", "updated_at": 1767369485}, {"id": 250457, "ingredient1": "Picosulfuric acid", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296681/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250458, "ingredient1": "Picosulfuric acid", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296682/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250459, "ingredient1": "Picosulfuric acid", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296683/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, Esomeprazole, Ranitidine, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 250460, "ingredient1": "Picosulfuric acid", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296684/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250461, "ingredient1": "Picosulfuric acid", "ingredient2": "Mezlocillin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296685/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250462, "ingredient1": "Picosulfuric acid", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296686/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250463, "ingredient1": "Picosulfuric acid", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296687/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250464, "ingredient1": "Picosulfuric acid", "ingredient2": "Milnacipran", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296688/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250465, "ingredient1": "Picosulfuric acid", "ingredient2": "Minocycline", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296689/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Amphotericin B, Miconazole, Clotrimazole, Epinephrine, Chlorhexidine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "updated_at": 1767369485}, {"id": 250466, "ingredient1": "Picosulfuric acid", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296690/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250467, "ingredient1": "Picosulfuric acid", "ingredient2": "Moexipril", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296692/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250468, "ingredient1": "Picosulfuric acid", "ingredient2": "Molindone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296693/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250469, "ingredient1": "Picosulfuric acid", "ingredient2": "Morphine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296694/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250470, "ingredient1": "Picosulfuric acid", "ingredient2": "Moxifloxacin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296695/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 250471, "ingredient1": "Picosulfuric acid", "ingredient2": "Muromonab", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296696/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250472, "ingredient1": "Picosulfuric acid", "ingredient2": "Nabumetone", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296697/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250473, "ingredient1": "Picosulfuric acid", "ingredient2": "Nafcillin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296698/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 250474, "ingredient1": "Picosulfuric acid", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296699/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250475, "ingredient1": "Picosulfuric acid", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296700/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250476, "ingredient1": "Picosulfuric acid", "ingredient2": "Naproxen", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296701/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Plecanatide, Magnesium citrate, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250477, "ingredient1": "Picosulfuric acid", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296702/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250478, "ingredient1": "Picosulfuric acid", "ingredient2": "Nelarabine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296703/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Cytarabine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250479, "ingredient1": "Picosulfuric acid", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296704/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Nystatin, Amphotericin B, Miconazole, Chlorhexidine, Povidone-iodine, Mupirocin, Chlorhexidine, Amphotericin B, Miconazole, Clotrimazole, Epinephrine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250480, "ingredient1": "Picosulfuric acid", "ingredient2": "Neostigmine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296705/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ambenonium, Pilocarpine, Cevimeline, Pyridostigmine, Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Betaxolol, Bimatoprost, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250481, "ingredient1": "Picosulfuric acid", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296706/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250482, "ingredient1": "Picosulfuric acid", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296707/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 250483, "ingredient1": "Picosulfuric acid", "ingredient2": "Nilutamide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296708/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250484, "ingredient1": "Picosulfuric acid", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296709/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250485, "ingredient1": "Picosulfuric acid", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296710/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250486, "ingredient1": "Picosulfuric acid", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296711/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250487, "ingredient1": "Picosulfuric acid", "ingredient2": "Novobiocin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296712/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250488, "ingredient1": "Picosulfuric acid", "ingredient2": "Ofloxacin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296713/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Chlorhexidine, Miconazole", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide", "updated_at": 1767369485}, {"id": 250489, "ingredient1": "Picosulfuric acid", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296714/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250490, "ingredient1": "Picosulfuric acid", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296715/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250491, "ingredient1": "Picosulfuric acid", "ingredient2": "Olmesartan", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296716/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250492, "ingredient1": "Picosulfuric acid", "ingredient2": "Omadacycline", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296717/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250493, "ingredient1": "Picosulfuric acid", "ingredient2": "Ondansetron", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296718/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250494, "ingredient1": "Picosulfuric acid", "ingredient2": "Opium", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296719/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250495, "ingredient1": "Picosulfuric acid", "ingredient2": "Oritavancin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296720/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250496, "ingredient1": "Picosulfuric acid", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296721/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250497, "ingredient1": "Picosulfuric acid", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296722/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250498, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxacillin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296723/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250499, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296724/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250500, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxamniquine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296725/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Praziquantel", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250501, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxaprozin", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296726/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250502, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296727/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250503, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296728/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250504, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296729/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250505, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxytetracycline", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296730/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Mupirocin, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "updated_at": 1767369485}, {"id": 250506, "ingredient1": "Picosulfuric acid", "ingredient2": "Oxytocin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296731/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Methylergometrine, Misoprostol, Ergometrine, Dinoprostone, Terlipressin, Desmopressin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250507, "ingredient1": "Picosulfuric acid", "ingredient2": "Ozanimod", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296732/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 250508, "ingredient1": "Picosulfuric acid", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296734/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250509, "ingredient1": "Picosulfuric acid", "ingredient2": "Palonosetron", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296735/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250510, "ingredient1": "Picosulfuric acid", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296736/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250511, "ingredient1": "Picosulfuric acid", "ingredient2": "Paromomycin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296737/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Nystatin, Amphotericin B, Miconazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250512, "ingredient1": "Picosulfuric acid", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296738/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250513, "ingredient1": "Picosulfuric acid", "ingredient2": "Pasireotide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296739/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250514, "ingredient1": "Picosulfuric acid", "ingredient2": "Pazopanib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296740/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250515, "ingredient1": "Picosulfuric acid", "ingredient2": "Peginterferon alfa-2a", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296741/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250516, "ingredient1": "Picosulfuric acid", "ingredient2": "Peginterferon alfa-2b", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296742/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250517, "ingredient1": "Picosulfuric acid", "ingredient2": "Peginterferon beta-1a", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296743/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250518, "ingredient1": "Picosulfuric acid", "ingredient2": "Pemoline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296744/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250519, "ingredient1": "Benzylpenicillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296745/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250520, "ingredient1": "Benzylpenicillin (potassium)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296746/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250521, "ingredient1": "Benzylpenicillin (sodium)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296747/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250522, "ingredient1": "Picosulfuric acid", "ingredient2": "Phenoxymethylpenicillin", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296748/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250523, "ingredient1": "Picosulfuric acid", "ingredient2": "Pentamidine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296749/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Miltefosine, Nifurtimox", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250524, "ingredient1": "Picosulfuric acid", "ingredient2": "Pentazocine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296750/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250525, "ingredient1": "Picosulfuric acid", "ingredient2": "Perflutren", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296751/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250526, "ingredient1": "Picosulfuric acid", "ingredient2": "Perindopril", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296752/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, More", "updated_at": 1767369485}, {"id": 250527, "ingredient1": "Picosulfuric acid", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296753/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250528, "ingredient1": "Picosulfuric acid", "ingredient2": "Phendimetrazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296754/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250529, "ingredient1": "Picosulfuric acid", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296755/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250530, "ingredient1": "Picosulfuric acid", "ingredient2": "Phentermine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296756/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250531, "ingredient1": "Picosulfuric acid", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296757/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250532, "ingredient1": "Picosulfuric acid", "ingredient2": "Phenylpropanolamine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296758/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pseudoephedrine, Phenylephrine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250533, "ingredient1": "Picosulfuric acid", "ingredient2": "Physostigmine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296759/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Betaxolol, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Guanethidine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250534, "ingredient1": "Picosulfuric acid", "ingredient2": "Pimavanserin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296760/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250535, "ingredient1": "Pimozide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296761/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250536, "ingredient1": "Piperacillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296762/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250537, "ingredient1": "Piperazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296763/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiabendazole, Levamisole, Pyrantel, Ivermectin, Mebendazole, Albendazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250538, "ingredient1": "Piroxicam", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296764/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250539, "ingredient1": "Pitolisant", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296765/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250540, "ingredient1": "Plazomicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296766/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250541, "ingredient1": "Polyethylene glycol (3350)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Concomitant use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) may increase the risk of serious gastrointestinal adverse effects associated with certain osmotic laxatives (e.g., polyethylene glycol (PEG), oral sulfate solution), such as colonic mucosal ulcerations or ischemic colitis.", "source": "DDInter", "management_text": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.  However, stimulant laxatives, in particular bisacodyl and sodium picosulfate, are sometimes used with PEG in certain bowel cleansing regimens to help reduce dose volume and improve patient tolerability and acceptance.  Please consult individual product labeling for specific recommendations and guidance.  Patients using osmotic bowel cleansing products and stimulant laxatives who present with sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis should be evaluated promptly.", "mechanism_text": "Synergism", "recommendation": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296768/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Baudet JS, Castro V, Redondo I \"Recurrent ischemic colitis induced by colonoscopy bowel lavage.\" Am J Gastroenterol 105 (2010):  700-1[4] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[5] Ajani S, Hurt RT, Teeters DA, Bellmore LR \"Ischaemic colitis associated with oral contraceptive and bisacodyl use.\" BMJ Case Rep 2012 (2012):[6] \"Product Information. MoviPrep (polyethylene glycol 3350 with electrolytes).\" Physicians Total Care  (2016):[7] \"Product Information. Plenvu (polyethylene glycol 3350 with electrolytes).\" Bausch Health US (formerly Valeant Pharmaceuticals)  (2020):[8] \"Product Information. GaviLyte-H and Bisacodyl with Flavor Packs (bisacodyl-PEG 3350 with electrolytes).\" Gavis Pharmaceuticals  (2022):[9] \"Product Information. Bi-Peglyte (bisacodyl-PEG 3350 with electrolytes).\" Pendopharm[10] Vaizman K, Li J, Iswara K, Tenner S \"Ischemic colitis induced by the combination of Bisacodyl and polyethylene glycol in preparation for colonoscopy.\" Am J Gastroenterol 102 (2007):  S267[11] Belsey J, Epstein O, heresbach D \"Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol.\" Aliment Pharmacol Ther 29 (2009):  15-28[12] Hung SY, Chen HC, Chen WT \"A randomized trial comparing the bowel cleansing efficacy of sodium picosulfate/magnesium citrate and polyethylene glycol/Bisacodyl (The Bowklean Study)\" Sci Rep 10 (2020):  5604[13] Adamcewicz M, Bearelly D, Porat G, Friedenberg FK \"Mechanism of action and toxicities of purgatives used for colonoscopy preparation.\" Expert Opin Drug Metab Toxicol 7 (2011):  89-101[14] Anastassopoulos K, Farraye FA, Knight T, Colman S, Cleveland MvB, Pelham RW \"A comparative study of treatment-emergent adverse events following use of common bowel preparations among a colonoscopy screening population: results from a post-marketing observational study.\" Dig Dis Sci 61 (2016):  2993-3006[15] Barbeau P, Wolfe D, Yazdi F, et al. \"Comparative safety of bowel cleansers: protocol for a systematic review and network meta-analysis.\" BMJ Open 8 (2018):  e021892", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, Sodium sulfate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250542, "ingredient1": "Polyethylene glycol (3350 with electrolytes)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Concomitant use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) may increase the risk of serious gastrointestinal adverse effects associated with certain osmotic laxatives (e.g., polyethylene glycol (PEG), oral sulfate solution), such as colonic mucosal ulcerations or ischemic colitis.", "source": "DDInter", "management_text": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.  However, stimulant laxatives, in particular bisacodyl and sodium picosulfate, are sometimes used with PEG in certain bowel cleansing regimens to help reduce dose volume and improve patient tolerability and acceptance.  Please consult individual product labeling for specific recommendations and guidance.  Patients using osmotic bowel cleansing products and stimulant laxatives who present with sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis should be evaluated promptly.", "mechanism_text": "Synergism", "recommendation": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296769/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Baudet JS, Castro V, Redondo I \"Recurrent ischemic colitis induced by colonoscopy bowel lavage.\" Am J Gastroenterol 105 (2010):  700-1[4] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[5] Ajani S, Hurt RT, Teeters DA, Bellmore LR \"Ischaemic colitis associated with oral contraceptive and bisacodyl use.\" BMJ Case Rep 2012 (2012):[6] \"Product Information. MoviPrep (polyethylene glycol 3350 with electrolytes).\" Physicians Total Care  (2016):[7] \"Product Information. Plenvu (polyethylene glycol 3350 with electrolytes).\" Bausch Health US (formerly Valeant Pharmaceuticals)  (2020):[8] \"Product Information. GaviLyte-H and Bisacodyl with Flavor Packs (bisacodyl-PEG 3350 with electrolytes).\" Gavis Pharmaceuticals  (2022):[9] \"Product Information. Bi-Peglyte (bisacodyl-PEG 3350 with electrolytes).\" Pendopharm[10] Vaizman K, Li J, Iswara K, Tenner S \"Ischemic colitis induced by the combination of Bisacodyl and polyethylene glycol in preparation for colonoscopy.\" Am J Gastroenterol 102 (2007):  S267[11] Belsey J, Epstein O, heresbach D \"Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol.\" Aliment Pharmacol Ther 29 (2009):  15-28[12] Hung SY, Chen HC, Chen WT \"A randomized trial comparing the bowel cleansing efficacy of sodium picosulfate/magnesium citrate and polyethylene glycol/Bisacodyl (The Bowklean Study)\" Sci Rep 10 (2020):  5604[13] Adamcewicz M, Bearelly D, Porat G, Friedenberg FK \"Mechanism of action and toxicities of purgatives used for colonoscopy preparation.\" Expert Opin Drug Metab Toxicol 7 (2011):  89-101[14] Anastassopoulos K, Farraye FA, Knight T, Colman S, Cleveland MvB, Pelham RW \"A comparative study of treatment-emergent adverse events following use of common bowel preparations among a colonoscopy screening population: results from a post-marketing observational study.\" Dig Dis Sci 61 (2016):  2993-3006[15] Barbeau P, Wolfe D, Yazdi F, et al. \"Comparative safety of bowel cleansers: protocol for a systematic review and network meta-analysis.\" BMJ Open 8 (2018):  e021892", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, Sodium sulfate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250543, "ingredient1": "Polymyxin B", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296770/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Chlorhexidine, Miconazole, Chlorhexidine, Tinidazole, Nystatin, Amphotericin B, Miconazole, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250544, "ingredient1": "Polythiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296771/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250545, "ingredient1": "Posaconazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296773/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250546, "ingredient1": "Pralsetinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296774/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "updated_at": 1767369485}, {"id": 250547, "ingredient1": "Prednisolone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296775/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250548, "ingredient1": "Prednisone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296776/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Budesonide, Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250549, "ingredient1": "Primaquine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296777/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250550, "ingredient1": "Probucol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296778/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250551, "ingredient1": "Procainamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296779/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250552, "ingredient1": "Prochlorperazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296781/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250553, "ingredient1": "Promazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296782/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250554, "ingredient1": "Promethazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296783/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250555, "ingredient1": "Propafenone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296784/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250556, "ingredient1": "Propiomazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296785/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250557, "ingredient1": "Propofol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296786/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250558, "ingredient1": "Dextropropoxyphene", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296787/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250559, "ingredient1": "Protriptyline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296788/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250560, "ingredient1": "Plantago seed", "ingredient2": "Picosulfuric acid", "severity": "Minor", "effect": "According to some manufacturers, bulk-forming laxatives may reduce the efficacy of bowel cleansing products containing sodium picosulfate, magnesium oxide, and citric acid anhydrous.", "source": "DDInter", "management_text": "Clinical significance is unknown.", "mechanism_text": "Antagonism", "recommendation": "Clinical significance is unknown.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296789/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250561, "ingredient1": "Pyrazinamide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296790/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250562, "ingredient1": "Quetiapine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296791/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250563, "ingredient1": "Quinapril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296792/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Lactitol, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 250564, "ingredient1": "Quinidine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296793/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 250565, "ingredient1": "Quinine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296794/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250566, "ingredient1": "Quinupristin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296795/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250567, "ingredient1": "Ramipril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296796/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250568, "ingredient1": "Ranolazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296797/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alprostadil, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250569, "ingredient1": "Relugolix", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296798/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250570, "ingredient1": "Remifentanil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296799/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250571, "ingredient1": "Ribociclib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296800/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250572, "ingredient1": "Rifabutin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296801/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid, Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 250573, "ingredient1": "Rifampicin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296802/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250574, "ingredient1": "Rifamycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296803/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine, Chlorhexidine, Miconazole, Mupirocin, Nystatin, Amphotericin B, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250575, "ingredient1": "Rifapentine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296804/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 250576, "ingredient1": "Rifaximin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296805/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Nystatin, Amphotericin B, Miconazole, Mupirocin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250577, "ingredient1": "Rilpivirine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296806/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250578, "ingredient1": "Rimantadine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296807/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250579, "ingredient1": "Risperidone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296808/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250580, "ingredient1": "Rivastigmine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296809/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250581, "ingredient1": "Rofecoxib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296810/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250582, "ingredient1": "Romidepsin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296811/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250583, "ingredient1": "Rucaparib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296812/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250584, "ingredient1": "Salsalate", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296813/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250585, "ingredient1": "Saquinavir", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296814/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, More", "updated_at": 1767369485}, {"id": 250586, "ingredient1": "Sarecycline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296815/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Sodium sulfate, Linaclotide, Plecanatide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250587, "ingredient1": "Secnidazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296816/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Quinacrine, Nitazoxanide, Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250588, "ingredient1": "Selpercatinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296817/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Linaclotide, Naloxone", "updated_at": 1767369485}, {"id": 250589, "ingredient1": "Sertraline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296818/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250590, "ingredient1": "Sevoflurane", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296819/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250591, "ingredient1": "Sibutramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296820/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250592, "ingredient1": "Siponimod", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296821/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250593, "ingredient1": "Solifenacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296824/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250594, "ingredient1": "Sorafenib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296825/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250595, "ingredient1": "Sotalol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296826/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acebutolol, Labetalol, Nadolol, Propranolol, Metoprolol, Carvedilol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250596, "ingredient1": "Sparfloxacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296827/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250597, "ingredient1": "Spectinomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296829/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250598, "ingredient1": "Spironolactone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296830/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Eplerenone, Finerenone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "updated_at": 1767369485}, {"id": 250599, "ingredient1": "Streptomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296831/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid, Nystatin, Amphotericin B, Miconazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250600, "ingredient1": "Sufentanil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296832/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250601, "ingredient1": "Sulfadiazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296833/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250602, "ingredient1": "Sulfadoxine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296834/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Proguanil, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250603, "ingredient1": "Sulfamethizole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296835/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Sorbitol, Sodium citrate, Magnesium citrate, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250604, "ingredient1": "Sulfamethoxazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296836/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250605, "ingredient1": "Sulfisoxazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296837/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250606, "ingredient1": "Sulindac", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296838/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250607, "ingredient1": "Sunitinib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296839/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250608, "ingredient1": "Tacrine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296840/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250609, "ingredient1": "Tacrolimus", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296841/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 250610, "ingredient1": "Tamoxifen", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296842/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250611, "ingredient1": "Tapentadol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296843/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250612, "ingredient1": "Tedizolid", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296845/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250613, "ingredient1": "Telavancin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296846/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250614, "ingredient1": "Telithromycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.  The recommended dosage and duration of treatment with sodium picosulfate should not be exceeded.  In addition, patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296847/", "reference_text": "[1] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[2] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Schaefer DC, Cheskin LJ \"Constipation in the elderly.\" Am Fam Physician 58 (1998):  907-14[7] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[10] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250615, "ingredient1": "Telmisartan", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296848/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250616, "ingredient1": "Terbutaline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296849/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Formoterol, Orciprenaline, Pirbuterol, Isoprenaline, Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Budesonide, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250617, "ingredient1": "Terfenadine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296850/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250618, "ingredient1": "Tetrabenazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296851/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250619, "ingredient1": "Tetracycline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296852/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Chlorhexidine, Miconazole, Tinidazole, Pantoprazole, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Cimetidine, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250620, "ingredient1": "Thalidomide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296853/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 250621, "ingredient1": "Theophylline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296854/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250622, "ingredient1": "Thiethylperazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296855/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250623, "ingredient1": "Thioridazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296856/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250624, "ingredient1": "Thiothixene", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296857/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250625, "ingredient1": "Ticarcillin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296858/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tazobactam, Sulbactam", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250626, "ingredient1": "Tigecycline", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296859/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250627, "ingredient1": "Tizanidine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296860/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Methocarbamol, Chlormezanone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250628, "ingredient1": "Tobramycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296861/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250629, "ingredient1": "Tolmetin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296862/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250630, "ingredient1": "Toremifene", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296863/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250631, "ingredient1": "Torasemide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296864/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250632, "ingredient1": "Tramadol", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296865/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250633, "ingredient1": "Trandolapril", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296866/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250634, "ingredient1": "Tranylcypromine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296867/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250635, "ingredient1": "Trazodone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296868/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250636, "ingredient1": "Triamcinolone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296869/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250637, "ingredient1": "Triamcinolone (ophthalmic)", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296870/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250638, "ingredient1": "Triamterene", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296871/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Eplerenone, Finerenone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250639, "ingredient1": "Trichlormethiazide", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296872/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 250640, "ingredient1": "Triclabendazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296873/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Praziquantel", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250641, "ingredient1": "Trifluoperazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296874/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250642, "ingredient1": "Triflupromazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296875/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250643, "ingredient1": "Alimemazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296876/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250644, "ingredient1": "Trimethoprim", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296877/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Pyridoxine, Pretomanid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 250645, "ingredient1": "Trimetrexate", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296878/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Quinacrine, Nitazoxanide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250646, "ingredient1": "Trimipramine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296879/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250647, "ingredient1": "Triptorelin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296880/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250648, "ingredient1": "Troleandomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296881/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250649, "ingredient1": "Trovafloxacin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296882/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250650, "ingredient1": "Urea", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296883/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tromethamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250651, "ingredient1": "Valbenazine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296884/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 250652, "ingredient1": "Valdecoxib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296885/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250653, "ingredient1": "Valsartan", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296886/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250654, "ingredient1": "Vancomycin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "Theoretically, use of sodium picosulfate during or following antibiotic treatment may result in a reduced laxative effect of sodium picosulfate.  The proposed mechanism involves antibiotic-induced reduction of colonic bacteria that hydrolyze sodium picosulfate, a prodrug, to its active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), a compound that stimulates colonic peristalsis.", "source": "DDInter", "management_text": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.  If concomitant use is required, additional bowel cleansing and colonoscopy may be required.", "mechanism_text": "Antagonism", "recommendation": "Consider use of an alternate laxative in patients who have recently taken or are currently taking an antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296887/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Clenpiq (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc  (2022):[5] \"MHRA. Medicines & Healthcare products Regulatory Agency (general site Reference)  http://www.mhra.gov.uk/spc-pil/index.htm\"   (2018):", "alternatives_a": "Tinidazole, Nystatin, Amphotericin B, Miconazole, Ganciclovir, Acyclovir, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 250655, "ingredient1": "Vandetanib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296888/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250656, "ingredient1": "Vardenafil", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296889/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250657, "ingredient1": "Vasopressin", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296890/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250658, "ingredient1": "Vemurafenib", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296891/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250659, "ingredient1": "Venlafaxine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296892/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250660, "ingredient1": "Vilazodone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296893/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250661, "ingredient1": "Voriconazole", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296895/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250662, "ingredient1": "Vortioxetine", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296896/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250663, "ingredient1": "Ziprasidone", "ingredient2": "Picosulfuric acid", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296898/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250664, "ingredient1": "Brentuximab vedotin", "ingredient2": "Simvastatin", "severity": "Moderate", "effect": "Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.  Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296902/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Guar gum, Gemfibrozil, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Ezetimibe, Bempedoic acid, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 250665, "ingredient1": "Somapacitan", "ingredient2": "Simvastatin", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296905/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Guar gum, Rosuvastatin, Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Ezetimibe, Niacin, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 250666, "ingredient1": "St. John's Wort", "ingredient2": "Simvastatin", "severity": "Moderate", "effect": "The interaction has been reported specifically with simvastatin and its pharmacologically active acid metabolite.  The mechanism is enhanced first-pass metabolism of simvastatin due to induction of hepatic and intestinal CYP450 3A4 activity by constituents of St. John's wort.  Reduced absorption of simvastatin secondary to induction of intestinal P-glycoprotein drug efflux pumps may also play a role.", "source": "DDInter", "management_text": "While clinical data are lacking, the possibility of a diminished therapeutic response to simvastatin should be considered in patients simultaneously treated with St. John's wort.  Other HMG-CoA reductase inhibitors that are substrates of CYP450 3A4 and P-glycoprotein such as lovastatin and atorvastatin are also expected to interact similarly with St. John's wort.  Fluvastatin, pravastatin, and rosuvastatin are not expected to participate in this interaction and may be suitable alternatives in patients using St. John's wort.", "mechanism_text": "Metabolism", "recommendation": "While clinical data are lacking, the possibility of a diminished therapeutic response to simvastatin should be considered in patients simultaneously treated with St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296906/", "reference_text": "[1] Bogman K, Peyer AK, Torok M, Kusters E, Drewe J \"HMG-CoA reductase inhibitors and P-glycoprotein modulation.\" Br J Pharmacol 132 (2001):  1183-92[2] Sugimoto K, Ohmori M, Tsuruoka S, et al. \"Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin.\" Clin Pharmacol Ther 70 (2001):  518-24[3] Holtzman CW, Wiggins BS, Spinler SA \"Role of P-glycoprotein in statin drug interactions.\" Pharmacotherapy 26 (2006):  1601-7", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Tranylcypromine, Vilazodone, Maprotiline, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Amoxapine, Protriptyline, More", "updated_at": 1767369485}, {"id": 250667, "ingredient1": "Telotristat ethyl", "ingredient2": "Simvastatin", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes.  The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296907/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc.  (2017):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250668, "ingredient1": "Sulfadoxine", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).  Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.  The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296909/", "reference_text": "[1] Petitpierre B, Perrin L, Rudhardt M, et al. \"Behaviour of chlorpropamide in renal insufficiency and under the effect of associated drug therapy.\" Int J Clin Pharmacol 6 (1972):  120-4[2] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[3] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[4] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[5] Shah SJ, Bhandarkar SD, Satoskar RS \"Drug interaction between chlorpropamide and non-steroidal anti-flammatory drugs, ibuprofen and phenylbutazone.\" Int J Clin Pharmacol Ther Toxicol 22 (1984):  470-2[6] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[7] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[8] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[9] Field JB, Ohta M, Boyle C, Remer A \"Potentiation of acetohexamide hypoglycemia by phenylbutazone.\" N Engl J Med 277 (1967):  889-94[10] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[11] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[12] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[13] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[14] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[15] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[16] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[17] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[18] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[19] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[20] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[21] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[22] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[23] Ravic M, Johnston A, Turner P \"Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs.\" Postgrad Med J 66 (1990):  s30-4[24] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[25] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[26] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[27] Nikkila EA, Ylikahri R, Huttunen JK \"Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.\" Proc R Soc Med 69 (1976):  58-63[28] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[29] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[30] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[31] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[32] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[33] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[34] Wing LM, Miners JO \"Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.\" Br J Clin Pharmacol 20 (1985):  482-5[35] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[36] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[37] Sjoberg S, Wiholm BE, Gunnarsson R, Emilsson H, Thunberg E, Christenson I, Ostman J \"Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole.\" Diabet Med 4 (1987):  245-7[38] Diwan PV, Sastry MS, Satyanarayana NV \"Potentiation of hypoglycemic response of glibenclamide by piroxicam in rats and humans.\" Indian J Exp Biol 30 (1992):  317-9[39] Tannenbaum H, Anderson LG, Soeldner JS \"Phenylbutazone-tolbutamide drug interaction.\" N Engl J Med 290 (1974):  344[40] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[41] David DS, Steere AC Jr, Pi-Sunyer XF, Sakai S, Clark SB \"Aspirin-induced hypoglycaemia in a patient on haemodialysis.\" Lancet 2 (1971):  1092-3[42] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[43] Pond SM, Birkett DJ, Wade DN \"Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.\" Clin Pharmacol Ther 22 (1977):  573-9[44] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[45] Harris EL \"Adverse reactions to oral antidiabetic agents.\" Br Med J 3 (1971):  29-30[46] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[47] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[48] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[49] \"Product Information. Micronase (glyburide).\" Pharmacia and Upjohn  (2002):[50] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[51] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[52] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[53] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[54] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[55] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[56] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[57] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[58] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[59] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[60] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[61] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[62] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[63] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[64] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[65] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[66] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[67] Lozada A, Dujovne CA \"Drug interactions with fibric acids.\" Pharmacol Ther 63 (1994):  163-76[68] Kradjan WA, Witt DM, Opheim KE, Wood FC \"Lack of interaction between glipizide and co-trimoxazole.\" J Clin Pharmacol 34 (1994):  997-1002[69] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[70] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[71] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[72] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[73] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[74] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[75] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[76] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[77] Hartmann D, Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK \"Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.\" Br J Clin Pharmacol 30 (1990):  245-52[78] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[79] Morrison PJ, Rogers HJ, Spector RG, Bradbrook ID, John VA \"Effect of pirprofen on glibenclamide kinetics and response.\" Br J Clin Pharmacol 14 (1982):  123-6[80] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[81] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[82] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[83] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[84] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[85] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[86] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[87] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[88] Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT \"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.\" Clin Pharmacol Ther 69 (2001):  194-200[89] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[90] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[91] Tran PO, Gleason CE, Robertson RP \"Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.\" Diabetes 51 (2002):  1772-8[92] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[93] Tremaine LM, Wilner KD, Preskorn SH \"A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide.\" Clin Pharmacokinet 32(Suppl 1) (1997):  31-36[94] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[95] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[96] Sone H, Takahashi A, Yamada N \"Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.\" Ann Intern Med 134 (2001):  344[97] Sawka AM, Burgart V, Zimmerman D \"Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors.\" Diabetes Care 24 (2001):  1845-6[98] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[99] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[100] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[101] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[102] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Empagliflozin, Dulaglutide, Exenatide, Miglitol, Albiglutide, Rosiglitazone, Ertugliflozin, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Tamsulosin, More", "updated_at": 1767369485}, {"id": 250669, "ingredient1": "Anisindione", "ingredient2": "Sulfadoxine", "severity": "Major", "effect": "Coadministration with a sulfonamide may increase the plasma concentrations and hypoprothrombinemic effects of coumarin anticoagulants.  The proposed mechanism is sulfonamide inhibition of coumarin metabolism via CYP450 2C9 and possibly also displacement of coumarin derivatives from plasma protein binding sites.", "source": "DDInter", "management_text": "Patients receiving coumarin anticoagulants should be closely monitored during concomitant therapy with sulfonamides.  The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of sulfonamide therapy in patients who are stabilized on their anticoagulant regimen.  The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Metabolism, Distribution", "recommendation": "Patients receiving coumarin anticoagulants should be closely monitored during concomitant therapy with sulfonamides.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296911/", "reference_text": "[1] O'Reilly RA \"Stereoselective interaction of trimethoprim-sulfamethaxazole with the separated enantiomorphs of racemic warfarin in man.\" N Engl J Med 302 (1980):  33-5[2] Kelly JG, O'Malley K \"Clinical pharmacokinetics of oral anticoagulants.\" Clin Pharmacokinet 4 (1979):  1-15[3] Sioris LJ, Weibert RT, Pentel PR \"Potentiation of warfarin anaticoagulation by sulfisoxazole.\" Arch Intern Med 140 (1980):  546-7[4] O'Donnell D \"Antibiotic-induced potentiation of oral anticoagulant agents.\" Med J Aust 150 (1989):  163-4[5] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[6] O'Reilly RA, Motley CH \"Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans.\" Ann Intern Med 91 (1979):  34-6[7] Self TH, Evans W, Ferguson T \"Interaction of sulfisoxizole and warfarin.\" Circulation 52 (1975):  528[8] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[9] Serlin MJ, Breckenridge AM \"Drug interactions with warfarin.\" Drugs 25 (1983):  610-20[10] Cook DE, Ponte CD \"Suspected trimethoprim sulfamethoxazole induced hypoprothrombinemia.\" J Fam Pract 39 (1994):  589-91[11] Hermans JJ, Thijssen HH \"Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.\" Br J Pharmacol 110 (1993):  482-90[12] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998):  525-38[13] Venkatakrishnan K, vonMoltke LL, Greenblatt DJ \"Effects of the antifungal agents on oxidative drug metabolism - Clinical relevance.\" Clin Pharmacokinet 38 (2000):  111-80[14] Thijssen HH, Flinois JP, Beaune PH \"Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.\" Drug Metab Disposition 28 (2000):  1284-90[15] Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH \"Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.\" Clin Pharmacol Ther 69 (2001):  451-7[16] Hermida J, Zarza J, Alberca I, et al. \"Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.\" Blood 99 (2002):  4237-9[17] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.\" Thromb Haemost 88 (2002):  705-10[18] Takahashi H, Wilkinson GR, Caraco Y, et al. \"Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.\" Clin Pharmacol Ther 73 (2003):  253-63[19] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44[20] Glasheen JJ, Fugit RV, Prochazka AV \"The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.\" J Gen Intern Med 20 (2005):  653-6[21] Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A \"Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study.\" Arch Intern Med 170 (2010):  617-21", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Chloroquine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250670, "ingredient1": "Brentuximab vedotin", "ingredient2": "Sulfadoxine", "severity": "Moderate", "effect": "Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296912/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Halofantrine, Primaquine, Proguanil, Tamsulosin, Ascorbic acid, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 250671, "ingredient1": "Cocaine (nasal)", "ingredient2": "Sulfadoxine", "severity": "Moderate", "effect": "Ester-type local anesthetics are hydrolyzed to paraaminobenzoic acid, which can inhibit the action of sulfonamides.", "source": "DDInter", "management_text": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.  Amide-type anesthetics are not expected to inhibit the action of sulfonamides and may be considered as alternatives (e.g., bupivacaine, levobupivacaine, lidocaine, mepivacaine).  However, caution is advised due to the potential for development of methemoglobinemia.  Likewise, caution should be exercised when topical formulations of ester-type local anesthetics are administered to patients receiving sulfonamides, particularly when applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Antagonism", "recommendation": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296914/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Tamsulosin, Tinidazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250672, "ingredient1": "Cocaine (topical)", "ingredient2": "Sulfadoxine", "severity": "Moderate", "effect": "Ester-type local anesthetics are hydrolyzed to paraaminobenzoic acid, which can inhibit the action of sulfonamides.", "source": "DDInter", "management_text": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.  Amide-type anesthetics are not expected to inhibit the action of sulfonamides and may be considered as alternatives (e.g., bupivacaine, levobupivacaine, lidocaine, mepivacaine).  However, caution is advised due to the potential for development of methemoglobinemia.  Likewise, caution should be exercised when topical formulations of ester-type local anesthetics are administered to patients receiving sulfonamides, particularly when applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Antagonism", "recommendation": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296915/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Tamsulosin, Tinidazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250673, "ingredient1": "Dicoumarol", "ingredient2": "Sulfadoxine", "severity": "Major", "effect": "Coadministration with a sulfonamide may increase the plasma concentrations and hypoprothrombinemic effects of coumarin anticoagulants.  The proposed mechanism is sulfonamide inhibition of coumarin metabolism via CYP450 2C9 and possibly also displacement of coumarin derivatives from plasma protein binding sites.", "source": "DDInter", "management_text": "Patients receiving coumarin anticoagulants should be closely monitored during concomitant therapy with sulfonamides.  The INR should be checked frequently and coumarin dosage adjusted accordingly, particularly following initiation or discontinuation of sulfonamide therapy in patients who are stabilized on their anticoagulant regimen.  The same precaution may be applicable during therapy with other oral anticoagulants (e.g., indandiones), although clinical data are lacking.  Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Metabolism, Distribution", "recommendation": "Patients receiving coumarin anticoagulants should be closely monitored during concomitant therapy with sulfonamides.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296916/", "reference_text": "[1] O'Reilly RA \"Stereoselective interaction of trimethoprim-sulfamethaxazole with the separated enantiomorphs of racemic warfarin in man.\" N Engl J Med 302 (1980):  33-5[2] Kelly JG, O'Malley K \"Clinical pharmacokinetics of oral anticoagulants.\" Clin Pharmacokinet 4 (1979):  1-15[3] Sioris LJ, Weibert RT, Pentel PR \"Potentiation of warfarin anaticoagulation by sulfisoxazole.\" Arch Intern Med 140 (1980):  546-7[4] O'Donnell D \"Antibiotic-induced potentiation of oral anticoagulant agents.\" Med J Aust 150 (1989):  163-4[5] Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM \"Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism.\" Clin Pharmacol Ther 17 (1975):  731-4[6] O'Reilly RA, Motley CH \"Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans.\" Ann Intern Med 91 (1979):  34-6[7] Self TH, Evans W, Ferguson T \"Interaction of sulfisoxizole and warfarin.\" Circulation 52 (1975):  528[8] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994):  676-83[9] Serlin MJ, Breckenridge AM \"Drug interactions with warfarin.\" Drugs 25 (1983):  610-20[10] Cook DE, Ponte CD \"Suspected trimethoprim sulfamethoxazole induced hypoprothrombinemia.\" J Fam Pract 39 (1994):  589-91[11] Hermans JJ, Thijssen HH \"Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.\" Br J Pharmacol 110 (1993):  482-90[12] Miners JO, Birkett DJ \"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.\" Br J Clin Pharmacol 45 (1998):  525-38[13] Venkatakrishnan K, vonMoltke LL, Greenblatt DJ \"Effects of the antifungal agents on oxidative drug metabolism - Clinical relevance.\" Clin Pharmacokinet 38 (2000):  111-80[14] Thijssen HH, Flinois JP, Beaune PH \"Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.\" Drug Metab Disposition 28 (2000):  1284-90[15] Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH \"Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.\" Clin Pharmacol Ther 69 (2001):  451-7[16] Hermida J, Zarza J, Alberca I, et al. \"Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.\" Blood 99 (2002):  4237-9[17] Visser LE, Penning-Van Bees FJ, Harrie Kasbergen AA, et al. \"Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.\" Thromb Haemost 88 (2002):  705-10[18] Takahashi H, Wilkinson GR, Caraco Y, et al. \"Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.\" Clin Pharmacol Ther 73 (2003):  253-63[19] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005):  439-44[20] Glasheen JJ, Fugit RV, Prochazka AV \"The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.\" J Gen Intern Med 20 (2005):  653-6[21] Fischer HD, Juurlink DN, Mamdani MM, Kopp A, Laupacis A \"Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study.\" Arch Intern Med 170 (2010):  617-21", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Primaquine, Chloroquine, More", "updated_at": 1767369485}, {"id": 250674, "ingredient1": "Dimethyl fumarate", "ingredient2": "Sulfadoxine", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296917/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Tacrolimus, Abatacept, Upadacitinib, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, More", "updated_at": 1767369485}, {"id": 250675, "ingredient1": "Diroximel fumarate", "ingredient2": "Sulfadoxine", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296918/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Tacrolimus, Abatacept, Upadacitinib, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, More", "updated_at": 1767369485}, {"id": 250676, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Sulfadoxine", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296919/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Tamsulosin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250677, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Sulfadoxine", "severity": "Moderate", "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng.  These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs).", "source": "DDInter", "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.  The insulin dosage may require adjustment if an interaction is suspected.  Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.  Patients should be observed for loss of glycemic control when these drugs are withdrawn.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296920/", "reference_text": "[1] Daubresse JC, Luyckx AS, Lefebvre PJ \"Potentiation of hypoglycemic effect of sulfonylureas by clofibrate.\" N Engl J Med 294 (1976):  613[2] Salmela PI, Sotaniemi EA, Viikari J, et al. \"Fenfluramine therapy in non-insulin-dependent diabetic patients effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.\" Diabetes Care 4 (1981):  535-40[3] Verdy M, Charbonneau L, Verdy I, Belanger R, Bolte E, Chiasson JL \"Fenfluramine in the treatment of non-insulin-dependent diabetics: hypoglycemic versus anorectic effect.\" Int J Obes 7 (1983):  289-97[4] Baciewicz AM, Swafford WB Jr \"Hypoglycemia induced by the interaction of chlorpropamide and co-trimoxazole.\" Drug Intell Clin Pharm 18 (1984):  309-10[5] Richardson T, Foster J, Mawer GE \"Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide-drug interaction or summation of similar effects.\" Br J Clin Pharmacol 22 (1986):  43-8[6] Johnson J, Dobmeier M \"Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction.\" DICP 24 (1990):  250-1[7] Goldberg IJ, Brown LK, Rayfield EJ \"Disopyramide (norpace)-induced hypoglycemia.\" Am J Med 69 (1980):  463-6[8] Quevedo SF, Krauss DS, Chazan JA, et al. \"Fasting hypoglycemia secondary to disopyramide therapy.\" JAMA 245 (1981):  2424[9] Semel JD, Wortham E, Karl DM \"Fasting hypoglycemia associated with disopyramide.\" Am Heart J 106 (1983):  1160-1[10] Nappi JM, Dhanani S, Lovejoy JR, VanderArk C \"Severe hypoglycemia associated with disopyramide.\" West J Med 138 (1983):  95-7[11] Rubin M, Zakheim B, Pitchumoni C \"Disopyramide-induced profound hypoglycemia.\" N Y State J Med July,Aug,S (1983):  1057-8[12] Croxson MS, Shaw DW, Henley PG, Gabriel HDLL \"Disopyramide-induced hypoglycaemia and increased serum insulin.\" N Z Med J July (1987):  407-8[13] Giugliano D, Ceriello A, Saccomanno F, et al. \"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus.\" J Clin Endocrinol Metab 61 (1985):  160-6[14] Wiederholt IC, Genco M, Foley JM \"Recurrent episodes of hypoglycemia induced by propoxyphene.\" Neurology 17 (1967):  703-6[15] Barbato M \"Another problem with Kinidin.\" Med J Aust 141 (1984):  685[16] Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P \"Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy.\" Am J Med 89 (1990):  811-3[17] Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y \"Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.\" Br J Clin Pharmacol 17 (1984):  89-91[18] Daubresse JC, Daigneux D, Bruwier M, Luyckx A, Lefebvre PJ \"Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.\" Br J Clin Pharmacol 7 (1979):  599-603[19] Whitcroft IA, Thomas JM, Rawsthorne A, et al. \"Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics.\" Horm Metab Res Suppl 22 (1990):  42-6[20] Ahmad S \"Gemfibrozil: interaction with glyburide.\" South Med J 84 (1991):  102[21] Konttinen A, Kuisma I, Ralli R, Pohjola S, Ojala K \"The effect of gemfibrozil on serum lipids in diabetic patients.\" Ann Clin Res 11 (1979):  240-5[22] de Salcedo I, Gorringe AL, Silva JL, Santos JA \"Gemfibrozil in a group of diabetics.\" Proc R Soc Med 69 (1976):  64-70[23] Phillips RE, Looareesuwan S, White NJ, et al. \"Hypoglycaemia and antimalarial drugs: quinidine and release of insulin.\" Br Med J 292 (1986):  1319-21[24] Davis TM, Karbwang J, Looareesuwan S, et al. \"Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers.\" Br J Clin Pharmacol 30 (1990):  397-403[25] Wu B, Sato T, Kiyosue T, Arita M \"Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.\" Cardiovasc Res 26 (1992):  1095-101[26] Nakabayashi H, Ito T, Igawa T, Hiraiwa Y, Imamura T, Seta T, Kawato M, Usukura N, Takeda R \"Disopyramide induces insulin secretion and plasma glucose diminution: studies using the in situ canine pancreas.\" Metabolism 38 (1989):  179-83[27] Strathman I, Schubert EN, Cohen A, Nitzberg DM \"Hypoglycemia in patients receiving disopyramide phosphate.\" Drug Intell Clin Pharm 17 (1983):  635-8[28] Cacoub P, Deray G, Baumelou A, Grimaldi A, Soubrie C, Jacobs C \"Disopyramide-induced hypoglycemia: case report and review of the literature.\" Fundam Clin Pharmacol 3 (1989):  527-35[29] Asplund K, Wiholm BE, Lithner F \"Glibenclamide-associated hypoglycaemia: a report on 57 cases.\" Diabetologia 24 (1983):  412-7[30] Slade IH, and Iosefa RN \"Fatal hypoglycemic coma from the use of tolbutamide in elderly patients: report of two cases.\" J Am Geriatr Soc 15 (1967):  948-50[31] Cattaneo AG, Caviezel F, Pozza G \"Pharmacological interaction between tolbutamide and acetylsalicylic acid: study on insulin secretion in man.\" Int J Clin Pharmacol Ther Toxicol 28 (1990):  229-34[32] Christensen LK, Hansen JM, Kristensen M \"Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics.\" Lancet 2 (1963):  1298-301[33] Turtle JR, Burgess JA \"Hypoglycemic action of fenfluramine in diabetes mellitus.\" Diabetes 22 (1973):  858-67[34] Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J \"Captopril and insulin sensitivity.\" Ann Intern Med 102 (1985):  134-5[35] Johnson JA, Kappel JE, Sharif MN \"Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient.\" Ann Pharmacother 27 (1993):  304-6[36] Almirall J, Montoliu J, Torras A, Revert L \"Propoxyphene-induced hypoglycemia in a patient with chronic renal failure.\" Nephron 53 (1989):  273-5[37] Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S \"Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release.\" Am J Physiol 265 (1993):  c337-42[38] Phillips AF, Matty PJ, Porte PJ, Raye JR \"Inhibition of glucose-induced insulin secretion by indomethacin and sodium salicylate in the fetal lamb.\" Am J Obstet Gynecol 148 (1984):  481-7[39] Baron SH \"Salicylates as hypoglycemic agents.\" Diabetes Care 5 (1982):  64-71[40] Prince RL, Larkins RG, Alford FP \"The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.\" Metabolism 30 (1981):  293-8[41] Ferrari C, Fressati S, Romussi M, et al. \"Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.\" Metabolism 26 (1977):  129-39[42] Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW \"Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resistance in rats.\" Diabetes 38 (1989):  499-503[43] Pestell RG, Crock PA, Ward GM, Alford FP, Best JD \"Fenfluramine increases insulin action in patients with NIDDM.\" Diabetes Care 12 (1989):  252-8[44] Harrison LC, King-Roach A, Martin FI, Melick RA \"The effect of fenfluramine on insulin binding and on basal and insulin-stimulated oxidation of 1-C-glucose by human adipose tissue.\" Postgrad Med J 51 Suppl 1 (1975):  110-4[45] Feldman JM, Chapman B \"Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insulin secretion.\" Diabetologia 11 (1975):  487-94[46] Aleyassine H, Gardiner RJ \"Dual action of antidepressant drugs (MAO inhibitors) on insulin release.\" Endocrinology 96 (1975):  702-10[47] Aleyassine H, Lee SH \"Inhibition of insulin release by substrates and inhibitors of monoamine oxidase.\" Am J Physiol 222 (1972):  565-9[48] Cooper AJ, Ashcroft G \"Potentiation of insulin hypoglycaemia by M.A.O.I. antidepressant drugs.\" Lancet 1 (1966):  407-9[49] Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A \"Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.\" Lancet 345 (1995):  1195-8[50] Ahmad S \"Drug interaction induces hypoglycemia.\" J Fam Pract 40 (1995):  540-1[51] Feher MD, Amiel S \"ACE inhibitors and hypoglycaemia.\" Lancet 346 (1995):  125-6[52] Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, Amato L, Varricchio M \"Lisinopril administration improves insulin action in aged patients with hypertension.\" J Hum Hypertens 9 (1995):  541-6[53] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[54] Kubacka RT, Antla EJ, Juhl RP, Welshman IR \"Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects.\" Ann Pharmacother 30 (1996):  20-6[55] Deeg MA, Lipkin EW \"Hypoglycemia associated with the use of fluoxetine.\" West J Med 164 (1996):  262-3[56] Hellman B \"Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.\" Metabolism 23 (1974):  839-46[57] Hekimsoy Z, Biberoglu S, Comlekci A, Tarhan O, Mermut C, Biberoglu K \"Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection.\" Eur J Endocrinol 136 (1997):  3046[58] Iida H, Morita T, Suzuki E, Iwasawa K, Toyooka T, Nakajima T \"Hypoglycemia induced by interaction between clarithromycin and disopyramide.\" Jpn Heart J 40 (1999):  91-6[59] Morris AD, Newton RW, Boyle DI, et al. \"ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes.\" Diabetes Care 20 (1997):  1363-7[60] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D \"Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.\" Br J Clin Pharmacol 52 (2001):  456-7[61] \"Product Information. Humalog (insulin lispro).\" Lilly, Eli and Company  (2002):[62] \"Product Information. Humulin 70/30 (insulin isophane-insulin regular).\" Lilly, Eli and Company  (2002):[63] Pollak PT, Mukherjee SD, Fraser AD \"Sertraline-induced hypoglycemia.\" Ann Pharmacother 35 (2001):  1371-4[64] Hundal RS, Petersen KF, Mayerson AB, et al. \"Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes.\" J Clin Invest 109 (2002):  1321-6[65] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[66] Fogari R, Zoppi A, Corradi L, Pierangelo L, Mugellini A, Lusardi P \"Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertension.\" Br J Clin Pharmacol 46 (1998):  467-71[67] Vuorinen-Markkola H, Yki-Jarvinen H \"Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus.\" Metabolism 44 (1995):  85-9[68] \"Product Information. Increlex (mecasermin).\" Tercica Inc  (2005):[69] Vuksan V, Sievenpiper JL, Koo VY, et al. \"American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus.\" Arch Intern Med 160 (2000):  1009-13[70] Vuksan V, Stavro MP, Sievenpiper JL, et al. \"Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes.\" Diabetes Care 23 (2000):  1221-6[71] Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V \"Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia.\" Eur J Clin Nutr 57 (2003):  243-8[72] Ben Salem C, Fathallah N, Hmouda H, Bouraoui K \"Drug-induced hypoglycaemia: an update.\" Drug Saf 34 (2011):  21-45[73] \"Product Information. Afrezza (insulin inhalation, rapid acting).\" MannKind Corporation  (2014):[74] \"Product Information. Ryzodeg 70/30 FlexTouch (insulin aspart-insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[75] \"Product Information. Tresiba FlexTouch (insulin degludec).\" Novo Nordisk Pharmaceuticals Inc  (2015):[76] World Health Organization \"WHO Public Assessment Reports (WHOPARs)  https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars\"   (2020):", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Primaquine, Proguanil, Tamsulosin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250678, "ingredient1": "Sulfadoxine", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Use of hepatotoxic drugs together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.  Patients treated with levoketoconazole or ketoconazole should have liver tests performed prior to and during treatment.  Levoketoconazole manufacturer recommends interrupting treatment immediately if signs of hepatotoxicity occur.  Refer to levoketoconazole labeling for specific instructions on management of hepatotoxicity.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296921/", "reference_text": "[1] \"Product Information. Ketoconazole (ketoconazole).\" Mylan Pharmaceuticals Inc  (2019):[2] \"Product Information. Recorlev (levoketoconazole).\" Xeris Pharmaceuticals Inc  (2022):[3] Auchus R, Pivonello R, Fleseriu M, et al. \"Levoketoconazole: a novel treatment for endogenous Cushing's syndrome.  https://www.tandfonline.com/doi/pdf/10.1080/17446651.2021.1945440\"   (2022):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Pyrimethamine, Artesunate, Tafenoquine, Proguanil, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Sulfadiazine, Lactic acid, Methazolamide, More", "updated_at": 1767369485}, {"id": 250679, "ingredient1": "Sulfadoxine", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296925/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250680, "ingredient1": "Sulfadoxine", "ingredient2": "Proparacaine (ophthalmic)", "severity": "Moderate", "effect": "Ester-type local anesthetics are hydrolyzed to paraaminobenzoic acid, which can inhibit the action of sulfonamides.", "source": "DDInter", "management_text": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.  Amide-type anesthetics are not expected to inhibit the action of sulfonamides and may be considered as alternatives (e.g., bupivacaine, levobupivacaine, lidocaine, mepivacaine).  However, caution is advised due to the potential for development of methemoglobinemia.  Likewise, caution should be exercised when topical formulations of ester-type local anesthetics are administered to patients receiving sulfonamides, particularly when applied to mucous membranes or given via the oropharyngeal route.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.", "mechanism_text": "Antagonism", "recommendation": "The administration of injectable ester-type local anesthetics to patients who are on sulfonamides should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296926/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Hydroxychloroquine, Halofantrine, Proguanil, Tamsulosin, Tinidazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250681, "ingredient1": "Diamorphine", "ingredient2": "Clonidine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296927/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, More", "alternatives_b": "Nalmefene, Disulfiram, Naltrexone", "updated_at": 1767369485}, {"id": 250682, "ingredient1": "Clonidine", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "The concurrent administration of some centrally acting alpha-agonists and nitroprusside may result in severe hypotension.  The proposed mechanism is additive pharmacodynamic effects.", "source": "DDInter", "management_text": "Management consists of carefully monitoring hemodynamics during coadministration and titrating the dosage of nitroprusside as necessary.", "mechanism_text": "Synergism", "recommendation": "Management consists of carefully monitoring hemodynamics during coadministration and titrating the dosage of nitroprusside as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296928/", "reference_text": "[1] Cohen IM, Mottet MM, Francis GS, Alpert JS \"Danger in nitroprusside therapy.\" Ann Intern Med 85 (1976):  205-6[2] \"Product Information. Nipride RTU (sodium nitroprusside).\" Roche Laboratories", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, More", "alternatives_b": "Diazoxide", "updated_at": 1767369485}, {"id": 250683, "ingredient1": "Clonidine", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296929/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, More", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Escitalopram", "updated_at": 1767369485}, {"id": 250684, "ingredient1": "Darunavir", "ingredient2": "Brentuximab vedotin", "severity": "Moderate", "effect": "Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296930/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 250685, "ingredient1": "Darunavir", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.  Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended.  Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296934/", "reference_text": "[1] \"Product Information. Invirase (saquinavir).\" Roche Laboratories  (2001):[2] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[3] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[4] Brooks J, Daily J, Schwamm L \"Protease inhibitors and anticonvulsants.\" AIDS Clin Care 9 (1997):  87,90[5] Barry M, Gibbons S, Back D, Mulcahy F \"Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.\" Clin Pharmacokinet 32 (1997):  194-209[6] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[7] Acosta EP, Henry K, Baken L, Page LM, Fletcher CV \"Indinavir concentrations and antiviral effect.\" Pharmacotherapy 19 (1999):  708-12[8] Sommadossi JP \"HIV protease inhibitors: pharmacologic and metabolic distinctions.\" AIDS 13 (1999):  s29-40[9] Hugen PWH, Burger DM, Brinkman K, terHofstede HJM, Schuurman R, Koopmans PP, Hekster YA \"Carbamazepine-indinavir interaction causes antiretroviral therapy failure.\" Ann Pharmacother 34 (2000):  465-70[10] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000):  1333-9[11] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[12] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[13] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[14] Liedtke MD, Lockhart SM, Rathbun RC \"Anticonvulsant and antiretroviral interactions.\" Ann Pharmacother 38 (2004):  482-9[15] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim  (2005):[16] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[17] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 250686, "ingredient1": "Darunavir", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Coadministration with St. John's wort may significantly reduce the plasma concentrations of HIV protease inhibitors and result in a potential loss of virologic response.  The mechanism is induction of CYP450 3A4 metabolism by constituents of St. John's wort.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of HIV protease inhibitors with St. John's wort is considered contraindicated.  The enzyme induction may last for up to 2 weeks after the last dose of St. John's wort.  Patients should be advised to consult with their caregivers before using any herbal or alternative medicines.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of HIV protease inhibitors with St.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296935/", "reference_text": "[1] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, More", "alternatives_b": "Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Amoxapine, Imipramine, Esketamine, More", "updated_at": 1767369485}, {"id": 250687, "ingredient1": "Darunavir", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes.  The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296936/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc.  (2017):", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Cobicistat, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250688, "ingredient1": "Elvitegravir", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.  Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296940/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences  (2014):", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 250689, "ingredient1": "Elvitegravir", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended.  In addition, other antiretroviral agents that are typically combined with elvitegravir may be contraindicated for use with potent CYP450 3A4 inducers.  Please refer to the manufacturer's labeling for the specific elvitegravir-containing product for more information.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of elvitegravir with potent CYP450 3A4 inducers is generally not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296941/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences  (2012):[4] \"Product Information. Vitekta (elvitegravir).\" Gilead Sciences  (2014):[5] \"Product Information. Tybost (cobicistat).\" Gilead Sciences  (2014):[6] \"Product Information. Genvoya (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences  (2015):", "alternatives_a": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, More", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "updated_at": 1767369485}, {"id": 250690, "ingredient1": "Glycopyrronium (topical)", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296943/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250691, "ingredient1": "Diamorphine", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296944/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, Tripelennamine, Azelastine, Cyclizine, More", "alternatives_b": "Nalmefene, Disulfiram, Acamprosate, Naltrexone", "updated_at": 1767369485}, {"id": 250692, "ingredient1": "Promethazine", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296945/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250693, "ingredient1": "St. John's Wort", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296946/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, More", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 250694, "ingredient1": "Colchicine", "ingredient2": "Brentuximab vedotin", "severity": "Moderate", "effect": "Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.  Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness.  Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296948/", "reference_text": "[1] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995):  201[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979):  663-6[3] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online.  http://www.appco.com.au/appguide/default.asp\"   (2006):[4] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[5] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):[6] \"Product Information. Danyelza (naxitamab).\" Y-mAbs Therapeutics  (2020):", "alternatives_a": "Lesinurad, Pegloticase, Sulfinpyrazone, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 250695, "ingredient1": "Dimethyl fumarate", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296949/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Tacrolimus, Abatacept, More", "alternatives_b": "Pegloticase, Febuxostat, Sulfinpyrazone, Rasburicase, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, More", "updated_at": 1767369485}, {"id": 250696, "ingredient1": "Dimethyl fumarate", "ingredient2": "Colchicine", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296950/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Pegloticase, Febuxostat, Sulfinpyrazone, Rasburicase", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Anakinra, More", "updated_at": 1767369485}, {"id": 250697, "ingredient1": "Diroximel fumarate", "ingredient2": "Probenecid", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296951/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Tacrolimus, Abatacept, More", "alternatives_b": "Pegloticase, Febuxostat, Sulfinpyrazone, Rasburicase, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, More", "updated_at": 1767369485}, {"id": 250698, "ingredient1": "Diroximel fumarate", "ingredient2": "Colchicine", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296952/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Pegloticase, Febuxostat, Sulfinpyrazone, Rasburicase", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Anakinra, More", "updated_at": 1767369485}, {"id": 250699, "ingredient1": "Probenecid", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296953/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Pegloticase, Febuxostat, Sulfinpyrazone, Rasburicase, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250700, "ingredient1": "Colchicine", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296954/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Pegloticase, Febuxostat, Sulfinpyrazone, Rasburicase", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250701, "ingredient1": "Colchicine", "ingredient2": "Radium Ra 223 dichloride", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.  Dose reductions of the other bone marrow depressants may be necessary.  Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.  The safety and efficacy of concomitant use of chemotherapy have not been established.  Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression.  If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, radium Ra 223 should be discontinued.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296956/", "reference_text": "[1] \"Product Information. Xofigo (radium Ra 223 dichloride).\" Bayer Pharmaceutical Inc  (2022):", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Sulfinpyrazone, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250702, "ingredient1": "Colchicine", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296957/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Sulfinpyrazone, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 250703, "ingredient1": "Abarelix", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296959/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250704, "ingredient1": "Abiraterone", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296960/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250705, "ingredient1": "Sodium sulfate", "ingredient2": "Acetazolamide", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296961/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250706, "ingredient1": "Sodium sulfate", "ingredient2": "Salbutamol", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296963/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250707, "ingredient1": "Aldesleukin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296964/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250708, "ingredient1": "Alfentanil", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296965/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250709, "ingredient1": "Alfuzosin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296966/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Terazosin, Tadalafil, Finasteride, Silodosin, Dutasteride", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250710, "ingredient1": "Amantadine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296967/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ropinirole, Opicapone, Cabergoline, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250711, "ingredient1": "Amifampridine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296968/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250712, "ingredient1": "Amiloride", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296969/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Eplerenone, Finerenone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250713, "ingredient1": "Aminophylline", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296970/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250714, "ingredient1": "Amiodarone", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296971/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Magnesium oxide, Linaclotide, Naloxone, More", "updated_at": 1767369485}, {"id": 250715, "ingredient1": "Amisulpride", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296972/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250716, "ingredient1": "Amitriptyline", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296973/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250717, "ingredient1": "Amoxapine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296974/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250718, "ingredient1": "Amphetamine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296975/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, More", "updated_at": 1767369485}, {"id": 250719, "ingredient1": "Anagrelide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296976/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250720, "ingredient1": "Sodium sulfate", "ingredient2": "Apalutamide", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296977/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250721, "ingredient1": "Sodium sulfate", "ingredient2": "Apomorphine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296978/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250722, "ingredient1": "Sodium sulfate", "ingredient2": "Aripiprazole", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296979/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250723, "ingredient1": "Sodium sulfate", "ingredient2": "Arsenic trioxide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296980/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250724, "ingredient1": "Sodium sulfate", "ingredient2": "Asenapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296982/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250725, "ingredient1": "Acetylsalicylic acid", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296983/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ticagrelor, Betrixaban, Clopidogrel, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, Magnesium citrate, More", "updated_at": 1767369485}, {"id": 250726, "ingredient1": "Sodium sulfate", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296984/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 250727, "ingredient1": "Sodium sulfate", "ingredient2": "Atomoxetine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296985/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250728, "ingredient1": "Sodium sulfate", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296986/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250729, "ingredient1": "Sodium sulfate", "ingredient2": "Azithromycin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296987/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Naloxone, More", "updated_at": 1767369485}, {"id": 250730, "ingredient1": "Sodium sulfate", "ingredient2": "Bedaquiline", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296988/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250731, "ingredient1": "Benazepril", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296989/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, More", "updated_at": 1767369485}, {"id": 250732, "ingredient1": "Bendroflumethiazide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296990/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250733, "ingredient1": "Benzphetamine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296991/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250734, "ingredient1": "Benzthiazide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296992/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 250735, "ingredient1": "Bepridil", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296993/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250736, "ingredient1": "Bethanechol", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296994/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ambenonium, Pilocarpine, Cevimeline, Pyridostigmine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250737, "ingredient1": "Bicalutamide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296995/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane, Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250738, "ingredient1": "Bisacodyl", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Concomitant use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) may increase the risk of serious gastrointestinal adverse effects associated with certain osmotic laxatives (e.g., polyethylene glycol (PEG), oral sulfate solution), such as colonic mucosal ulcerations or ischemic colitis.", "source": "DDInter", "management_text": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.  However, stimulant laxatives, in particular bisacodyl and sodium picosulfate, are sometimes used with PEG in certain bowel cleansing regimens to help reduce dose volume and improve patient tolerability and acceptance.  Please consult individual product labeling for specific recommendations and guidance.  Patients using osmotic bowel cleansing products and stimulant laxatives who present with sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis should be evaluated promptly.", "mechanism_text": "Synergism", "recommendation": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296996/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Baudet JS, Castro V, Redondo I \"Recurrent ischemic colitis induced by colonoscopy bowel lavage.\" Am J Gastroenterol 105 (2010):  700-1[4] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[5] Ajani S, Hurt RT, Teeters DA, Bellmore LR \"Ischaemic colitis associated with oral contraceptive and bisacodyl use.\" BMJ Case Rep 2012 (2012):[6] \"Product Information. MoviPrep (polyethylene glycol 3350 with electrolytes).\" Physicians Total Care  (2016):[7] \"Product Information. Plenvu (polyethylene glycol 3350 with electrolytes).\" Bausch Health US (formerly Valeant Pharmaceuticals)  (2020):[8] \"Product Information. GaviLyte-H and Bisacodyl with Flavor Packs (bisacodyl-PEG 3350 with electrolytes).\" Gavis Pharmaceuticals  (2022):[9] \"Product Information. Bi-Peglyte (bisacodyl-PEG 3350 with electrolytes).\" Pendopharm[10] Vaizman K, Li J, Iswara K, Tenner S \"Ischemic colitis induced by the combination of Bisacodyl and polyethylene glycol in preparation for colonoscopy.\" Am J Gastroenterol 102 (2007):  S267[11] Belsey J, Epstein O, heresbach D \"Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol.\" Aliment Pharmacol Ther 29 (2009):  15-28[12] Hung SY, Chen HC, Chen WT \"A randomized trial comparing the bowel cleansing efficacy of sodium picosulfate/magnesium citrate and polyethylene glycol/Bisacodyl (The Bowklean Study)\" Sci Rep 10 (2020):  5604[13] Adamcewicz M, Bearelly D, Porat G, Friedenberg FK \"Mechanism of action and toxicities of purgatives used for colonoscopy preparation.\" Expert Opin Drug Metab Toxicol 7 (2011):  89-101[14] Anastassopoulos K, Farraye FA, Knight T, Colman S, Cleveland MvB, Pelham RW \"A comparative study of treatment-emergent adverse events following use of common bowel preparations among a colonoscopy screening population: results from a post-marketing observational study.\" Dig Dis Sci 61 (2016):  2993-3006[15] Barbeau P, Wolfe D, Yazdi F, et al. \"Comparative safety of bowel cleansers: protocol for a systematic review and network meta-analysis.\" BMJ Open 8 (2018):  e021892", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250739, "ingredient1": "Blinatumomab", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296997/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250740, "ingredient1": "Bosutinib", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296998/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250741, "ingredient1": "Brexpiprazole", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296999/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250742, "ingredient1": "Bromfenac", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297000/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Fluocinolone acetonide, Cortisone, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250743, "ingredient1": "Bumetanide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297001/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250744, "ingredient1": "Buprenorphine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297002/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250745, "ingredient1": "Bupropion", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297003/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250746, "ingredient1": "Butorphanol", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297004/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250747, "ingredient1": "Cabozantinib", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297005/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250748, "ingredient1": "Captopril", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297007/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250749, "ingredient1": "Cariprazine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297008/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250750, "ingredient1": "Frangula purshiana bark", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Concomitant use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) may increase the risk of serious gastrointestinal adverse effects associated with certain osmotic laxatives (e.g., polyethylene glycol (PEG), oral sulfate solution), such as colonic mucosal ulcerations or ischemic colitis.", "source": "DDInter", "management_text": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.  However, stimulant laxatives, in particular bisacodyl and sodium picosulfate, are sometimes used with PEG in certain bowel cleansing regimens to help reduce dose volume and improve patient tolerability and acceptance.  Please consult individual product labeling for specific recommendations and guidance.  Patients using osmotic bowel cleansing products and stimulant laxatives who present with sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis should be evaluated promptly.", "mechanism_text": "Synergism", "recommendation": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297009/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Baudet JS, Castro V, Redondo I \"Recurrent ischemic colitis induced by colonoscopy bowel lavage.\" Am J Gastroenterol 105 (2010):  700-1[4] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[5] Ajani S, Hurt RT, Teeters DA, Bellmore LR \"Ischaemic colitis associated with oral contraceptive and bisacodyl use.\" BMJ Case Rep 2012 (2012):[6] \"Product Information. MoviPrep (polyethylene glycol 3350 with electrolytes).\" Physicians Total Care  (2016):[7] \"Product Information. Plenvu (polyethylene glycol 3350 with electrolytes).\" Bausch Health US (formerly Valeant Pharmaceuticals)  (2020):[8] \"Product Information. GaviLyte-H and Bisacodyl with Flavor Packs (bisacodyl-PEG 3350 with electrolytes).\" Gavis Pharmaceuticals  (2022):[9] \"Product Information. Bi-Peglyte (bisacodyl-PEG 3350 with electrolytes).\" Pendopharm[10] Vaizman K, Li J, Iswara K, Tenner S \"Ischemic colitis induced by the combination of Bisacodyl and polyethylene glycol in preparation for colonoscopy.\" Am J Gastroenterol 102 (2007):  S267[11] Belsey J, Epstein O, heresbach D \"Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol.\" Aliment Pharmacol Ther 29 (2009):  15-28[12] Hung SY, Chen HC, Chen WT \"A randomized trial comparing the bowel cleansing efficacy of sodium picosulfate/magnesium citrate and polyethylene glycol/Bisacodyl (The Bowklean Study)\" Sci Rep 10 (2020):  5604[13] Adamcewicz M, Bearelly D, Porat G, Friedenberg FK \"Mechanism of action and toxicities of purgatives used for colonoscopy preparation.\" Expert Opin Drug Metab Toxicol 7 (2011):  89-101[14] Anastassopoulos K, Farraye FA, Knight T, Colman S, Cleveland MvB, Pelham RW \"A comparative study of treatment-emergent adverse events following use of common bowel preparations among a colonoscopy screening population: results from a post-marketing observational study.\" Dig Dis Sci 61 (2016):  2993-3006[15] Barbeau P, Wolfe D, Yazdi F, et al. \"Comparative safety of bowel cleansers: protocol for a systematic review and network meta-analysis.\" BMJ Open 8 (2018):  e021892", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250751, "ingredient1": "Castor oil", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Concomitant use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) may increase the risk of serious gastrointestinal adverse effects associated with certain osmotic laxatives (e.g., polyethylene glycol (PEG), oral sulfate solution), such as colonic mucosal ulcerations or ischemic colitis.", "source": "DDInter", "management_text": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.  However, stimulant laxatives, in particular bisacodyl and sodium picosulfate, are sometimes used with PEG in certain bowel cleansing regimens to help reduce dose volume and improve patient tolerability and acceptance.  Please consult individual product labeling for specific recommendations and guidance.  Patients using osmotic bowel cleansing products and stimulant laxatives who present with sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis should be evaluated promptly.", "mechanism_text": "Synergism", "recommendation": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297010/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Baudet JS, Castro V, Redondo I \"Recurrent ischemic colitis induced by colonoscopy bowel lavage.\" Am J Gastroenterol 105 (2010):  700-1[4] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[5] Ajani S, Hurt RT, Teeters DA, Bellmore LR \"Ischaemic colitis associated with oral contraceptive and bisacodyl use.\" BMJ Case Rep 2012 (2012):[6] \"Product Information. MoviPrep (polyethylene glycol 3350 with electrolytes).\" Physicians Total Care  (2016):[7] \"Product Information. Plenvu (polyethylene glycol 3350 with electrolytes).\" Bausch Health US (formerly Valeant Pharmaceuticals)  (2020):[8] \"Product Information. GaviLyte-H and Bisacodyl with Flavor Packs (bisacodyl-PEG 3350 with electrolytes).\" Gavis Pharmaceuticals  (2022):[9] \"Product Information. Bi-Peglyte (bisacodyl-PEG 3350 with electrolytes).\" Pendopharm[10] Vaizman K, Li J, Iswara K, Tenner S \"Ischemic colitis induced by the combination of Bisacodyl and polyethylene glycol in preparation for colonoscopy.\" Am J Gastroenterol 102 (2007):  S267[11] Belsey J, Epstein O, heresbach D \"Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol.\" Aliment Pharmacol Ther 29 (2009):  15-28[12] Hung SY, Chen HC, Chen WT \"A randomized trial comparing the bowel cleansing efficacy of sodium picosulfate/magnesium citrate and polyethylene glycol/Bisacodyl (The Bowklean Study)\" Sci Rep 10 (2020):  5604[13] Adamcewicz M, Bearelly D, Porat G, Friedenberg FK \"Mechanism of action and toxicities of purgatives used for colonoscopy preparation.\" Expert Opin Drug Metab Toxicol 7 (2011):  89-101[14] Anastassopoulos K, Farraye FA, Knight T, Colman S, Cleveland MvB, Pelham RW \"A comparative study of treatment-emergent adverse events following use of common bowel preparations among a colonoscopy screening population: results from a post-marketing observational study.\" Dig Dis Sci 61 (2016):  2993-3006[15] Barbeau P, Wolfe D, Yazdi F, et al. \"Comparative safety of bowel cleansers: protocol for a systematic review and network meta-analysis.\" BMJ Open 8 (2018):  e021892", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250752, "ingredient1": "Cefiderocol", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297011/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250753, "ingredient1": "Celecoxib", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297012/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tamsulosin, Tinidazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250754, "ingredient1": "Ceritinib", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297013/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250755, "ingredient1": "Chloroquine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297014/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250756, "ingredient1": "Chlorothiazide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297015/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250757, "ingredient1": "Chlorpromazine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including chlorpromazine.", "source": "DDInter", "management_text": "If coadministration of chlorpromazine is necessary, administer at least 2 hours before and not less than 6 hours after Suprep Bowel Prep.  Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "If coadministration of chlorpromazine is necessary, administer at least 2 hours before and not less than 6 hours after Suprep Bowel Prep.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297016/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250758, "ingredient1": "Chlorthalidone", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297017/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250759, "ingredient1": "Choline salicylate", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297018/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250760, "ingredient1": "Cilostazol", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297019/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ticagrelor, Betrixaban, Clopidogrel, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250761, "ingredient1": "Cinoxacin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297020/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250762, "ingredient1": "Ciprofloxacin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297021/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Tetracycline, Polymyxin B, Chloramphenicol, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Naloxone, Sodium chloride", "updated_at": 1767369485}, {"id": 250763, "ingredient1": "Cisapride", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297022/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250764, "ingredient1": "Citalopram", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297023/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250765, "ingredient1": "Clarithromycin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297024/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250766, "ingredient1": "Clofazimine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297025/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dapsone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250767, "ingredient1": "Clomipramine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297026/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250768, "ingredient1": "Clozapine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297027/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250769, "ingredient1": "Cocaine (nasal)", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297028/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250770, "ingredient1": "Codeine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297029/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone, Benzonatate, Clofedanol, Dextromethorphan, Pentoxyverine", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250771, "ingredient1": "Crizotinib", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297030/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250772, "ingredient1": "Cyclobenzaprine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297031/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Methocarbamol, Chlormezanone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250773, "ingredient1": "Cycloserine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297032/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250774, "ingredient1": "Dalfampridine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297033/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250775, "ingredient1": "Dasatinib", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297034/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250776, "ingredient1": "Daunorubicin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297035/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250777, "ingredient1": "Doxorubicin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297036/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250778, "ingredient1": "Degarelix", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297037/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250779, "ingredient1": "Delafloxacin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297038/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250780, "ingredient1": "Desipramine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297039/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250781, "ingredient1": "Desvenlafaxine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297040/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250782, "ingredient1": "Deutetrabenazine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297041/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250783, "ingredient1": "Dexfenfluramine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297042/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250784, "ingredient1": "Dexmethylphenidate", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297043/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250785, "ingredient1": "Dextroamphetamine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297044/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250786, "ingredient1": "Dezocine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297045/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250787, "ingredient1": "Diclofenamide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297046/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250788, "ingredient1": "Diclofenac", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297047/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Fluocinolone acetonide, Cortisone, Hydrocortisone, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250789, "ingredient1": "Diethylpropion", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297048/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250790, "ingredient1": "Diflunisal", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297049/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250791, "ingredient1": "Disopyramide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297050/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250792, "ingredient1": "Dofetilide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297051/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250793, "ingredient1": "Dolasetron", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297052/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250794, "ingredient1": "Donepezil", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297053/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250795, "ingredient1": "Doxapram", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297054/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Nitric Oxide, Ivacaftor, Elexacaftor, Lumacaftor", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250796, "ingredient1": "Doxepin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297055/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250797, "ingredient1": "Doxepin (topical)", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297056/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250798, "ingredient1": "Dronabinol", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297057/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250799, "ingredient1": "Dronedarone", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297058/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, More", "updated_at": 1767369485}, {"id": 250800, "ingredient1": "Droperidol", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297059/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250801, "ingredient1": "Duloxetine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297060/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, Magnesium citrate, More", "updated_at": 1767369485}, {"id": 250802, "ingredient1": "Efavirenz", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297061/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250803, "ingredient1": "Enalapril", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297062/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250804, "ingredient1": "Encorafenib", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297063/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250805, "ingredient1": "Enoxacin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297064/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250806, "ingredient1": "Entrectinib", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297065/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250807, "ingredient1": "Enzalutamide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297066/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250808, "ingredient1": "Ephedrine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297067/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250809, "ingredient1": "Epirubicin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297068/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250810, "ingredient1": "Eprosartan", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297069/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250811, "ingredient1": "Eribulin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297070/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250812, "ingredient1": "Ertapenem", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297071/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250813, "ingredient1": "Erythromycin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297072/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dirithromycin, Lincomycin, Troleandomycin, Clindamycin, Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Naloxone, Magnesium gluconate, More", "updated_at": 1767369485}, {"id": 250814, "ingredient1": "Escitalopram", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297073/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250815, "ingredient1": "Etacrynic acid", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297074/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250816, "ingredient1": "Etodolac", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297075/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250817, "ingredient1": "Ezogabine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297076/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250818, "ingredient1": "Fenfluramine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297077/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone, Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250819, "ingredient1": "Fenoprofen", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297078/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250820, "ingredient1": "Fentanyl", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297079/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine, Dihydrocodeine, More", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250821, "ingredient1": "Flecainide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297082/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250822, "ingredient1": "Fluconazole", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297083/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Caspofungin, Micafungin, Amphotericin B, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250823, "ingredient1": "Fludeoxyglucose (18F)", "ingredient2": "Magnesium sulfate", "severity": "Moderate", "effect": "Certain medications may interfere with the results of diagnostic studies using fludeoxyglucose F18 by increasing or decreasing uptake of the agent into tissues.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference associated with the following medications:  colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.", "mechanism_text": "Distribution", "recommendation": "Clinicians should be aware of possible diagnostic interference associated with the following medications:  colony-stimulating factors may increase uptake in spleen and bone marrow; glucose-induced hyperglycemia may interfere with uptake; dopamine and insulin may decrease myocardial and tumor cell uptake; laxative-induced intestinal muscle activity and/or irritation may increase intestinal uptake.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297084/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Mannitol, More", "alternatives_b": "Capromab pendetide, Gallium Ga-68 gozetotide, Indium In-111 pentetreotide", "updated_at": 1767369485}, {"id": 250824, "ingredient1": "Fluoxetine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297085/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250825, "ingredient1": "Fluphenazine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297086/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250826, "ingredient1": "Flurbiprofen", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297087/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Neomycin, Chlorhexidine, Povidone-iodine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250827, "ingredient1": "Flutamide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297088/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250828, "ingredient1": "Fluvoxamine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297089/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250829, "ingredient1": "Foscarnet", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297090/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250830, "ingredient1": "Fosinopril", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297091/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250831, "ingredient1": "Fostemsavir", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297092/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250832, "ingredient1": "Furosemide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297093/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250833, "ingredient1": "Galantamine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297094/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250834, "ingredient1": "Gatifloxacin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297095/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250835, "ingredient1": "Gemifloxacin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297096/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250836, "ingredient1": "Gilteritinib", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297097/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, More", "updated_at": 1767369485}, {"id": 250837, "ingredient1": "Glasdegib", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297098/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, More", "updated_at": 1767369485}, {"id": 250838, "ingredient1": "Goserelin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297099/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250839, "ingredient1": "Granisetron", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297100/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250840, "ingredient1": "Grepafloxacin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297101/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250841, "ingredient1": "Halofantrine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297102/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250842, "ingredient1": "Haloperidol", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297103/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250843, "ingredient1": "Halothane", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297104/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250844, "ingredient1": "Diamorphine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297105/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250845, "ingredient1": "Histrelin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297106/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250846, "ingredient1": "Hydrochlorothiazide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297107/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Sacubitril, Aliskiren, Nebivolol, Amlodipine, Aliskiren, Tamsulosin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250847, "ingredient1": "Hydrocodone", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297108/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Benzonatate, Clofedanol, Dextromethorphan, Pentoxyverine", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250848, "ingredient1": "Hydroflumethiazide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297109/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250849, "ingredient1": "Hydromorphone", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297110/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250850, "ingredient1": "Hydroxychloroquine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297111/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250851, "ingredient1": "Hydroxyzine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297112/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Clobazam, Meprobamate, Alprazolam, Lorazepam, Chlordiazepoxide, Halazepam, Clorazepic acid, Buspirone, Diazepam, Oxazepam", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250852, "ingredient1": "Ibuprofen", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297113/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Alprostadil, Ubidecarenone, Ivabradine, Adenosine, Regadenoson, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250853, "ingredient1": "Ibutilide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297114/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250854, "ingredient1": "Idarubicin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297115/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250855, "ingredient1": "Iloperidone", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297116/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250856, "ingredient1": "Imipramine", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297117/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250857, "ingredient1": "Indapamide", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297118/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250858, "ingredient1": "Indomethacin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297119/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Rabeprazole, Misoprostol, Chondroitin sulfate, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Plecanatide, Magnesium citrate, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250859, "ingredient1": "Inotuzumab ozogamicin", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297120/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250860, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297121/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250861, "ingredient1": "Interferon alfa-2b", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297122/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250862, "ingredient1": "Interferon alfa-n1", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297123/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250863, "ingredient1": "Interferon alfa-n3", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297124/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250864, "ingredient1": "Interferon alfacon-1", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297125/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250865, "ingredient1": "Interferon beta-1a", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297126/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250866, "ingredient1": "Interferon gamma-1b", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297127/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250867, "ingredient1": "Irbesartan", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297128/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250868, "ingredient1": "Isocarboxazid", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297129/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250869, "ingredient1": "Sodium sulfate", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297130/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250870, "ingredient1": "Sodium sulfate", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297131/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Linaclotide, Naloxone, More", "updated_at": 1767369485}, {"id": 250871, "ingredient1": "Sodium sulfate", "ingredient2": "Ketoprofen", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297132/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250872, "ingredient1": "Sodium sulfate", "ingredient2": "Ketorolac", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297133/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250873, "ingredient1": "Sodium sulfate", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297134/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250874, "ingredient1": "Sodium sulfate", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297135/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Methenamine, Spectinomycin, Nitrofurantoin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250875, "ingredient1": "Sodium sulfate", "ingredient2": "Lenvatinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297136/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250876, "ingredient1": "Sodium sulfate", "ingredient2": "Leuprolide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297137/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250877, "ingredient1": "Sodium sulfate", "ingredient2": "Levofloxacin", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297138/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250878, "ingredient1": "Sodium sulfate", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297140/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250879, "ingredient1": "Sodium sulfate", "ingredient2": "Levomilnacipran", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297141/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250880, "ingredient1": "Sodium sulfate", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297142/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250881, "ingredient1": "Sodium sulfate", "ingredient2": "Lidocaine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297143/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Neomycin, Chlorhexidine, Povidone-iodine, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250882, "ingredient1": "Sodium sulfate", "ingredient2": "Lindane", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297144/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Disulfiram", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250883, "ingredient1": "Sodium sulfate", "ingredient2": "Lisdexamfetamine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297145/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250884, "ingredient1": "Sodium sulfate", "ingredient2": "Lisinopril", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297146/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250885, "ingredient1": "Sodium sulfate", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297147/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250886, "ingredient1": "Sodium sulfate", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297148/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250887, "ingredient1": "Sodium sulfate", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297149/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250888, "ingredient1": "Sodium sulfate", "ingredient2": "Losartan", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297150/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250889, "ingredient1": "Sodium sulfate", "ingredient2": "Loxapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297151/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250890, "ingredient1": "Sodium sulfate", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297152/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250891, "ingredient1": "Sodium sulfate", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297153/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250892, "ingredient1": "Sodium sulfate", "ingredient2": "Macimorelin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297155/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Methacholine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250893, "ingredient1": "Sodium sulfate", "ingredient2": "Mannitol", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297158/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Sorbitol, Sulfamethizole, Sodium citrate, Magnesium citrate, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Alvimopan, Sorbitol, Tegaserod, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250894, "ingredient1": "Sodium sulfate", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297159/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250895, "ingredient1": "Sodium sulfate", "ingredient2": "Mazindol", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297160/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250896, "ingredient1": "Sodium sulfate", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297161/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250897, "ingredient1": "Sodium sulfate", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297162/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Plecanatide, More", "updated_at": 1767369485}, {"id": 250898, "ingredient1": "Sodium sulfate", "ingredient2": "Mefloquine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297163/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250899, "ingredient1": "Sodium sulfate", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297164/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ropivacaine, Chloroprocaine, Levobupivacaine, Tetracaine, Bupivacaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Rabeprazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250900, "ingredient1": "Sodium sulfate", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297165/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250901, "ingredient1": "Sodium sulfate", "ingredient2": "Meropenem", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297166/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250902, "ingredient1": "Sodium sulfate", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297167/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250903, "ingredient1": "Sodium sulfate", "ingredient2": "Methadone", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297168/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250904, "ingredient1": "Sodium sulfate", "ingredient2": "Metamfetamine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297169/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250905, "ingredient1": "Sodium sulfate", "ingredient2": "Methazolamide", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297170/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250906, "ingredient1": "Sodium sulfate", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297171/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250907, "ingredient1": "Sodium sulfate", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297172/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250908, "ingredient1": "Sodium sulfate", "ingredient2": "Methylphenidate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297174/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250909, "ingredient1": "Sodium sulfate", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297175/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250910, "ingredient1": "Sodium sulfate", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297176/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250911, "ingredient1": "Sodium sulfate", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297177/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250912, "ingredient1": "Sodium sulfate", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297178/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250913, "ingredient1": "Sodium sulfate", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297179/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250914, "ingredient1": "Sodium sulfate", "ingredient2": "Milnacipran", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297180/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250915, "ingredient1": "Sodium sulfate", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297181/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250916, "ingredient1": "Sodium sulfate", "ingredient2": "Moexipril", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297183/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250917, "ingredient1": "Sodium sulfate", "ingredient2": "Molindone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297184/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250918, "ingredient1": "Sodium sulfate", "ingredient2": "Morphine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297185/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250919, "ingredient1": "Sodium sulfate", "ingredient2": "Moxifloxacin", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297186/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250920, "ingredient1": "Sodium sulfate", "ingredient2": "Muromonab", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297187/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250921, "ingredient1": "Sodium sulfate", "ingredient2": "Nabumetone", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297188/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250922, "ingredient1": "Sodium sulfate", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297189/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250923, "ingredient1": "Sodium sulfate", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297190/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250924, "ingredient1": "Sodium sulfate", "ingredient2": "Naproxen", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297191/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Plecanatide, Magnesium citrate, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250925, "ingredient1": "Sodium sulfate", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297192/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250926, "ingredient1": "Sodium sulfate", "ingredient2": "Nelarabine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297193/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Cytarabine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250927, "ingredient1": "Sodium sulfate", "ingredient2": "Neostigmine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297194/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ambenonium, Pilocarpine, Cevimeline, Pyridostigmine, Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Betaxolol, Bimatoprost, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250928, "ingredient1": "Sodium sulfate", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297195/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250929, "ingredient1": "Sodium sulfate", "ingredient2": "Nilutamide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297196/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250930, "ingredient1": "Sodium sulfate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297197/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250931, "ingredient1": "Sodium sulfate", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297198/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250932, "ingredient1": "Sodium sulfate", "ingredient2": "Ofloxacin", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297199/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, Sodium chloride", "updated_at": 1767369485}, {"id": 250933, "ingredient1": "Sodium sulfate", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297200/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250934, "ingredient1": "Sodium sulfate", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297201/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250935, "ingredient1": "Sodium sulfate", "ingredient2": "Olmesartan", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297202/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250936, "ingredient1": "Sodium sulfate", "ingredient2": "Ondansetron", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297203/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250937, "ingredient1": "Sodium sulfate", "ingredient2": "Opium", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297204/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250938, "ingredient1": "Sodium sulfate", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297205/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250939, "ingredient1": "Sodium sulfate", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297206/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250940, "ingredient1": "Sodium sulfate", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297207/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250941, "ingredient1": "Sodium sulfate", "ingredient2": "Oxamniquine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297208/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Praziquantel", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250942, "ingredient1": "Sodium sulfate", "ingredient2": "Oxaprozin", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297209/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250943, "ingredient1": "Sodium sulfate", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297210/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250944, "ingredient1": "Sodium sulfate", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297211/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250945, "ingredient1": "Sodium sulfate", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297212/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250946, "ingredient1": "Sodium sulfate", "ingredient2": "Oxytocin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297213/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Methylergometrine, Misoprostol, Ergometrine, Dinoprostone, Terlipressin, Desmopressin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250947, "ingredient1": "Sodium sulfate", "ingredient2": "Ozanimod", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297214/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Sodium phosphate, monobasic, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 250948, "ingredient1": "Sodium sulfate", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297216/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250949, "ingredient1": "Sodium sulfate", "ingredient2": "Palonosetron", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297217/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250950, "ingredient1": "Sodium sulfate", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297218/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250951, "ingredient1": "Sodium sulfate", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297219/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250952, "ingredient1": "Sodium sulfate", "ingredient2": "Pasireotide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297220/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250953, "ingredient1": "Sodium sulfate", "ingredient2": "Pazopanib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297221/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250954, "ingredient1": "Sodium sulfate", "ingredient2": "Peginterferon alfa-2a", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297222/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250955, "ingredient1": "Sodium sulfate", "ingredient2": "Peginterferon alfa-2b", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297223/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250956, "ingredient1": "Sodium sulfate", "ingredient2": "Peginterferon beta-1a", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297224/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250957, "ingredient1": "Sodium sulfate", "ingredient2": "Pemoline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297225/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250958, "ingredient1": "Sodium sulfate", "ingredient2": "Pentamidine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297226/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Miltefosine, Nifurtimox, Benznidazole", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250959, "ingredient1": "Sodium sulfate", "ingredient2": "Pentazocine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297227/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250960, "ingredient1": "Sodium sulfate", "ingredient2": "Perflutren", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297228/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250961, "ingredient1": "Sodium sulfate", "ingredient2": "Perindopril", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297229/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, More", "updated_at": 1767369485}, {"id": 250962, "ingredient1": "Sodium sulfate", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297230/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250963, "ingredient1": "Sodium sulfate", "ingredient2": "Phendimetrazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297231/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250964, "ingredient1": "Sodium sulfate", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297232/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250965, "ingredient1": "Sodium sulfate", "ingredient2": "Phenolphthalein", "severity": "Moderate", "effect": "Concomitant use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) may increase the risk of serious gastrointestinal adverse effects associated with certain osmotic laxatives (e.g., polyethylene glycol (PEG), oral sulfate solution), such as colonic mucosal ulcerations or ischemic colitis.", "source": "DDInter", "management_text": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.  However, stimulant laxatives, in particular bisacodyl and sodium picosulfate, are sometimes used with PEG in certain bowel cleansing regimens to help reduce dose volume and improve patient tolerability and acceptance.  Please consult individual product labeling for specific recommendations and guidance.  Patients using osmotic bowel cleansing products and stimulant laxatives who present with sudden abdominal pain, rectal bleeding, or other symptoms of ischemic colitis should be evaluated promptly.", "mechanism_text": "Synergism", "recommendation": "The manufacturers for some osmotic bowel cleansing products recommend avoiding the concurrent use of stimulant laxatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297233/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Baudet JS, Castro V, Redondo I \"Recurrent ischemic colitis induced by colonoscopy bowel lavage.\" Am J Gastroenterol 105 (2010):  700-1[4] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[5] Ajani S, Hurt RT, Teeters DA, Bellmore LR \"Ischaemic colitis associated with oral contraceptive and bisacodyl use.\" BMJ Case Rep 2012 (2012):[6] \"Product Information. MoviPrep (polyethylene glycol 3350 with electrolytes).\" Physicians Total Care  (2016):[7] \"Product Information. Plenvu (polyethylene glycol 3350 with electrolytes).\" Bausch Health US (formerly Valeant Pharmaceuticals)  (2020):[8] \"Product Information. GaviLyte-H and Bisacodyl with Flavor Packs (bisacodyl-PEG 3350 with electrolytes).\" Gavis Pharmaceuticals  (2022):[9] \"Product Information. Bi-Peglyte (bisacodyl-PEG 3350 with electrolytes).\" Pendopharm[10] Vaizman K, Li J, Iswara K, Tenner S \"Ischemic colitis induced by the combination of Bisacodyl and polyethylene glycol in preparation for colonoscopy.\" Am J Gastroenterol 102 (2007):  S267[11] Belsey J, Epstein O, heresbach D \"Systematic review: adverse event reports for oral sodium phosphate and polyethylene glycol.\" Aliment Pharmacol Ther 29 (2009):  15-28[12] Hung SY, Chen HC, Chen WT \"A randomized trial comparing the bowel cleansing efficacy of sodium picosulfate/magnesium citrate and polyethylene glycol/Bisacodyl (The Bowklean Study)\" Sci Rep 10 (2020):  5604[13] Adamcewicz M, Bearelly D, Porat G, Friedenberg FK \"Mechanism of action and toxicities of purgatives used for colonoscopy preparation.\" Expert Opin Drug Metab Toxicol 7 (2011):  89-101[14] Anastassopoulos K, Farraye FA, Knight T, Colman S, Cleveland MvB, Pelham RW \"A comparative study of treatment-emergent adverse events following use of common bowel preparations among a colonoscopy screening population: results from a post-marketing observational study.\" Dig Dis Sci 61 (2016):  2993-3006[15] Barbeau P, Wolfe D, Yazdi F, et al. \"Comparative safety of bowel cleansers: protocol for a systematic review and network meta-analysis.\" BMJ Open 8 (2018):  e021892", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250966, "ingredient1": "Sodium sulfate", "ingredient2": "Phentermine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297234/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250967, "ingredient1": "Sodium sulfate", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297235/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250968, "ingredient1": "Sodium sulfate", "ingredient2": "Phenylpropanolamine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297236/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Pseudoephedrine, Phenylephrine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250969, "ingredient1": "Sodium sulfate", "ingredient2": "Physostigmine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297237/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Betaxolol, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Guanethidine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250970, "ingredient1": "Sodium sulfate", "ingredient2": "Pimavanserin", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297238/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250971, "ingredient1": "Sodium sulfate", "ingredient2": "Pimozide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297239/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250972, "ingredient1": "Sodium sulfate", "ingredient2": "Piperazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297240/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiabendazole, Levamisole, Pyrantel, Ivermectin, Mebendazole, Albendazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250973, "ingredient1": "Sodium sulfate", "ingredient2": "Piroxicam", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297241/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Fluocinolone acetonide, Cortisone, Hydrocortisone, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 250974, "ingredient1": "Sodium sulfate", "ingredient2": "Pitolisant", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297242/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250975, "ingredient1": "Sodium sulfate", "ingredient2": "Polythiazide", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297243/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250976, "ingredient1": "Sodium sulfate", "ingredient2": "Posaconazole", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297245/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250977, "ingredient1": "Sodium sulfate", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297246/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 250978, "ingredient1": "Sodium sulfate", "ingredient2": "Primaquine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297247/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250979, "ingredient1": "Sodium sulfate", "ingredient2": "Probucol", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297248/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250980, "ingredient1": "Sodium sulfate", "ingredient2": "Procainamide", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297249/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250981, "ingredient1": "Sodium sulfate", "ingredient2": "Prochlorperazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297250/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250982, "ingredient1": "Sodium sulfate", "ingredient2": "Promazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297251/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250983, "ingredient1": "Sodium sulfate", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297252/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250984, "ingredient1": "Sodium sulfate", "ingredient2": "Propafenone", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297253/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250985, "ingredient1": "Sodium sulfate", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297254/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 250986, "ingredient1": "Sodium sulfate", "ingredient2": "Propofol", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297255/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 250987, "ingredient1": "Dextropropoxyphene", "ingredient2": "Sodium sulfate", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297256/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 250988, "ingredient1": "Sodium sulfate", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297257/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250989, "ingredient1": "Sodium sulfate", "ingredient2": "Quetiapine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297258/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 250990, "ingredient1": "Sodium sulfate", "ingredient2": "Quinapril", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297259/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Lactitol, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 250991, "ingredient1": "Sodium sulfate", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297260/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Linaclotide, Naloxone, Magnesium gluconate, More", "updated_at": 1767369485}, {"id": 250992, "ingredient1": "Sodium sulfate", "ingredient2": "Quinine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297261/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250993, "ingredient1": "Sodium sulfate", "ingredient2": "Ramipril", "severity": "Moderate", "effect": "Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.  Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered.  Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297262/", "reference_text": "[1] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[2] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 250994, "ingredient1": "Sodium sulfate", "ingredient2": "Ranolazine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297263/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alprostadil, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250995, "ingredient1": "Sodium sulfate", "ingredient2": "Relugolix", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297264/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 250996, "ingredient1": "Sodium sulfate", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297265/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 250997, "ingredient1": "Sodium sulfate", "ingredient2": "Ribociclib", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297266/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 250998, "ingredient1": "Sodium sulfate", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297267/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 250999, "ingredient1": "Sodium sulfate", "ingredient2": "Rimantadine", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297268/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 251000, "ingredient1": "Sodium sulfate", "ingredient2": "Risperidone", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold, including psychotherapeutic agents (antidepressants; neuroleptics; lithium), fluoroquinolones, some antimalarial agents (chloroquine; hydroxychloroquine; mefloquine), and some narcotic analgesics.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/297269/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}]